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Abstract 
 
This thesis combines genetic and physiological studies of Friedreich’s 
ataxia (FRDA), an autosomal recessive disorder caused by a GAA triplet 
expansion mutation leading to a deficiency of the protein frataxin. This gives 
rise to a complex pathophysiology that affects not only the nervous system 
but also cardiac function, with the majority of FRDA patients dying from 
heart-related complications. In the genetic study, a sample of 2000 clinically 
undiagnosed ataxia cases referred to the National Hospital for Neurology 
and Neurosurgery (NHNN) over a 20-year period and who had not been 
previously screened for FRDA, were screened for the presence of any of 
the known FRDA mutations. Only 3 FRDA-positive cases were found, all 
conforming to the regular FRDA genotype of homozygous GAA triplet 
repeat expansion. These findings indicated the reliability of current FRDA 
diagnostic method and increased understanding of the FRDA genotype-
phenotype correlation among atypical FRDA cases, such as late-onset 
FRDA. In the physiological study, I studied the unexplored role of Ca2+ 
dysregulation in FRDA heart pathology. Frataxin was knocked-down in 
neonatal and adult FRDA-like cardiomyocyte models and Ca2+ homeostasis 
investigated. Both revealed a decreased Ca2+ sarcoplasmic reticulum (SR) 
content, combined with increased cellular and mitochondrial ROS levels. 
These data were confirmed in primary heart cells from well-established 
FRDA mouse models, such as the YG8R model. This was linked to 
increased leakage from the ryanodine receptors (RyR), causing Ca2+ to exit 
the SR, indicating a possible RyR potentiation in FRDA model heart cells 
due to frataxin deficiency. Together, these studies may lead to a better 
understanding of the impact of genetics on the FRDA clinical phenotype, 
and also widen our knowledge of the underlying mechanisms of the disease, 
with particular focus on the impact on Ca2+ signaling in heart cells affected 
by reduced frataxin. 
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Chapter 1 : Introduction 
 
 
1.1 Introduction 
 
Friedreich’s ataxia (FRDA) is an autosomal recessive condition that results 
in selective neuronal atrophy, affecting the dorsal root ganglia (DRG; Dyck 
et al., 1968) and the cerebellum (Koeppen et al., 2007).  FRDA affects the 
central and peripheral nervous system, the musculoskeletal system, the 
heart and the endocrine pancreas. The ataxia is of mixed origin, resulting 
from spinocerebellar degeneration and an axonal peripheral sensory 
neuropathy with pyramidal signs (Delatycki & Corben, 2012). The 
neuropathology is characterized by mild cerebellar and DRG atrophy and a 
subsequent proliferation of the synaptic terminals of the dentate nucleus, 
that lead to loss of the dentate nucleus and its efferent fibres (Koeppen et 
al., 2007).  
 
The development of the neuropathology involved in FRDA has been 
correlated with age at onset of disease, clinical severity and disease 
duration (Akhlaghi et al., 2011). The decrease in size and early atrophy of 
the DRG (Durr et al., 1996; Harding, 1981; Morral et al., 2010; Schols et al., 
1997) has been linked to the FRDA clinical characteristics of progressive 
ataxia, scoliosis and cardiomyopathy (De Biase et al., 2007). Around two-
thirds of all patients are found to have severe, life-threatening 
cardiomyopathy in the middle and late stages of the disease, making this 
an issue of tremendous clinical relevance (Durr et al., 1996; Harding, 1981; 
Payne et al., 2011). Indeed, progressive hypertrophic cardiomyopathy is the 
predominant cause of death in FRDA patients (Hanley et al., 2010; Tsou et 
al., 2011). The disease is caused by a deficiency of the protein frataxin, 
which was linked with the FRDA genetic defect discovered in 1996. The 
precise function of frataxin remains unclear, although it has been linked to 
changes in iron metabolism, mitochondrial respiration and reactive oxygen 
species (ROS) levels that have themselves been linked to aspects of FRDA 
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pathophysiology (Pandolfo & Pastore, 2009). However, no proven disease-
modifying treatment exists for FRDA (Perlman, 2012; Wilson, 2012). This 
introductory chapter reviews the history and chronology of the evolving 
understanding of FRDA, including the discovery of its genetic basis; details 
the current understanding of pathogenic mechanisms of the disease; 
describes its clinical features; and places the aims of my study within the 
broader context of FRDA research.  
 
 
1.2 Background 
 
In 1863, Dr Nikolaus Friedreich performed what was to become the seminal 
study of Friedreich’s ataxia. Ataxia is a Greek term (ατάξις) meaning ‘lack 
of order’. Although the term has been in use since the time of Hippocrates 
in medical descriptions, it was not until the 19th century that it adopted its 
current meaning of incoordination due to neurological dysfunction. In a 
subgroup of six ataxic patients from two families, Friedreich observed that 
the form of ataxia he had discovered was hereditary, early-onset, and 
associated with a slow progression of disease involving an absence of 
sensory loss in its early stages (Friedreich 1863c, Friedreich 1863a, 
Friedreich 1863b). His clinical definition still characterises the classical 
FRDA phenotype. Friedreich observed fatty degeneration of heart tissue in 
three of his patients, and the early 20th century saw the first reports of 
cardiac involvement and electrocardiogram (ECG) changes in FRDA. Along 
with the further observation of diabetes in FRDA, this established FRDA as 
a multisystem disorder. 
 
In the years since 1863, FRDA has been fully characterized as a unique 
disorder, with increasingly detailed descriptions of its genetic aetiology, 
pathophysiology and phenotype. Advances by the 1970s allowed for a 
reliable set of diagnostic criteria to be developed, in particular through 
Harding’s seminal case series of 115 FRDA patients (Geoffroy et al., 1976; 
Harding, 1981). The genetic abnormality underlying the great majority of 
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FRDA cases, a GAA expansion mutation, was discovered in 1996 
(Campuzano et al., 1996). This allowed for genotype-phenotype correlation, 
which in turn led to the discovery of a greater phenotypic spectrum than had 
been previously assumed. The original diagnostic criteria were thus found 
to have excluded more atypical FRDA cases that present with very early or 
late onset of disease, retained reflexes, spasticity and limited disease 
progression. 
 
 
1.3 Genetics of Friedreich’s Ataxia 
 
FRDA is the most common inherited ataxia in Europe. Studies currently set 
the prevalence of the condition at between 1:20,000 and 1:125,000 in 
several western European populations (Filla et al., 1992; Vankan, 2013). 
The GAA expansion mutation has only been discovered among European, 
north African, Middle Eastern and Indian populations (Labuda et al., 2000). 
Estimates of the carrier frequency range between 1:60 and 1:110 (Cossee 
et al., 1997; Epplen et al., 1997; Filla et al., 1992; Harding & Zilkha, 1981; 
Romeo et al., 1983). Cases within families normally involve either an 
isolated individual or multiple siblings, indicating an autosomal recessive 
genetic disorder, although pseudodominance has also been observed 
(Harding & Zilkha, 1981). The disease occurs at equal frequency among 
males and females (Schols et al., 1997). 
 
Genetic Basis for FRDA 
The causative human frataxin gene (FXN) was first mapped by genetic 
linkage studies to chromosome 9p22 (Chamberlain et al., 1988), and then 
more fully described in 1996 as underlying an autosomal, recessively 
inherited condition (Campuzano et al., 1996). The discovery of the 
causative gene allowed for further extension and refinement of studies on 
the FRDA phenotype. The mutation responsible for the vast majority of 
FRDA cases was characterized by a homozygous, unstable genetic GAA 
triplet expansion, and was located in intron 1 of the FXN gene on the long 
arm of chromosome 9 (localized on 9q21.11) (Campuzano et al., 1996, 
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1997; Koutnikova et al., 1997). In general, these FRDA patients have 
between 70 and 1700 repeats in both alleles, clustering mostly between 600 
and 900 repeats (Campuzano et al., 1996; Entezam et al., 2017; Epplen et 
al., 1997; Fig. 1). The largest case series to date, carried out on 592 
EFACTS patients, gave an average GAA1 (smaller allele) size of 648 
repeats and an average GAA2 (larger allele) size of 912 repeats (Reetz et 
al., 2015). All FRDA patients have at least one pathological triplet expansion 
in the first intron of the FXN gene. While most patients are homozygous for 
the expansion mutation, 1-3% are compound heterozygous for the GAA 
expansion in one allele and either a nonsense, missense, or deletion 
mutation in the other allele (Campuzano et al., 1996; Cossee et al., 1999; 
Gellera et al., 2007).  
 
 
Figure 1. FXN gene, chromosome 9q21.11. 
Effect of mutations on FXN gene 
The GAA expansion, associated with epigenetic changes (Festenstein, 
2006), leads to transcriptional inhibition and partial silencing of the FXN 
gene, which in turn leads to pathological suppression of frataxin protein 
expression. The mechanisms of gene silencing have been studied at length 
in order to discover a method for targeting the initial gene and finding a 
viable therapy for FRDA. It is thought to occur due to GAA repeats forming 
R-loops and ‘sticky DNA’ triple helices containing non-Watson-Crick pairs, 
which could physically block transcription by impeding RNA polymerase II 
(Gacy et al., 1998; Sakamoto et al., 1999). Increased DNA methylation has 
also been observed upstream of the GAA repeat expansion in peripheral 
blood mononuclear cells from FRDA patients (Castaldo et al., 2008). The 
level of methylation is inversely correlated with FXN expression and age at 
onset, suggesting an important role in FRDA, most likely in abnormal 
(GAA)n
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
Healthy: 10<n<70
FRDA: 70<n<1700
5kb
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excessive heterochromatinisation leading to gene inactivation (Evans-
Galea et al., 2012). Histones are also increasingly deacetylated in FRDA, 
leading to repressed gene expression (Yandim et al., 2013). These 
epigenetic studies into FRDA have already allowed histone deacetylase 
inhibition to be tested as a novel therapeutic strategy through the use of 
nicotinamide (Libri et al., 2014). 
 
Frataxin Protein 
This gene codes for the protein frataxin, a small, globular, highly conserved, 
nuclear-encoded protein localized to the inner mitochondrial membrane 
(IMM) in eukaryotes (Puccio & Koenig, 2000). Frataxin is expressed 
ubiquitously, but its highest expression levels are in the cells of the heart 
and spinal cord, its intermediate levels in the cerebellum, liver, pancreas 
and muscle, and its lowest expression levels in the other organs of the body 
including the cerebral cortex (Campuzano et al., 1996). Thus, frataxin 
appears to be expressed more in organs or tissues with high energy 
demand, such as cardiomyocytes, sensory DRG neurons, pancreatic islet 
-cells and cells of the cerebellar dentate nuclei and spinocerebellar tracts, 
which are all particularly affected in FRDA. 
 
Figure 2. Schematic representation of GAA expansion in FXN intron 1 causing 
decreased frataxin production. 
Effects of FRDA mutations on frataxin protein levels 
Studies comparing frataxin levels in FRDA patients against controls through 
methods such as lateral flow immunoassay of peripheral blood 
Exon 1          Intron 1          Exon 2 
(GAA)20 
(GAA)500 
Normal 
FRDA 
FXN 
FXN 
Frataxin 
Frataxin 
Exon 1          Intron 1          Exon 2 
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mononuclear cells showed that the GAA expansion mutation leads to the 
partial yet significant reduction of frataxin to about 5-30% of original levels 
(Sacca et al., 2011; Willis et al., 2008; Fig. 2). Some clinical trials have 
attempted to simply restore frataxin levels in FRDA by using the 
glycoprotein erythropoietin, which has been shown to increase frataxin 
levels in FRDA models, but the trials have not displayed any clinical benefits 
(Mariotti et al., 2013; Nachbauer et al., 2011). The frataxin produced is 
structurally and functionally normal in typical FRDA (Gottesfeld, 2007; 
Schmucker & Puccio, 2010). On the other hand, the other rarer FRDA-
associated mutations in FXN lead to non-functional or partially functional 
frataxin (Correia et al., 2008). This frataxin decrease is consistent with other 
loss-of-function, recessive genetic conditions. As shown in knockout animal 
models, complete absence of frataxin protein is lethal to the embryo in 
development (Cossee et al., 2000). In most cases, compound heterozygous 
patients are phenotypically similar to patients who are homozygous for the 
GAA expansion. However, some missense mutations, such as G130V, 
D122Y, R165P and L106S, cause an atypical form of FRDA, as do large 
deletion mutations (Cossee et al., 2000; Gellera et al., 2007). Homozygous 
point mutations have yet to be described in FRDA cases (Campuzano et 
al., 1996; Cossee et al., 1999; Gellera et al., 2007). Heterozygous carriers 
of the GAA expansion mutation, such as the parents of FRDA patients who 
are not compound heterozygotes, are thought to be clinically unaffected if 
they lack any other genetic abnormality (Andermann et al., 1976; Harding, 
1981). However, these heterozygous carriers are known to produce 
significantly less frataxin than normal controls (Deutsch et al., 2010; Sacca 
et al., 2011; Willis et al., 2008). It is evident from these data that frataxin is 
essential for a healthy life, but its function remains to be fully elucidated. 
 
Genotype-Phenotype Correlation 
The FRDA phenotype is distinct, yet symptoms can be highly variable. 
Discovery of the causative gene allowed for further extension and 
refinement of studies on the FRDA phenotype (Campuzano et al., 1996). 
This allowed for atypical cases to be revealed via genotype-phenotype 
correlations following neurogenetic tests, where previously they might have 
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been misinterpreted based on clinical data.  It was discovered in population 
studies that up to a quarter of genetically diagnosed patients did not fit the 
original diagnostic criteria proposed by Geoffroy and Harding (Durr et al., 
1996; Filla et al., 2000; McCabe et al., 2000; Schols et al., 1997), expanding 
the phenotypic spectrum of FRDA. These atypical cases are normally either 
of early onset (before 15 years of age) or late onset (after 25 years of age). 
 
The effect of the GAA expansion mutation on gene transcription has been 
shown to cause the FRDA phenotype, and the severity of the phenotype is 
related to the expansion size. The size has been correlated with incidence 
of cardiomyopathy and rate of progression of disease symptoms, and 
inversely correlated with age at onset and age of start of wheelchair use 
(Durr et al., 1996; Filla et al., 1996; Montermini et al., 1997; Rajagopalan et 
al., 2010). Specifically, around 50% of the variability in age at onset of FRDA 
has been shown to be accounted for by the size of the GAA expansion (Filla 
et al., 1996). This variability is caused by intergenerational instability of the 
GAA triplet expansion (Monros et al., 1997) as well as somatic mosaicism, 
fluctuations in expansion size during life, interruptions in the expansion and 
other modifying genetic or environmental elements (Pandolfo & Pastore, 
2009). 
 
In recent studies, the GAA expansion size has been statistically shown to 
account for only 40% of the symptoms in FRDA, which may explain the 
variability in FRDA symptoms that have been historically observed (Reetz 
et al., 2015, 2016). This is in contrast to dominant disorders caused by CAG 
repeats, where the correlation between expansion size and phenotype is 
considerably stronger. In FRDA, the correlation described is stronger with 
the smaller in size of the two expansions, GAA1 (Reetz et al., 2015; Schols 
et al., 1997). Most atypical presentations of FRDA are caused by extremely 
small or large GAA expansion sizes (particularly of GAA1), as well as by 
compound heterozygotes with point mutations (Parkinson et al., 2013). The 
smallest non-interrupted GAA1 expansion reported so far in a patient with 
FRDA was of 44 triplet repeats, only a little more than in the equivalent 
expansion size in controls, that has been shown to reach up to 33 repeats 
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(Sharma et al., 2002). Patients with late-onset atypical FRDA have in most 
cases between 100 and 500 repeats in the GAA1 allele (Bhidayasiri et al., 
2005; Durr et al., 1996; Schols et al., 1997). It has also been shown that 
compound heterozygotes incorporating a missense point mutation on one 
allele located near the amino end of the carboxy-terminal domain of the 
protein may result in a milder FRDA phenotype (Cossee et al., 1999). A 
study by Saccà et al on white blood cells was the first to combine the 
determination of frataxin protein deficiency with an mRNA level decrease in 
FRDA and correlate the results with the genotype and disease severity of 
the patients. It discovered an inverse correlation between frataxin 
protein/mRNA levels and the length of both the shorter and longer GAA 
alleles, as well as a correlation between frataxin protein level, frataxin 
mRNA level and the age at onset of FRDA (Sacca et al., 2011). However, it 
should be noted that the vast majority of studies on FRDA patients measure 
white cell GAA expansion size, a tissue that is not clinically affected in 
FRDA. 
 
Frataxin Protein: translation and cleavage 
Frataxin is first translated in the cytoplasm into a 23.1kDa, 210-amino acid 
species known as frataxin precursor polypeptide (FXN1-210) and is then 
targeted to the mitochondria (Campuzano et al., 1996). The amino acid 
terminal residues are then cleaved proteolytically by the mitochondrial 
processing peptidase (MPP). These amino acid residues most likely act as 
a mitochondrial targeting sequence in this case, and several studies have 
been carried out to determine which are involved. Although several 
cleavage sites have been elucidated in a variety of experiments, it is 
believed that the processing of frataxin precursor occurs in a two-stage 
process. Firstly, the mitochondrial signal peptide is cleaved (residues 1-42) 
to produce 18.8kDa, 169-amino acid long intermediate frataxin protein 
(FXN42-210). Secondly, cleavage of the intermediate N-terminal tail (residues 
42-81) creates the mature 14.2kDa, 130-amino acid protein (FXN81-210) 
(Branda et al., 1999; Cavadini et al., 2000; Condo et al., 2007).  The mature 
form of the protein is a large, twisted -sheet made from a minimum of six 
anti-parallel -strands (1-6) encircled by two α-helices (α1 & α2: Fig. 3). 
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Figure 3. Mature frataxin protein. α-helices shown as ribbons, β-strands as arrows 
and C-terminal tail in red. Image in public domain, based on PyMOL rendering. 
 
 
1.4 Pathophysiology of Friedreich’s 
Ataxia 
 
1.4.1 Role of Frataxin 
 
Biopsy studies on FRDA individuals have uncovered three main 
biochemical features characterising the pathophysiology of the disease: 
 
1. Intracellular iron deposits in the heart (Lamarche et al., 1980; Sanchez-
Casis et al., 1976). 
2. A deficit in mitochondrial iron-sulphur cluster (ISC)-containing enzymes 
such as aconitase and the mitochondrial respiratory chain complexes I, 
II and III in the heart (Rotig et al., 1997). 
3. The presence of markers of oxidative damage in blood and urine 
samples (Bradley et al., 2004; Emond et al., 2000; Schulz et al., 2000). 
 
We have yet to fully understand the precise function of the frataxin protein 
based on the biochemical features that result from its deficiency. It is now 
evident from studies, including on the yeast frataxin homolog Yfh1p, that 
free iron accumulates in the mitochondria, potentially causing oxidative 
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stress and lowering mitochondrial energy production (Babcock et al., 1997; 
Branda et al., 1999; Lodi et al., 2001). Some data suggests frataxin is a 
multifunctional protein involved in a variety of mitochondrial pathways, 
interacting with other proteins in iron-sulphur (Fe-S) cluster assembly (Shan 
et al., 2007), haem biosynthesis (Yoon & Cowan, 2004) and intracellular 
iron homeostasis (Huang et al., 2009).  More recent in vitro and in vivo 
FRDA studies indicate that the major functional role of frataxin is in ISC 
biogenesis.  
 
Iron-Sulphur Clusters (ISCs) 
ISCs are small inorganic redox-active protein cofactors that play a role in 
fundamental cellular pathways including oxidative phosphorylation and 
metabolic processes such as enzyme catalysis. They are also involved in 
gene regulation. Enzymes involved in mitochondrial respiration that contain 
ISCs include aconitase and mitochondrial complexes I, II and III (Lill, 2009; 
Martelli et al., 2011). De novo ISC biogenesis is a highly conserved but still 
poorly understood process that occurs in the mitochondria of eukaryotes 
(Lill, 2009; Rouault, 2012). Upon the scaffold protein ISCU, the platform 
upon which the rest of the cluster is built, inorganic iron and sulphur form 
the ISC. The sulphur is produced, via a highly reactive persulphide 
intermediate, by a cysteine desulphurase (made up of a NFS1-ISD11 
protein subcomplex). This enzyme catalyses the conversion of cysteine to 
alanine to produce the persulphide required to interact with the ionic iron 
and form the ISC (Pandolfo & Pastore, 2009; Prischi et al., 2010).  
 
Frataxin and ISCs: role as iron donor 
The Rötig study first associated frataxin with ISC-containing enzymes (Rotig 
et al., 1997). A time-dependent molecular and functional analysis of MCK-
Cre, a conditional mouse model that reproduced the cardiomyopathy of 
FRDA (see Mouse Models section), also pointed towards an essential role 
of frataxin in ISC biogenesis (Puccio et al., 2001). This confirmed 
predictions made by a phylogenetic study into the frataxin interactome, 
which discovered two genes that co-occur with frataxin and whose 
expressed proteins are required in yeast mitochondria for ISC assembly 
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(Huynen et al., 2001).  Later studies in yeast, where the yeast homolog of 
frataxin was depleted (Yfh1p), also indicated a key role for frataxin in ISC 
biogenesis (Duby et al., 2002; Muhlenhoff et al., 2002).  
 
In vitro studies on bacterial, yeast and human frataxin made evident a low 
iron affinity of the protein. The iron was found to bind to a conserved acidic 
ridge in the α1-β1 region of the mature frataxin protein (Cook et al., 2006; 
Nair et al., 2004). However, in vivo studies under physiological conditions 
have yet to demonstrate iron binding by frataxin. Nevertheless, a specific 
role for frataxin as an iron donor for the in vivo assembly of ISC clusters is 
indicated by: 
 
1. The iron-dependent interaction of yeast frataxin with Nfs1 and Isu1, 
the yeast homologs of NFS1 and ISCU (Gerber et al., 2003). 
2. In vitro reconstitution studies that reveal the ability of human frataxin 
to transfer iron to ISCU (Yoon & Cowan, 2003). 
3. The capacity of CyaY (the bacterial homolog of frataxin) to contribute 
iron towards ISC formation (Layer et al., 2006). 
 
Frataxin and ISCs: interaction with ISCU-NFS1-ISD11 complex 
Frataxin has been described as interacting with both enzymes of the 
cysteine desulphurase sub-complex involved in producing the inorganic 
sulphur, NFS1 and ISD11, in addition to its apparent role as an iron donor 
(Gerber et al., 2003; Layer et al., 2006; Li et al., 2009; Shan et al., 2007). 
This interaction is essential for ISC assembly. More recent studies using 
mammalian immunoprecipitant and recombinant proteins revealed that 
frataxin interacts with NFS1, ISD11 and ISCU in a pre-packaged complex. 
This interaction also causes increased cysteine desulphurase activity, 
indicating that frataxin modulates the ability of NFS1 to provide sulphur for 
ISC biogenesis (Tsai & Barondeau, 2010; Schmucker et al., 2011). It has 
been shown that iron is not essential for interaction between frataxin and 
the ISCU-NFS1-ISD11 complex (Schmucker et al., 2011), despite iron 
being shown to improve the activation of NFS1 activity by frataxin (Tsai & 
Barondeau, 2010). However, data gathered using isothermal titration 
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calorimetry showed that the interaction of yeast homologs Yfh1p and Isu1 
(in absence of Nfs1 and Isd11) depends on iron-binding (Cook et al., 2010), 
which indicates conversely that the binding of frataxin with iron is a 
fundamental part of the process culminating in ISC formation. The region of 
interaction with the complex was shown by an NMR study of Yfh1p to be 
the α1-β1 region, previously observed to bind iron in vitro, as well as a large 
portion of the β-sheet (Cook et al., 2010). These results are supported by 
mutagenesis experiments determining the region of interaction between 
mouse frataxin and the ISCU-NFS1-ISD11 complex (Schmucker et al., 
2011). However, the exact nature of the interaction remains to be 
established. 
 
Frataxin and ISCs: unclear role of frataxin 
It is clear from kinetics studies that eukaryotic frataxin increases the rate of 
ISC production. It facilitates the transfer of sulphur on the ISC assembly 
protein ISCU by acting as an allosteric modulator (Bridwell-Rabb et al., 
2014). In addition, extramitochondrial frataxin regulates transfer of ISCs to 
cytosolic aconitase, and thereby exercises molecular control of a switch 
between enzymatic and RNA-binding cellular functions (Condo et al., 2010). 
However, how iron delivery and the modulation of NFS1 activity by frataxin 
are coordinated in the process of ISC biogenesis remains unclear. Some 
data obtained using the bacterial frataxin homolog can be used as an 
example of this uncertainty. CyaY has been shown to have a high affinity 
for the preformed IscS-IscU complex, the bacterial equivalent of the 
mammalian ISCU-NFS1-ISD11 complex (Prischi et al., 2010). However, in 
vitro reconstitution experiments made evident an inhibition of ISC 
biogenesis by CyaY, rather than an activation as expected based on 
previous data (Adinolfi et al., 2009). In stoichiometric conditions, CyaY 
specifically decreased IscS enzymatic activity in the presence of IscU. Thus, 
the effect of CyaY on IscS is opposite to that seen in the equivalent proteins 
of the mammalian system (Iannuzzi et al., 2011). An understanding of the 
basis for these differences, as well as an understanding of how this 
activation or inhibition precisely impacts upon the ability of the complex to 
form ISCs, is as yet unavailable. This understanding may be achieved 
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through in vitro biochemical experiments, as well as a 3D-structure 
determination of the eukaryotic and bacterial complexes using X-ray 
crystallography.  
 
 
Frataxins & ISCs: point mutation studies 
That frataxin appears to be both an iron donor and an activator of cysteine 
desulphurase activity, allows for studies to use FRDA missense mutations 
(see section 1.5.5 for more clinical information on FRDA point mutations) to 
assess the role and function of frataxin. Four different sets of frataxin point 
mutations were identified based on their biochemical properties (Bridwell-
Rabb et al., 2011; Tsai et al., 2011; Yoon et al., 2012): 
 
1. Genetic variants affecting both frataxin binding to the ISCU-NFS1-
ISD11 complex and the cysteine desulphurase activity of the 
complex (Q153A, W155R) 
2. Variants causing a greatly reduced frataxin binding ability, but an 
only mildly reduced cysteine desulphurase activity (R165C, N146K, 
W155A) 
3. Variants which do not affect frataxin binding, but cause a greatly 
reduced cysteine desulphurase activity (Q148R) 
4. Variants that have only mild defects in both frataxin binding ability 
and cysteine desulphurase activity (W155F, N146A, Q148G, I154F). 
 
Results indicated however that missense mutations that affected the role of 
frataxin through different biochemical pathways all led to a very similar 
FRDA phenotype. An interesting further study could be to observe how point 
mutation variants that cause atypical presentation of FRDA affect the 
process of ISC formation (Cossee et al., 1999; Gellera et al., 2007). 
 
Proposed role of frataxin in other mitochondrial pathways 
In addition to its well-established role in ISC biogenesis, frataxin has been 
proposed to have other functions. This includes providing iron through direct 
protein-protein interactions with a variety of mitochondrial proteins, 
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including mitochondrial aconitase (Bulteau et al., 2004), ferrochelatase for 
haem biosynthesis (He et al., 2004; Yoon & Cowan, 2004) and succinate 
dehydrogenase, or respiratory chain complex II (Gonzalez-Cabo et al., 
2005). However, as subsequent replication studies were unable to 
reproduce several of the protein-protein interactions, their relevance has 
been questioned. Further in vivo experiments using a murine fibroblast 
FRDA model containing human frataxin and deleted for endogenous 
frataxin, made evident a clear correlation between cellular viability and the 
ability of frataxin to interact with the ISCU-NFS1-ISD11 complex 
(Schmucker et al., 2011). This indicates that interaction with this complex is 
an essential function of frataxin in in vivo ISC biogenesis. Thus, although it 
cannot be excluded that direct protein-protein interactions involving frataxin 
occur in a particular biochemical context or under certain experimental 
conditions, the hypothesis of frataxin involvement in other mitochondrial 
pathways requires greater validation through complementary in vivo 
approaches in order to study the metabolic effects of frataxin deficiency. 
 
Frataxin and ISCs: Summary 
In order to fully decipher the cellular consequences of the frataxin 
knockdown, an understanding of its function is fundamental. Although the 
role of frataxin in ISC biogenesis is now clear, what remains unclear is the 
correlation between the role of frataxin in ISC biogenesis and the 
pathophysiology of FRDA. As ISC biogenesis is an essential pathway 
involved in many cellular processes, a ISC deficiency can lead to multiple 
and aggregating cellular dysregulations, and an increasing amount of 
diseases are linked to them (Lill, 2009). How exactly the cell senses the 
frataxin deficit also remains a challenging question for future studies to 
answer. Nevertheless, knowledge of the direct link between ISC biogenesis 
and frataxin levels has opened the door for novel investigations into the 
cellular and molecular pathophysiology of FRDA.  
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1.4.2 Iron Accumulation and Oxidative Stress in 
Friedreich’s Ataxia 
 
The first findings connecting frataxin directly with iron metabolism were 
made in yeast mitochondria from cells incorporating a deletion of the frataxin 
homolog gene, YFH1. An iron accumulation was observed in these 
mitochondria, in addition to a loss of mitochondrial respiratory chain function 
and aconitase dysfunction (Babcock et al., 1997). A further study on Yfh1p 
deficiency in yeast confirmed a strong link between frataxin and 
mitochondrial iron overload, with increasing susceptibility to oxidative stress 
(Branda et al., 1999). Lower frataxin levels have been found to lead to 
increased intracellular iron deposits in heart cells from both FRDA patients 
(Bradley et al., 2000; Lamarche et al., 1980; Sanchez-Casis et al., 1976) 
and mouse models (Al-Mahdawi et al., 2006; Puccio et al., 2001), with 
several studies also indicating that iron deposits mainly in mitochondria. The 
reduction in the activity of ISC-containing mitochondrial respiratory chain 
complexes I, II and III in endomyocardial biopsy analyses from FRDA 
patients revealed increased iron deposition in parallel (Rotig et al., 1997).  
 
It is important to note that the role of intracellular iron accumulation in the 
FRDA cardiac pathology is better established than in the neuronal 
pathology, although it has been indicated to occur in glial cells supporting 
the dentate nucleus and dorsal root ganglia (Koeppen et al., 2012; Koeppen 
et al., 2016). Iron accumulation tends to cause an increase in oxidative 
stress, as iron is a highly redox-reactive metal whose regulation is critical. 
Indeed, a link between frataxin deficiency and impaired iron homeostasis 
leading to mitochondrial iron accumulation and oxidative stress is now well-
established (Abeti et al., 2016; Bradley et al., 2004; Emond et al., 2000; 
Schulz et al., 2000). This is a potential key causal factor in the cell 
degeneration and death observed in affected tissues in FRDA (Schulz & 
Pandolfo, 2013; Wilson, 2012).  
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Frataxin: role in iron accumulation 
The precise nature of the interaction of frataxin with iron remains 
controversial. Data from the yeast FRDA model first indicated that frataxin 
was involved in regulation of cellular iron levels, through its ability to directly 
bind iron (Adamec et al., 2000). This functional hypothesis was later 
expanded into considering frataxin as an iron storage protein akin to ferritin. 
This was based on reports that the frataxin protein formed large aggregates 
that retained iron in ferric (Fe3+) form to help reduce iron toxicity in the cell 
(Cavadini et al., 2002; Yoon & Cowan, 2003). However, the protein also 
appears to act as an iron chaperone by providing bioavailable, labile ferrous 
(Fe2+) iron to ISCs, a role that appears counterproductive to its other 
proposed role as an iron storage protein. For example, there is a correlation 
in all studied genomes in FRDA between the expression of the frataxin gene 
and the hscB gene in bacteria, which codes for a chaperonine that is part of 
the ISC machinery (Huynen et al., 2001). However, this role is yet to be fully 
proven physiologically. 
 
Mitochondrial iron accumulation: ISC deficit link 
Mitochondrial iron accumulation is claimed to result from defective ISC 
biosynthesis, following yeast studies that showed that iron accumulates in 
the mitochondria of all mutant cells with this ISC deficit (Chen et al., 2004; 
Radisky et al., 1999). In both animal and human models of FRDA, defects 
in Fe-S enzymes are detectable before mitochondrial iron accumulation 
(Puccio et al., 2001). However, the mechanism for this remains unclear. 
Through regulation of iron homeostasis, ISCs necessarily participate in 
reversible redox reactions, due to the ability of ionic iron to toggle valency 
between Fe2+ and Fe3+. The role of ISCs as a prosthetic group for 
mitochondrial aconitase and mitochondrial complexes I, II and III allows 
these proteins to become the site of redox reactions that are required for 
the correct functioning of the tricarboxylic acid cycle and the mitochondrial 
electron transport chain respectively (Johnson et al., 2005; Lill, 2009). Thus, 
the source of iron accumulation in FRDA may be in the dysregulation of 
these crucial redox reactions, as ROS generation can itself cause iron 
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accumulation. Furthermore, the iron-responsive element binding protein 
(IRP1) also contains ISCs. This protein binds to iron-responsive elements 
(IRE) on the mRNA of proteins with a role in iron metabolism.  
 
Thus, defective ISC biosynthesis could lead to an increase in IRP1-
mediated cellular iron uptake, and this has in fact been detected in frataxin-
deficient cells (Lobmayr et al., 2005). A vicious cycle may be created with 
iron transported by transferrin receptor 1 to the mitochondria to increase 
ISC synthesis, and then accumulating there as the frataxin deficiency 
continues to block ISC biosynthesis (Pandolfo & Hausmann, 2013). Frataxin 
has also been shown to interact with a mitochondrial protein known as 
ferrochelatase, which mediates the insertion of iron into the porphyrin 
precursor during haem biosynthesis (Lesuisse et al., 2003). However, as 
faulty haem synthesis has never been observed as an important aspect of 
FRDA, its significance remains poorly understood. From these studies, it is 
evident that frataxin plays an essential, if still partially understood, role in 
mitochondrial iron metabolism. 
 
Frataxin and oxidative stress 
It is widely accepted that high free iron levels lead to increased ROS 
production and greater oxidative stress. In addition, lack of frataxin in 
affected cells causes changes in gene expression leading to down-
regulation of proteins involved in mitochondrial ISC synthesis, as well as 
cytosolic and mitochondrial iron uptake. This iron dysregulation itself 
increases the fraction of labile redox-active iron in the mitochondria, 
inhibiting mitochondrial respiration and progressively enhancing ROS 
generation (Isaya, 2014). This can lead to mitochondrial dysfunction, 
oxidative stress and further mitochondrial iron accumulation (Pandolfo & 
Pastore, 2009). Frataxin deficiency has been shown to lead to oxidative 
damage in humans (Schulz et al., 2000), mice (Abeti et al., 2016; Abeti et 
al., 2015; Ristow et al., 2003), yeast (Karthikeyan et al., 2003) and 
Caenorhabditis elegans (Vazquez-Manrique et al., 2006). Specifically, in 
cerebellar granule neurons from a FRDA mouse model a mitochondrial 
energy imbalance between respiratory chain complexes I and II was 
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observed, leading to a basal excess of ROS and subsequent lipid 
peroxidation, glutathione depletion and cellular death (Abeti et al., 2016). In 
addition to mitochondrial iron accumulation, the frataxin-deficient yeast 
model (Babcock et al., 1997) and the FRDA patient fibroblast model (Wong 
et al., 1999) showed increased sensitivity to H2O2. The H2O2 molecule, 
through reaction with ferrous iron (Fe2+) through the Fenton reaction, 
generates the highly toxic hydroxyl (∙OH) radical. The frataxin deficiency 
causes both ingredients of the Fenton reaction to increase: the iron, through 
malfunctioning ISC biosynthesis, and the H2O2 via a decrease in respiratory 
chain function caused by impairment of the ISC-containing complexes I, II 
and III.  
 
This pathway provides evidence that oxidative damage in both 
mitochondrial and nuclear DNA and to ISCs in aconitase and the electron 
transport chain (ETC) is at least worsened by the mitochondrial iron 
overload that results from frataxin deficiency (Babcock et al., 1997; Cavadini 
et al., 2002; Karthikeyan et al., 2002), even if the ISC defects appear to 
occur before the mitochondrial iron accumulation (Puccio et al., 2001). The 
evidence that frataxin-deficient cells are more sensitive to oxidative stress 
was increased by further studies (Condo et al., 2007; Tan et al., 2001), 
some of which showed a specific role for frataxin in protecting the cell 
against iron-induced oxidative damage (Gakh et al., 2006; O’Neill et al., 
2005), a function that could be linked to the concept of frataxin as an iron 
chaperone or iron-storage molecule (Park et al., 2003).   
 
Therapeutic goals in FRDA Physiology Studies 
Therapeutic studies consequential to these physiological FRDA studies on 
downstream effects of frataxin deficiency logically included antioxidants 
such as idebenone and iron chelators such as deferiprone used alone or in 
combination, but although there has been halting progress, no clinical trial 
has stopped or reversed disease progression (Pandolfo et al., 2014; 
Parkinson et al., 2013). Therefore, more pathophysiological insights into 
FRDA are crucial. FRDA pathophysiology studies have yet to answer the 
following riddle: is the increased ROS production in FRDA primarily due to 
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a progressive reduction in ISC-containing enzymes via imbalanced 
oxidative phosphorylation, due to inhibition of the mitochondrial electron 
transport chain (ETC) complexes I, II and III? Or alternatively, is the 
increased ROS production due primarily to an accumulation of reactive iron 
in the mitochondria through the reduction in ISC biosynthesis, or a cellular 
or mitochondrial issue with Ca2+ homeostasis, leading in turn to oxidative 
stress and a worsening of mitochondrial abnormalities (Fig. 4)? That the 
Abeti study was able to rescue the FRDA model mouse from its toxic 
oxidative pathophysiology not by correcting the upstream energy imbalance 
at the mitochondrial respiratory chain, but simply by preventing lipid 
peroxidation and activating antioxidant pathways within the mitochondria, 
offers some hope that therapeutic measures in FRDA need not necessarily 
address the ISC deficit directly (Abeti et al., 2015).  Resolving these 
questions will be crucial for determining which of the multiple physiological 
pathways involved in FRDA is of most direct relevance to the clinical 
presentation of the disease, and therefore to an eventual disease therapy.  
 
 
Figure 4: Potential pathway for FRDA pathophysiology. 
A ‘vicious cycle hypothesis’, in which frataxin depletion leads to cell dysfunction and death 
through a pathophysiology rooted in iron overload, oxidative stress and/or ISC loss. For 
example, frataxin deficiency has been shown to lead to ISC deficiency, which usually 
precedes a mitochondrial iron overload. The iron overload leads to increased production of 
free radicals such as superoxide and hydrogen peroxide, which in turn affects ISC levels 
and ISC-containing proteins involved in mitochondrial function, leading to cellular 
dysfunction and death. Deficiency of antioxidant defences are also directly caused by loss 
of frataxin leading to a hypersensitivity to ROS of ISCs (which may itself also be directly 
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caused by frataxin deficiency). This again leads to mitochondrial iron accumulation and 
cellular dysfunction. It is important to note that all of these pathophysiological elements are 
interrelated, and likely to be at play in FRDA. However, one particular element of the 
pathway may be more responsible for the FRDA phenotype, and thus more therapeutically 
relevant.  
 
 
1.4.3 Ca2+ Signalling and Oxidative Stress in 
Cardiomyocytes  
 
Ca2+ Studies in FRDA: introduction and future 
The established oxidative stress in FRDA has been associated with 
increased mitophagy, impaired cytoskeletal dynamics and mitochondrial 
transport, abnormal lipid metabolism, and abnormal Ca2+ homeostasis 
(Gonzalez-Cabo & Palau, 2013). In studies of disorders other than FRDA, 
iron-induced oxidative stress has very often been associated with altered 
Ca2+ homeostasis. In particular, it has been associated with reduced peak 
systolic Ca2+ levels, slowed rates of Ca2+ relaxation and elevated diastolic 
Ca2+ levels in diseases such as hereditary haemolytic anaemia and other 
iron-overload conditions (Oudit et al., 2006; Schwartz et al., 2002). These 
can lead to arrhythmias and sudden death, both of which have also been 
found to occur in FRDA.  
 
Although Ca2+ homeostasis has been very rarely observed in FRDA studies, 
those that have been performed do indicate an altered Ca2+ homeostasis in 
DRG neurons (Mincheva-Tasheva et al., 2014; Molla et al., 2017). The 
study by the Palau group in particular discovered dysfunctional 
mitochondria within axonal spheroids in frataxin-deficient sensory neurons 
of the DRG from the YG8R mouse models, and indicated that these axonal 
spheroids may be a direct consequence of Ca2+ overload, alongside 
oxidative stress and mitochondrial depolarisation (Molla et al., 2017). These 
defects in Ca2+ levels and in mitochondrial function had previously been 
experimentally related to retrograde axonal transport failure alongside an 
abnormal distribution of distal mitochondria, leading to dying-back 
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neuropathy in a Drosophila melanogaster larvae model with reduced 
frataxin expression (Shidara & Hollenbeck, 2010).  
 
Frataxin overexpression in 3T3-L1 adipocytes increased mitochondrial 
buffer Ca2+ capacity, as well as mitochondrial bioenergetics (Ristow et al., 
2000). Conversely in an SH-SY5Y human neuroblastoma model 
incorporating stable frataxin silencing, mitochondrial buffer Ca2+ capacity 
was decreased, associated with mitochondrial dysfunction (Bolinches-
Amoros et al., 2014). A study of Ca2+ homeostasis in FRDA model 
cardiomyocytes, which have a different pathophysiology to neurons, has 
only been carried out extremely recently in the Giunti lab where I have 
produced this thesis, to which I contributed several novel findings which are 
elucidated and discussed alongside other experiments performed by other 
scientists from the lab in Chapter 4 of this thesis (Abeti et al, 2018). Given 
the known association between iron-induced oxidative stress and altered 
Ca2+ homeostasis, as well as the overlap in symptoms between FRDA and 
other iron-overload diseases, such studies could be of great benefit in 
unpicking the pathophysiological mechanism of FRDA in heart cells.  
 
Importance of the SR and RYR2 in Ca2+ Signalling and E-C Coupling 
In order to form a hypothesis regarding the effect of Ca2+ dysregulation in 
FRDA, we must first look at the fundamental role of Ca2+ signalling in 
excitation-contraction coupling in cardiomyocytes. Ca2+ homeostasis in 
cardiomyocytes is achieved through the integration of transsarcolemmal 
influx and efflux pathways. This homeostasis is modulated by membrane 
potential and by a system of intracellular Ca2+ uptake and release controlled 
chiefly by the sarcoplasmic reticulum (SR). The crucial importance of the 
SR as the dynamic Ca2+ store in cardiomyocytes, providing an essential 
source of Ca2+ signals to cardiac muscle, is universally accepted. In 
cardiomyocytes, Ca2+ influx mostly occurs through voltage-gated L-type 
Ca2+ channels. Once in the cell, the Ca2+ ions can then bind to the RYR2 
protein, the cardiac isoform of the ryanodine receptor that is found in the 
sarcoplasmic reticulum membrane. This binding in turn leads to the release 
of Ca2+ ions from the SR Ca2+ store through the RYR2 into the cytosol (Fig. 
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5). This process is known as Ca2+-induced Ca2+ release (CICR), where the 
presence of Ca2+ itself induces further Ca2+ release from SR stores (Ramay 
et al., 2010). The Ca2+ binds to the C domain of troponin, a complex of three 
proteins integral to muscle contraction in the heart. This shifts the 
tropomyosin protein to allow the myosin ATPase to bind to actin, and 
thereby cause cardiac muscle contraction (Berridge et al., 2003; Bootman 
et al., 2001).  
 
 
Figure 5. Ca2+ Signalling in Cardiomyocytes. 
After an action potential depolarizes the cell membrane, the voltage-gated L-type channels 
are activated. The resulting Ca2+ influx activates the RYR2 on the SR membrane, leading 
to CICR. This in turn results in a Ca2+ spark that initiates muscle contraction and gene 
transcription. The role of the mitochondria as a Ca2+ store, and the SR Ca2+ ATPase 
(SERCA) and Na+-Ca2+ exchanger (NCX) as Ca2+ transporters, is also visualised. Figure 
from Berridge et al., 2003. 
 
SR-mitochondria microdomains and ROS regulation 
In cardiac myocytes, the RYR2 proteins on the SR form regular 
microdomains with mitochondria. Within these microdomains, the 
mitochondria and SR can sustain local interorganellar Ca2+ communication 
(Csordas et al., 2006; Garcia-Perez et al., 2008). As mitochondria are one 
of the major sources of intracellular ROS production, mitochondria-derived 
ROS could regulate Ca2+ spark activity in intact cardiac myocytes. It has 
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been shown that mitochondrial ROS exerts bidirectional regulation of Ca2+ 
sparks in a dose- and time-dependent manner (Yan et al., 2008).   
 
Oxidation-sensitive residues in receptors relevant to Ca2+ Signalling 
Both the SR Ca2+ ATPase (SERCA) pump, which pumps Ca2+ into the SR 
at the expense of ATP, and the ryanodine receptors contain many free 
cysteine (Cys) residues that are sensitive to oxidation. For example, studies 
on rabbit cardiac and skeletal muscle first indicated that hydroxyl radicals 
bind to residues of the SERCA pump within the active site of the enzyme 
(Xu et al., 1997). From this it was later found that Cys674 appears to play a 
key and dual role in the oxidative regulation of the SERCA. Mild oxidative 
conditions lead to S-glutathionylation of Cys674 and increases pump 
activity. Extensive or extended exposure to oxidative stress leads to 
oxidation of other Cys residues and sulphonylation of Cys674, irreversibly 
inhibiting the pump (Adachi et al., 2004; Sharov et al., 2006). As the RyRs 
contain many free Cys residues, it has proved difficult to identify a specific 
target residue on which oxidative stress acts. However, S-glutathionylation 
and S-nitrosylation are two oxidative mechanisms that have been proposed 
as relevant to RYR2 regulation. In addition, it has been shown that oxidative 
stress leads to disulphide bonds forming between adjacent subunits in the 
RYR2, potentiating its activity (Zima & Mazurek, 2016). Thus, in the case of 
both the SERCA and the ryanodine receptor, distinct functional changes 
brought about by mild or severe oxidative stress illustrate that ROS can be 
either a signalling event or a harmful stress condition depending on the 
amount present. 
 
Effects of iron-induced Oxidative Stress in Cardiomyocytes 
For the purposes of my study, the possible effects on Ca2+ homeostasis 
through the oxidative stress generated by iron overload in cardiomyocytes 
is of special interest. As previously mentioned, iron-induced oxidative stress 
in the heart and its effects are associated with hereditary haemolytic 
anaemia and other iron-overload conditions. Oxidative damage has also 
been shown to affect the electrical and contractile properties of 
cardiomyocytes through several key regulators of excitation-contraction 
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coupling that are highly sensitive to changes in the cellular redox state. 
These are specifically:  
1. An increase in sarcoplasmic reticulum Ca2+ leak through the cardiac 
ryanodine receptors in SR vesicles isolated from canine cardiac 
heavy muscle (Kawakami & Okabe, 1998) and rat ventricular 
cardiomyocytes (Cherednichenko et al., 2004). 
2. Inhibition of activity of the SERCA pump in isolated SR vesicles from 
rabbit cardiac and skeletal muscle (Xu et al., 1997) and guinea pig 
ventricular cardiomyocytes (Goldhaber & Qayyum, 2000).  
3. A reduction of L-type Ca2+ channel current in guinea pig ventricular 
cardiomyocytes (Lacampagne et al., 1995), a finding corroborated in 
mouse cerebral cortical neurons (Shirotani et al., 2001). 
 
 
 
 
 
1.4.4 Cellular and Animal Models of FRDA 
 
In the 20-year span since the link between FRDA and the FXN gene 
mutation was identified, a variety of FRDA models have led to 
advancements in the understanding of frataxin protein function, FRDA 
pathophysiology and mechanisms of gene silencing and instability. Due to 
its high evolutionary conservation, the effect of frataxin has been modeled 
in a variety of organisms, including yeast (Babcock et al., 1997; Foury & 
Cazzalini, 1997), Caenorhabditis elegans (Vazquez-Manrique et al., 2006; 
Ventura et al., 2006; Zarse et al., 2007), Drosophila melanogaster 
(Anderson et al., 2008; Llorens et al., 2007) and mice (Al-Mahdawi et al., 
2006; Miranda et al., 2002; Puccio et al., 2001). These models have 
confirmed mitochondrial dysfunction with iron accumulation and 
hypersensitivity to oxidative stress as relevant factors in FRDA.  
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The difficulty of replicating the triplet repeat nature of the common FXN 
mutation poses a problem in modeling FRDA in cell and animal models. As 
FRDA has a complex clinical phenotype and several species-specific 
disease pathways, mouse or other mammalian-based cell models are better 
suited to answering pathophysiological questions. Thus far, the generation 
of conditional and, increasingly, GAA-based mouse models have been 
more rewarding than the design of stable cellular models using cell types 
relevant to the disease, despite the limitations inherent to each model. Both 
methods remain however of great interest for understanding FRDA 
pathophysiology (Al-Mahdawi et al., 2006; Miranda et al., 2002; Puccio et 
al., 2001). Much current work in FRDA is focused on producing superior 
mouse models that accurately reproduce the partial frataxin deficiency to 
better model individual FRDA patients. This is usually done by introducing 
GAA expansion-containing constructs in either mouse or cellular models, or 
increasingly by the use of induced pluripotent stem cell (iPSC)-derived cells. 
 
 
Conditional and GAA-based mouse models of FRDA 
The first working FRDA mouse models were conditional knockout models, 
which reproduced the disease pathophysiology in the heart and nervous 
system and allowed for the testing of a variety of therapeutic approaches. 
These models produced a conditional ablation of the mouse Fxn gene by 
using the Cre-loxP recombination system for deletion of Fxn exon 4 from a 
conditional floxed allele (FxnL3) using tissue-specific (and sometimes 
inducible) Cre mouse lines. These lines include the cardiac-specific model 
MCK-Cre (Puccio et al., 2001), the neuronal model NSE-Cre (Puccio et al., 
2001), and the neuronal model Prp-CreERT (Simon et al., 2004), which had 
a complete absence of the frataxin protein only in their respective target 
tissues. 
 
GAA-based mouse models of FRDA instead incorporate a knock-in of a 
human FXN GAA expansion mutation into a mouse in which the native Fxn 
gene has been fully ablated. This means expression of frataxin is entirely 
dependent on the knock-in human gene and brings about a low level of 
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structurally normal frataxin protein in affected tissues that mimicks FRDA. 
These GAA-based models, generated both by the Pook lab (Al-Mahdawi et 
al., 2006) and the Pandolfo lab (Miranda et al., 2002), are more reliable 
mimics of the human disease than the previously produced conditional 
knockout models. This is because the progressive disease found in patients 
is the result of constant atypically low levels of frataxin, rather than the 
sudden, total tissue-specific frataxin deficit that occurs with the conditional 
knockout approach. The GAA-based model is also preferable as GAA 
expansions themselves could be a contributing factor in disease 
development. For example, the intrinsic somatic instability of long GAA 
tracts indicates they may have a role in the tissue specificity of FRDA. This 
model also allows for studies looking at how to increase transcription of the 
FXN gene. However, the phenotype of these animals is less severe than in 
the conditional knockout model. The models can also help to elucidate 
molecular and cellular mechanisms associated with GAA-mediated 
silencing of the FXN gene in vivo, as well as being crucial for the therapeutic 
evaluation of drugs that attempt to target this process precisely. However, 
generation of adequate GAA-based models that reproduce the FRDA 
phenotype is experimentally difficult for several reasons. These include the 
difficulty in generating a GAA expansion lengthy enough to cause 
pathogenesis, and also identifying the locus for genomic integration. The 
intrinsic instability of GAA tracts also leads to unaccounted contraction or 
elongation of the expansion.  
Two major GAA-based mouse models have thus far been developed: 
 
1. The KIKI/KIKO mouse model, obtained via a knock-in approach 
based on homologous recombination. 
2. The YG8R mouse model, obtained via a human genomic yeast 
artificial chromosome (YAC) transgenic approach.  
 
KIKI/KIKO 
The knock-in (KIKI) mouse incorporates a homozygous 230 GAA-repeat 
expansion knock-in in both alleles and shows a 25% decrease in frataxin 
expression. The knock-in-knockout (KIKO) mouse is compound 
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heterozygous, with one allele fully deleted for frataxin: this model expresses 
25 to 35% of wild-type mouse frataxin levels, which accurately reflects 
pathological levels in human patients (Miranda et al., 2002). However, no 
pathological phenotype was evident in the KIKO mice, despite some minor 
motor deficits upon rotarod testing and gait analysis. This suggests that 
despite the low frataxin levels, the transcriptional frataxin decrease does not 
reach the required threshold to induce FRDA. Despite this, transcriptome 
analysis of KIKI and KIKO mice showed transcriptional modifications that 
are significantly different from control mice (Coppola et al., 2009).  
 
YG8R 
Between the years 2001 and 2004, the Pook lab developed a new mouse 
model for improved replication of the FRDA phenotype. The human 
genomic YAC FRDA transgenic mice integrate the human FXN locus and 
its regulatory elements, inserted into the murine genome via a 370kb YAC 
on a genetic background in which the murine Fxn gene has been completely 
deleted. These unstable GAA-repeat expansions rescue the embryonic 
lethality of the Fxn knockout through expression of only human frataxin. Two 
pathological models have been developed, YG22 and YG8, which contain 
GAA190 and GAA190+90 respectively (Al-Mahdawi et al., 2006). The rescued 
YG8 mice, referred to as YG8R mice, display lower levels of human frataxin 
mRNA and frataxin protein, as well as mild motor coordination deficits, a 
progressive decrease in locomotor activity and increased weight. They also 
show large neurodegeneration vacuoles in the DRG and decreased 
aconitase activity in the cerebellum (Al-Mahdawi et al., 2006), reminiscent 
of features also found in the NSE-Cre and Prp-CreERT conditional FRDA 
mouse models (Puccio et al., 2001; Simon et al., 2004).  
 
Although no severe heart dysfunction is seen in YG8R mice, studies of heart 
tissue revealed decreased aconitase activity, mitochondrial iron 
accumulation and evidence of lipid peroxidation indicative of ROS damage. 
They also revealed a non-significant reduction in the activities of 
mitochondrial respiratory chain complexes I, II and III. There are increased 
biomarkers of oxidative stress in brain, cerebellum and heart cells, 
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displayed through increased levels of oxidized proteins via oxyblot analysis, 
as well as through increased levels of malondialdehyde, a marker of lipid 
peroxidation (Al-Mahdawi et al., 2006). More recently, Abeti et al discovered 
that cerebellar granule neuronal cells from the YG8R mouse model have a 
mitochondrial energy imbalance between respiratory chain complexes I and 
II, leading to free radical production causing lipid peroxidation, glutathione 
depletion and cell death (Abeti et al., 2016), and that could be rescued with 
activation of mitochondrial antioxidant pathways and blocking lipid 
peroxidation (Abeti et al., 2015). This model has also proved very useful in 
studies into the instability of the GAA repeat in FRDA, as it reproduces the 
age-related somatic instability (particularly in the cerebellum) and 
intergenerational instability characteristic of the disease. 
 
 
Conclusion on GAA-based models 
Both the KIKI/KIKO and YG8R mice have proved extremely useful in studies 
into the mechanisms of GAA-mediated silencing and, in the case of YG8R, 
GAA somatic instability. The status of the YG8R model in particular as a 
good representation of FRDA was strengthened by further studies showing 
a similar epigenetic profile of DNA methylation in the brain, cerebellum and 
heart to patients with the disease (Al-Mahdawi et al., 2008), as well as an 
initial pathophysiological profile further developed by newer studies (Abeti 
et al., 2016; Abeti et al., 2015). Mouse models are currently being created 
with a larger GAA expansion size within the human FXN transgene in order 
to produce a more severe phenotype and more accurately mimic FRDA. To 
this end, bacterial artificial chromosomes (BACs) with the ability to 
incorporate the entire FXN locus with larger GAA expansions are being 
generated. These novel constructs will be valuable in further FRDA 
research. 
 
Mouse Models Summary/Future 
Many aspects of molecular FRDA pathophysiology remain to be addressed 
in molecular and cellular level studies using the different mouse models 
generated. For example, experiments on the YG8R FRDA mouse models 
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have shown that autophagy is certainly involved in the neurodegeneration 
of the large sensory neurons of the DRG, although the molecular and 
cellular mechanisms remain unknown (Al-Mahdawi et al., 2006; Simon et 
al., 2004). Increased autophagy has also been observed in the SH-SY5Y 
human neuroblastoma cell model silenced for frataxin, and proposed as a 
defence mechanism against oxidative stress (Bolinches-Amoros et al., 
2014). Although the role of oxidative stress in pathology remains poorly 
understood, iron dysregulation is commonly observed in FRDA, usually 
through mitochondrial iron accumulation (Koeppen et al., 2007; Lamarche 
et al., 1980; Michael et al., 2006). Indeed, iron chelators are considered as 
potential therapeutic agents in FRDA (Richardson, 2003), and deferiprone 
is currently being tested in clinical trials. Mouse model-based FRDA studies 
will continue to be crucial in understanding the precise molecular 
mechanisms in the disease pathophysiology, as well as to assess potential 
therapeutic agents. They may also be crucial for understanding the long-
term outcome in FRDA heart disease via in vivo and in vitro studies, and for 
developing therapies which ameliorate this aspect of the multisystem 
disorder. 
 
Cellular models of FRDA 
Cell culture models that replicate FRDA accurately are of crucial importance 
in further elucidating the molecular mechanisms of FRDA, as well as for use 
in novel therapeutic studies. The majority of cell culture-based studies into 
FRDA pathogenesis used patient-specific immortalized lymphoblasts, 
primary fibroblasts or peripheral lymphocytes, and these cell lines are still 
used in FRDA studies. These patient-derived cells reproduced several 
molecular features of FRDA, such as the epigenetic silencing of FXN 
expression. However, they develop none of the phenotypic characteristics 
of FRDA (Rotig et al., 1997; Sturm et al., 2005). A variety of cell lines (such 
as fibroblasts, neuronal cell lines and Schwann cells) have undergone 
siRNA- or shRNA-mediated silencing in order to reduce frataxin expression 
and attempt to generate a disease model with more relevant features (Lu et 
al., 2009; Napoli et al., 2007; Santos et al., 2001; Stehling et al., 2004; 
Zanella et al., 2008). However, these cell models have shown an 
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excessively variable phenotype in studies, most likely due to the variable 
efficiency of frataxin knockdown, ranging from almost complete knockout of 
frataxin expression to about 40% of normal frataxin levels. Thus, there is 
still a requirement for stable, disease-relevant cellular models in FRDA 
studies. 
 
Two other strategies have also been developed in recent years to develop 
new FRDA cellular models: 
 
1. Using murine fibroblasts to express a transgenic human frataxin 
gene incorporating various point mutations previously identified in 
compound heterozygous patients (G130V, I154F or N146K), prior to 
the deletion of endogenous Fxn (Calmels et al., 2009; Schmucker et 
al., 2011). 
2. Generation of iPSCs from FRDA patient fibroblasts using newly 
developed techniques (Ku et al., 2010; Liu et al., 2011; Wu & 
Hochedlinger, 2011). 
 
 
 
 
 
1.5 Clinical Features 
 
EFACTS 
The European Friedreich’s Ataxia Consortium for Translational Studies 
(EFACTS) was founded in 2010 in order to form a single expert body in 
clinical neurology, biochemistry, molecular biology, genetics and 
bioinformatics for a more translational approach to the study of FRDA. A 
large, pan-European patient cohort with genetically confirmed FRDA was 
recruited. Their presentation and progression are recorded, forming a 
patient registry linked to a database of biological samples collected during 
study, which can be used in therapeutic trials and research studies. The 
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EFACTS program thus has the potential to increase our understanding of 
the clinical features of FRDA, and their relation to FRDA genetics (Reetz et 
al., 2015, 2016). 
 
1.5.1 Early Onset Friedreich’s Ataxia 
 
Harding found that under 20% of FRDA patients developed symptoms prior 
to the age of 5, and such cases are now clinically classified as early onset 
Freidreich’s ataxia (Harding, 1981). This minority of patients have a 
phenotype that is more severe and rapidly progressive than in classical 
FRDA and also involves a greater risk of cardiac symptoms, pes cavus and 
scoliosis. It is characterized by defective development instead of the 
degenerative phenotype associated with classical and late-onset FRDA: the 
patients are often undersized, with short limbs (Harding, 1981). Early onset 
Freidreich’s ataxia patients are associated with a larger GAA1 expansion 
(Durr et al., 1996; Schols et al., 1997). Specifically, patients in the Durr study 
with over 780 GAA1 repeats had an average age at onset of 9.7 years, 
compared with a mean age at onset of 22.5 years in patients with a GAA1 
expansion of fewer than 520 repeats (Durr et al., 1996). Compound 
heterozygosity with exonic deletions has also been shown to cause an 
earlier onset and more severe form of FRDA, although the rarity of this 
genetic form of FRDA in the literature currently suggests that it has little 
impact on the clinical picture of early onset FRDA (see section 1.6.2, 
Chapter 1). 
 
1.5.2 Classical Friedreich’s Ataxia 
 
 
Neurological Features 
 
Age at Onset 
The typical age at onset of FRDA is around the beginning of puberty, 
between the ages of 10 and 16. Three major early case series testing mean 
age at onset gave a mean of 10.57.4 years (Harding, 1981), 11.64.5 
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years (Filla et al., 1990) and of 15.58 years of age (Durr et al., 1996).  The 
modal age at onset is 10-12 years in one study (Harding, 1981) and 12-15 
years in another (Filla et al., 1990). However, as the age at symptom onset 
is studied retrospectively, there is a possibility of inaccurate recall. Also, in 
case studies preceding the discovery of the genetic basis for FRDA, the 
clinical criteria were skewed toward an average age of onset that was earlier 
than the actual age, as many atypical FRDA cases were not included in the 
studies. In the largest case series so far, 592 EFACTS patients were tested 
giving a mean age at onset of 15.710.4 years of age (Reetz et al., 2015).  
Earlier onset cases tend to have a faster disease progression and display a 
higher frequency of non-neurological disease features such as 
cardiomyopathy and pes cavus.  
 
Symptom Introduction 
FRDA is a neurodegenerative disease characterized by slow, relentlessly 
progressive spinocerebellar and sensory ataxia. The classical phenotype 
regularly involves gait and limb ataxia, poor coordination and balance, leg 
weakness, sensory loss, areflexia, dysarthria, dysphagia, eye movement 
abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes. 
The most frequent presenting symptoms of FRDA are gait ataxia and 
clumsiness (Delatycki et al., 1999; Durr et al., 1996; Filla et al., 1990; 
Harding, 1981). A small number of patients also present with scoliosis 
alongside additional neurological features. FRDA is commonly confirmed by 
presence of pyramidal signs, muscular weakness, positive extensor plantar 
response and an absence of deep tendon reflexes (Harding, 1981; Pandolfo 
& Pastore, 2009). Gait and limb ataxia, dysarthria and lower limb areflexia 
are found in practically all cases, although their frequency may have been 
overestimated in early FRDA case series as they were required clinical 
features in diagnostic criteria before the discovery of the genetic basis of 
FRDA. It is important to clinically differentiate FRDA from other neurological 
disorders that are also characterized by early onset cerebellar ataxia and 
the presence of neuropathy in combination with non-neurological features 
such as spasticity. These similar disorders include ataxia with vitamin E 
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deficiency, ataxia with oculomotor apraxia types 1 and 2, ataxia with 
coenzyme Q10 deficiency and late-onset Tay-Sachs disease. (Delatycki & 
Corben, 2012; Schulz et al., 2009). 
 
Gait & Limb ataxia 
Patients classically present with an unsteady gait, and have typically lost 
the ability to stand or walk due to loss of motor skills an average of 15.5 
years after age at onset, ranging between 3 and 44 years (Harding, 1981). 
Patients also usually display truncal ataxia that causes swaying while sitting, 
and a positive Romberg’s test. This requires progressively increasing levels 
of support, and most patients require a wheelchair within 10 to 15 years 
after disease onset (Durr et al., 1996; Harding, 1981; Schols et al., 1997). 
Distal upper limb wasting and loss of vibrational and joint position sense 
was usually present by 45 to 50 years after onset (Harding, 1981), and the 
mean age at onset of upper limb ataxia was of 19.8 years of age. (Schols 
et al., 1997). Limb ataxia leads to increasing difficulties with daily activities 
involving dexterity and coordination. 
 
Pyramidal weakness/Muscle weakness 
Pyramidal weakness is usually a relatively late sign in FRDA, present in the 
lower limbs by 25 to 30 years after onset (Harding, 1981). An underlying 
pyramidal pathology is however already present early in FRDA due to the 
frequency of extensor plantars as a sign. Upper limb strength is better 
maintained, with only mild distal upper limb weakness which can however 
affect fine manual dexterity. Distal muscle wasting is seen as a late sign in 
a significant amount of cases, although this issue does not apply to early-
onset cases where muscle bulk may never establish itself in the first place 
(Durr et al., 1996; Filla et al., 1990; Harding, 1981). 
 
Areflexia 
Areflexia, especially in the lower limbs, is an early and extremely frequent 
FRDA sign in patients and is a reflection of the underlying peripheral 
neuropathy. Extensor plantar reactions are an early sign of FRDA present 
in between 73% and 89% of cases (Delatycki et al., 1999; Durr et al., 1996; 
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Harding, 1981). Muscle tone in the early stages is however usually normal 
or only slightly reduced. In more advanced stages when patients are 
wheelchair-bound, spasticity of the lower limbs can manifest, which can lead 
to muscle spasms and contractures. One study however used 
biomechanical methods to detect spasticity of the lower limbs in patients 
with disease durations of under 10 years, demonstrating once again the 
wide phenotypic range of FRDA (Milne et al., 2016). 
 
Dysarthria 
Dysarthria is a frequent sign of FRDA that is already present in many 
patients at onset and progresses during the course of disease, with over 
90% of patients developing it at some stage. A study of 38 FRDA patients 
showed that 68% had mild dysarthria characterized by consonant 
imprecision, decreased pitch variation and impaired loudness maintenance 
(Folker et al., 2010). The mean age at onset of dysarthria was calculated at 
20.8 years in one study, 6.6 years after the average age at onset (Schols et 
al., 1997), and all patients in another study developed dysarthria 10 to 15 
after age at onset (Harding, 1981). Speech progressively becomes slower 
and more slurred, and intelligibility is impaired in severe or advanced cases.  
 
Dysphagia 
Mild dysphagia is also a common symptom of FRDA, and can become a 
serious clinical issue in later stages of the disease, where specific diets or 
even nasogastric feeding or gastrostomy may be required (Durr et al., 
1996). Various case series give the frequency of dysphagia at between 27% 
and 74% (Durr et al., 1996; Filla et al., 1990; Schols et al., 1997).   
 
Sensory neuropathy  
Neurophysiological studies on the neuropathy in FRDA have shown 
severely reduced or even absent sensory action potentials that do not seem 
to change significantly over time. Peripheral nerve biopsies in FRDA 
patients have also shown an increase in the proportion of large myelinated 
fibres, which may be a compensatory mechanism against inefficient 
myelination. The severity of both of the above findings correlates with GAA 
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expansion size (Santoro et al., 1999). Thus, the sensory neuropathy present 
in FRDA is currently understood as a combination of inefficient myelination 
and slowly progressive axonopathy (Koeppen & Mazurkiewicz, 2013; Morral 
et al., 2010). 
 
Saccades/Nystagmus 
Oculomotor abnormalities, or abnormal eye movements, are a common 
early feature of FRDA. Fixation instability interrupted by frequent involuntary 
saccades (or ‘square wave jerks’) is the most usual sign. These jerks can 
occur in horizontal or vertical fixation (Fahey et al., 2008; Furman et al., 
1983; Schols et al., 1997) and can also interrupt smooth pursuit movements 
and block the assessment of nystagmus, which is less frequent but also 
observed. It commonly presents as a horizontal gaze-evoked nystagmus on 
lateral gaze, and less usually on vertical gaze (Durr et al., 1996; Harding, 
1981; Schols et al., 1997).  
 
Decreased visual acuity 
Decreased visual acuity is rarer in FRDA than eye movement abnormalities, 
although around two-thirds of patients show a clinical or subclinical optic 
neuropathy on assessment. Around 20% of patients have decreased acuity 
that progressively declines (Durr et al., 1996; Fahey et al., 2008; Geoffroy 
et al., 1976; Harding, 1981). Conversely, a small subpopulation of patients 
experiences acute bilateral vision loss (Fortuna et al., 2009). All FRDA 
patients show lowered retinal nerve fibre layer thickness in optical 
coherence tomography (OCT) scans, and pattern visual-evoked potentials 
show increased latency in 34% to 70% of patients (Carroll et al., 1980; Durr 
et al., 1996; Fortuna et al., 2009). These findings taken together indicate 
that, although few patients are clinically affected, the whole visual system is 
in some way affected in FRDA. 
 
Hearing Difficulties 
Hearing difficulties are due to auditory neuropathy caused by faulty central 
auditory processing. They are a frequent issue which carry severe social 
impacts, as the temporal distortion of stimuli can worsen verbal 
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communication problems (Rance et al., 2010). Hearing loss in several 
studies is measured at between 8% to 39% (Durr et al., 1996; Geoffroy et 
al., 1976; Harding, 1981; Schols et al., 1997).  In the Harding study, hearing 
loss was adjudged to be mild in 5.2% of cases, moderate in 1.7% of cases 
and severe in 0.9% of cases. 
 
Sphincter Disturbance/Bowel problems 
Urinary urgency is increased, with 80% of patients showing lower urinary 
tract symptoms (Lad et al., 2017). Late onset FRDA patients report these 
symptoms more often, most likely due to longer disease duration. The 
increased bladder activity may also indicate pyramidal pathology. Although 
disturbance of the sphincter is poorly studied in FRDA, its prevalence has 
been shown to range between 7% and 41% in several case series 
(Andermann et al., 1976; Delatycki et al., 1999; Durr et al., 1996; Filla et al., 
1990; Schols et al., 1997). Bowel problems such as constipation or 
incontinence have also been observed in 64% of FRDA patients (Lad et al., 
2017) and may be related to FRDA corticospinal pathology. 
 
 
Non-Neurological Features 
 
The primary non-neurological features of FRDA are hypertrophic 
cardiomyopathy, increased incidence of diabetes and scoliosis. There is 
evidence of cardiac abnormalities in virtually all FRDA cases upon diagnosis 
to a variable degree, even if the patient does not display cardiac symptoms 
(Durr et al., 1996; Harding, 1981; Malo et al., 1976). Cardiac hypertrophy 
affects both ventricles, particularly the left, involving focal necrosis and 
diffuse fibrosis (Hewer, 1969). Systole is usually relatively unaffected until 
shortly before death (Rajagopalan et al., 2010). Overt symptoms of heart 
failure are not common in FRDA: blood pressure and hypertension tend to 
be normal. Ischaemic heart disease also occurs very rarely in FRDA.  
However, in advanced FRDA, arrhythmias are sometimes reported which 
can affect systolic function leading to clinical heart failure, which is 
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responsible for over half the deaths of FRDA patients (Hanley et al., 2010; 
Tsou et al., 2011).  
 
It is very rare for cardiac symptoms to develop before the neurological ones, 
although when they do heart transplantation can precede FRDA diagnosis 
(Leonard & Forsyth, 2001). Even in cases where a patient is initially referred 
to a cardiologist, on detailed examination neurological features are found 
that almost always precede the cardiological ones. An absence of any 
correlation between the severity of the neurological features and cardiac 
involvement in FRDA has also been reported, which may relate to the 
tissue-specific somatic instability and mosaicism of the GAA expansion 
observed in the disease (Weidemann et al., 2012). At least probable cardiac 
dysfunction accounted for 62% of the deaths in the largest study to date on 
FRDA mortality, a retrospective study of the clinical notes of 61 deceased 
FRDA patients. The mean age of death was 36.5 years (range between 12 
and 87 years). Of the deaths caused by cardiac issues, most were due to 
congestive cardiac failure or arrhythmia (Tsou et al., 2011). Neuropathology 
has traditionally been the focus of FRDA clinical research, with over ten 
times as many publications on this subject compared with on cardiological 
issues. FRDA cardiopathology is however emerging as an important field in 
FRDA study, particularly as it is the primary cause of death among FRDA 
patients (Hanley et al., 2010). 
 
Symptoms Summary and Proposed Therapies 
The cardiopathology is characterized by a slow progression of left 
ventricular hypertrophy (LVH) as well as an increase in left ventricular 
dilatation. There is reduction in contractile sarcomeres, as well as the 
proliferation of mitochondria that contain electron-dense particles possibly 
indicating mitochondrial iron deposition (Michael et al., 2006). This finding 
is also corroborated in the heart of the FRDA MCK Cre-lox conditional KO 
mouse model (see Mouse Models section; Puccio et al., 2001). In the large 
case series studies that have been carried out so far, evidence of 
hypertrophic cardiomyopathy or LVH was found in 28% to 100% of cases 
although the definitions of these conditions varied between the studies 
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(Ackroyd et al., 1984; Delatycki et al., 1999; Durr et al., 1996; Filla et al., 
1990; Geoffroy et al., 1976; McCabe et al., 2000; Schols et al., 1997). 
Significantly less myocardial energy generation in FRDA patients has been 
shown compared to controls, with the degree of energy reduction correlating 
with the degree of hypertrophy (Bunse et al., 2003). Idebenone, an 
antioxidant and coenzyme Q mimetic, has been used as a therapeutic 
strategy against this myocardial energy deficiency due to both its 
antioxidant properties and its ability to enhance electron transport within the 
mitochondria (Mariotti et al., 2003; Rustin et al., 2002). However, when 
carried out over a period longer than a year, idebenone therapeutic studies 
show no decrease in arrhythmias or disease progression, despite an 
apparent decrease in the visible hypertrophy (Pineda et al., 2008; Velasco-
Sanchez et al., 2011). Antioxidant therapies have also not improved FRDA 
cardiac symptoms thus far, although extending the half-life of antioxidant 
agents may improve their therapeutic potential (Lynch et al., 2010).  
 
Echocardiogram 
Echocardiographic studies are very useful for evaluation of ventricular wall 
function and thickness over time. Abnormalities in the cardiac wall are 
present in a majority of FRDA patients, though these are often 
symptomless. The ventricles show retained systolic function and impaired 
diastolic filling, with 84% of 173 FRDA patients showing signs of diastolic 
dysfunction in one study (Dutka et al., 2000; Palagi et al., 1988). However, 
impaired systolic function alongside a relatively unaffected ejection fraction 
is instead observed early in disease progression (Kipps et al., 2009; Regner 
et al., 2012). A recent study showed FRDA patients dividing distinctly over 
a 10-year period into one group with slowly declining, normal ejection 
fraction, and another with a much sharper progressive decline (Pousset et 
al., 2015). The rate of ejection fraction decline is shown to be correlated with 
the size of the GAA1 repeat, although not with the hypertrophy itself (Dutka 
et al., 1999). Echocardiogram studies have generally been confirmed by 
cardiac MRI studies, which have also evidenced an increased left 
ventricular mass in FRDA that is greater in cases with a longer GAA 
expansion (Meyer et al., 2007; Rajagopalan et al., 2010; Weidemann et al., 
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2012). A tendency towards left ventricular thinning due to dilation has also 
been observed in cases with longer disease duration, which may give the 
false indication that the ventricular defects have improved (Rajagopalan et 
al., 2010). 
 
Electrocardiogram 
Subtle electrocardiographic findings revealing repolarization abnormalities 
are often among the first signs of cardiomyopathy. The electrocardiogram 
(ECG) is abnormal in almost all FRDA cases, with the most typically 
observed anomaly being an inferolateral or widespread T-wave inversion. 
Other non-specific ST segment and T-wave abnormalities are also seen 
(Dutka et al., 1999; Schadt et al., 2012). Sinus rhythm and sinus tachycardia 
are also regularly found, and patients are troubled with paroxysmal or 
sustained arrhythmias in advanced FRDA, particularly atrial fibrillation 
which can become palpitations. However, patients rarely need insertion of 
a pacemaker or a defibrillator (Bourke & Keane, 2011). Evidence of LVH is 
only infrequently seen, and usually ECGs need to be combined with 
echocardiographic evidence as alone they are insufficient for FRDA 
diagnosis. 
 
Diabetes 
An association between FRDA and diabetes mellitus was first confirmed in 
a study of a cohort of 50 patients almost 100 years after the original disease 
discovery (Hewer & Robinson, 1968; Thoren, 1962). In several case series, 
diabetes mellitus was found in between 1% and 32% of cases (Andermann 
et al., 1976; Delatycki et al., 1999; Durr et al., 1996; Filla et al., 1990; 
Harding, 1981; McCabe et al., 2000; Reetz et al., 2015; Schols et al., 1997). 
The mechanism of the pathology remains unclear, but has been proposed 
to be a combination of decreased insulin secretion due to pancreatic β-cell 
apoptosis, and also increased insulin resistance in peripheral tissues 
(Finocchiaro et al., 1988). Diabetes, like cardiomyopathy, is associated with 
a longer pathological GAA expansion in both alleles, making diabetes more 
frequent in younger-onset cases as well as in more advanced FRDA (Filla 
et al., 1996). It has been shown that asymptomatic heterozygous carriers of 
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the GAA expansion may have increased incidence of insulin resistance 
(Fantus et al., 1991; Hebinck et al., 2000).  
 
Scoliosis and Foot Abnormalities 
Musculoskeletal abnormalities such as scoliosis, pes cavus and talipes 
equinovarus are frequently observed in FRDA. Scoliosis often requires 
surgical correction in earlier onset cases, although in less severe cases of 
later onset it may be mild and not require surgery (Tsirikos & Smith, 2012). 
Scoliosis of more than 10 degrees was found in 100% of patients in one 
study. Case series observing foot abnormalities show an incidence of 55% 
to 90% of cases with foot deformities (Ackroyd et al., 1984; Delatycki et al., 
1999; Durr et al., 1996; Filla et al., 1990; Geoffroy et al., 1976; Harding, 
1981; McCabe et al., 2000; Schols et al., 1997). 
 
 
 
1.5.3 Late-Onset FRDA 
 
LOFA and Symptoms 
FRDA is typically classed as an early-onset disorder, and accounts for 75% 
of all ataxia patients who have an age at onset prior to 25 (Cossee et al., 
1997). The literature describes two main forms of atypical FRDA: (i) Late-
Onset (LOFA, defined as onset after 25) or Very Late-Onset Friedreich’s 
Ataxia (VLOFA, defined as onset after 40), and (ii) FRDA with retained 
reflexes or FARR (Coppola et al., 1999; Klockgether et al., 1996; Parkinson 
et al., 2013; Verma & Gupta, 2012). LOFA/VLOFA is phenotypically distinct 
from classical FRDA, with a milder phenotype, slower disease progression 
and a more variable set of symptoms, also as patients with a longer disease 
duration do not always progress in a slow, regular manner.  As with classical 
FRDA, the presenting features of LOFA in several case series are gait and 
limb ataxia (Bhidayasiri et al., 2005; Gellera et al., 1997). Contrary to 
classical FRDA, dysarthria develops later in the disease, although it is still 
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usually present. Pyramidal involvement is less understood in LOFA than in 
classical FRDA. Spasticity or retained reflexes are present in 30 to 40% of 
LOFA patients, although extensor plantar responses are present in 40 to 
100% of atypical cases (Bhidayasiri et al., 2005; Coppola et al., 1999; De 
Michele et al., 1994; Gellera et al., 1997; Klockgether et al., 1993; Martinez 
et al., 2017; Montermini et al., 1997; Ragno et al., 1997).  
 
In a recent study, a phenotypic and genotypic comparison between 44 
LOFA patients, 30 VLOFA patients and 180 classical FRDA patients was 
carried out. It showed a reduced frequency of symptoms such as dysarthria, 
abolished tendon reflexes, extensor plantar reflexes, weakness, 
amyotrophy, cerebellar atrophy, scoliosis, and cardiomyopathy in delayed-
onset FRDA patients compared to classical FRDA patients (Lecocq et al., 
2016).  Although little data has been collected on the presence of lower limb 
neuropathy in LOFA, one study showed that only 1 in 13 LOFA patients has 
an absence of any sensory neuropathy, which is invariably present in 
classical FRDA (Bhidayasiri et al., 2005). A further study showed 
abnormalities in peripheral sensory and motor conduction in 16 atypical 
FRDA cases, usually involving sensory axonal degenerative neuropathy 
(De Michele et al., 1994). 
 
VLOFA and Symptoms 
FRDA onset has been rarely observed after 50 years of age (Berciano et 
al., 2005; Galimanis et al., 2008). In VLOFA cases, spastic tetraparesis 
without marked ataxia is usually seen (Berciano et al., 2002; Labauge, 
2002; Lhatoo et al., 2001). These patients have been reported to display 
subtle sensory neuropathy (Berciano et al., 2005; Lhatoo et al., 2001). All 
of these cases may more easily be misdiagnosed than other FRDA cases. 
 
Non-neurological Symptoms in LOFA 
Non-neurological aspects of the disease, such as pes cavus, scoliosis, 
cardiomyopathy and diabetes are much less common in LOFA/VLOFA (De 
Michele et al., 1996; Durr et al., 1996; Gellera et al., 1997; Reetz et al., 
2015). Several studies have shown the presence of pes cavus to be 
 56 
between 33 and 45%, while scoliosis is milder and present in under 40% of 
cases (Bhidayasiri et al., 2005; Coppola et al., 1999; De Michele et al., 1994; 
Durr et al., 1996; Gellera et al., 1997; Klockgether et al., 1993; Ragno et al., 
1997; Schols et al., 1997). Two recent studies on the heart in over 350 
LOFA/VLOFA FRDA patients showed an absence of cardiomyopathy in up 
to 40% of patients: where it was present, there was a correlation of the 
severity of the cardiac abnormalities with the size of the GAA1 allele 
(Regner et al., 2012; Weidemann et al., 2012). ECG studies show an 
abnormal ECG in which the characteristics of T-wave inversion, left axis 
deviation and repolarization abnormalities resemble those found in classical 
FRDA. The findings from LOFA echocardiogram studies also show 
abnormal findings in the atypical FRDA range (Bhidayasiri et al., 2005; 
Coppola et al., 1999; De Michele et al., 1994; Durr et al., 1996; Gellera et 
al., 1997; Schols et al., 1997). Despite these findings, mortality in 
LOFA/VLOFA is less related to cardiac symptoms than in classical FRDA. 
 
Protein and mRNA Expression in LOFA/VLOFA Patients 
Measuring frataxin protein, gene dosage, and mRNA expression levels 
could pick up atypical FRDA cases that remain undiagnosed through 
genetic techniques. The mean residual frataxin levels, compared with 100% 
in controls, are 35.8% in classical FRDA and 65.6% in LOFA, with an 
evident correlation between frataxin protein levels and GAA repeat size and 
an inverse correlation between frataxin protein levels and age at onset 
(Sacca et al., 2011). The GAA expansion size has also been found to 
negatively correlate with age at disease onset in LOFA/VLOFA patients, 
with the GAA1 allele accounting for 62.9% of age at onset variation and the 
larger GAA allele accounting for 15.6% of the variation (Lecocq et al., 2016). 
Studies of frataxin mRNA levels in LOFA have also shown reduced levels, 
ranging between 20 and 50% of controls (Pianese et al., 2004; Sacca et al., 
2011). However, the same study also showed considerable overlap in 
frataxin protein and mRNA levels in FRDA between LOFA patients, controls 
and carriers. This indicates that frataxin protein and mRNA levels are not 
exclusive determinants of FRDA disease progression (Sacca et al., 2011).  
 
 57 
Conclusion 
FRDA patients have a distinct neurological and non-neurological 
phenotype, which varies between three established subtypes: early onset, 
classical and late onset FRDA. Early or late onset FRDA patients can now 
be clearly pinpointed by genetic and clinical analysis. Earlier disease onset 
is strongly associated with a more severe, quickly progressive, and 
developmental rather than degenerative phenotype. Late onset patients 
usually have a more benign phenotype and later age at onset, with a 
reduced frequency of symptoms such as dysarthria and areflexia. This is 
also true of non-neurological symptoms such as cardiomyopathy and 
diabetes, and this reduced severity has been linked to higher frataxin protein 
and mRNA levels in the cells of LOFA patients. From a consultant’s point of 
view, to only have an understanding of the classical diagnostic criteria of 
FRDA is to ignore or misidentify atypical cases that do not fulfil all the 
criteria.  
 
 
1.6 FRDA Compound Heterozygotes 
 
1.6.1 Compound Heterozygotes with Point 
Mutations 
 
 
The initial study of the genetic basis of Friedreich’s ataxia discovered that 
around 1-3% of patients show, instead of the more common homozygosity 
for the GAA expansion in the FXN gene, a compound heterozygosity for a 
point mutation in the FXN gene in combination with the pathological GAA 
expansion (Campuzano et al., 1996). Since then, over 40 different point 
mutations from loci in all five exons of the frataxin gene transcript have been 
discovered. Among these are missense mutations caused by base pair 
substitutions, null mutations caused by base pair substitutions in the start 
codon that cause faulty translational initiation, and nonsense insertions, 
deletions and indels that produce frameshift variants leading to premature 
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termination. Intronic variants have also been discovered at all of the four 
splice-sites. No cases of homozygosity for FXN point mutations have yet 
been discovered (Campuzano et al., 1996; Cossee et al., 1999; Gellera et 
al., 2007).  
 
Studies on Point Mutations 
The first three FXN point mutations were discovered alongside the FXN 
GAA expansion, and included one missense (p. I154F), one nonsense (p. 
L106X), and one splice-site (g. IVS3-2A>G) mutation (Campuzano et al., 
1996). The most common point mutation, p.G130V, was discovered soon 
after (Bidichandani et al., 1997). A comparative study was carried out on a 
series of five FXN compound heterozygotes. The study made evident the 
severe phenotype invariably associated with splice-site, nonsense and 
initiation codon mutations due to absence of functional frataxin, although 
the phenotype associated with missense mutations was more variable 
depending on which amino acid residue was affected (Forrest et al., 1998). 
A further study compared clinical features of 25 compound FRDA 
heterozygotes from 19 families with 196 FRDA patients with the 
homozygous GAA expansion. Patients with truncating or missense 
mutations in sequences encoding the carboxy-terminal half of frataxin 
protein had a phenotype that resembled the classic pathology of patients 
with homozygous GAA expansions. Patients who instead had a missense 
mutation in sequences encoding the amino-terminal half of the frataxin 
protein (e.g. D122Y/G130V) had a milder, more slowly progressive clinical 
phenotype (Cossee et al., 1999). 
 
Recurrent Point Mutations and Hot-Spots 
The majority of point mutations reported have been private mutations 
(Gellera et al., 2007). However, there are certain mutations that recur 
throughout studies. These include the following four missense mutations: p. 
G130V (Bidichandani et al., 1997; Cossee et al., 1999; Forrest et al., 1998), 
p. I154F (Campuzano et al., 1996; Cossee et al., 1999; Filla et al., 1996; 
Gellera et al., 2007), p. R165C (Forrest et al., 1998; McCormack et al., 
2000) and p. W173G (Cossee et al., 1999; Gellera et al., 2007).  Some of 
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these cases may share a common founder, and especially in the case of 
the p. G130V mutation, a later age at onset and slow progression may allow 
for generation of progeny and subsequent further spread of the mutation in 
a population.  
 
Point Mutation Study: Differing Severity 
A study by De Castro et al searched for pathological GAA expansions in 
FXN patients with early-onset spinocerebellar ataxia. Among the 175 in 
which a GAA expansion was discovered, seven (4%) had just one 
expansion, indicating their possible genetic status as compound 
heterozygotes based on their phenotype. Of the seven patients, four were 
confirmed as compound heterozygotes for four different point mutations: 
three nonsense mutations (p. W155X, p. E100fsX and p. R39fsX) and a 
splice-site variant (g. IVS3-2A>G). While the three patients with nonsense 
mutations had GAA expansion sizes of between 800 and 900 repeats that 
led to a classical FRDA phenotype with an early onset between ages 3 and 
4, the patient with the splice-site variant had an expansion of only 250 
repeats and a late-onset, slowly progressive phenotype. Thus, the size of 
the single pathological GAA expansion in point mutation compound 
heterozygotes determines FRDA severity (De Castro et al., 2000). 
 
A larger study specifically explored the relationship between age at onset 
and GAA expansion size in 13 FRDA compound heterozygotes with point 
mutations and discovered a significant inverse correlation. The study also 
found a significant inverse correlation between GAA expansion size and 
frataxin protein expression, as measured by western blot analysis of 
lymphoblastoid cell lines derived from the patients (excluding two outliers), 
as well as a correlation between age at onset and frataxin expression. 
These results further confirmed the importance of the size of the single GAA 
expansion in determining frataxin production, and thus clinical severity in 
FRDA. This was particularly true for nonsense mutations, as the allele 
containing the GAA expansion becomes exclusively responsible for levels 
of frataxin production (Gellera et al., 2007). 
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Large Study of the Effects of Point Mutations on Frataxin Structure 
Galea et al performed the largest study to date of FXN compound 
heterozygotes. This group specifically studied the effect of FXN point 
mutations on the tertiary structure of the frataxin protein, frataxin stability 
and protein function. It was discovered that amino acid residues that are 
deeper within the protein interior form a tightly packed hydrophobic core that 
stabilises protein structure, and that point mutations affecting residues 
within this core therefore had a more severe impact upon protein stability. 
Specifically, mutations generated steric clashes in the case of substitution 
by larger residues, cavities in the case of substitution by smaller residues 
and unfavourable interactions in the case of substitutions of hydrophobic 
residues for charged ones. The clinical effect of the different missense 
mutations was thus shown to be dependent on a variety of factors acting at 
the mutation site, and hence on the overall functionality of frataxin (Galea 
et al., 2016). 
 
Conclusion 
Out of the large range of FXN point mutations that have now been 
described, it is the splice-site, nonsense and initiation codon mutations that 
have the most severe clinical effects. Missense mutations, that usually 
occur in the last three exons of FXN (within the mature frataxin protein), 
have more variable effects depending on the how they impact upon the 
tertiary structure of the protein and upon the ability of frataxin to interact with 
other proteins. Also, GAA expansion size of the single allele of compound 
heterozygotes remains of great relevance to clinical severity, and this is 
particularly true when the point mutations lead to the GAA expansion 
becoming the sole driver of frataxin production, as is the case with null or 
nonsense mutations. 
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1.6.2 Compound Heterozygotes with Large 
Deletions 
 
Recent developments in measuring gene dosage by multiplex ligation-
dependent probe amplification (MLPA) have enabled identification of 
compound heterozygotes with large deletions in the frataxin gene (Deutsch 
et al., 2010). There have thus far only been twelve recorded cases, some 
of which present atypical features. The first case described involved a 2776 
base pair deletion around exon 5a of FXN, by using a quantitative duplex 
PCR assay with exon-specific oligonucleotide probes analogous to MLPA, 
followed by sequencing of the 5a exon (g. 120032_122808del). Clinically, 
the patient had a typical FRDA phenotype, progressing from age of onset 
to wheelchair use in over six years (Zuhlke et al., 2004). Another lab 
described a further two cases: an individual with a deletion in exons 2 to 3 
with a typical FRDA phenotype (aside from a lack of dysarthria) and a rapid 
progression from age at onset to wheelchair use in four years, and another 
case with a deletion of exon 5 and a classical, if severe FRDA presentation 
(Brigatti et al., 2012; Deutsch et al., 2010).  
 
A further study described a large deletion of between 1603kbp and 
2477kbp, including the entire FXN gene: poor probe coverage prevented 
knowledge of the exact length of the deletion. The individual had an unusual 
FRDA presentation, with chorea, intention tremor and very slow progression 
over almost thirty years (van den Ouweland et al., 2012). 
 
The largest exonic FXN deletion case series was carried out by a 
collaboration of specialist centres in France and described six cases from 
five families. Four of these cases caused deletions in exons 4 and 5, one 
involved only exon 4 and the last involved exons 2 and 3.  All cases had a 
young age at onset of between three and twelve years of age and a severe 
neurological phenotype, indicating a possible founder effect. One half had 
diabetes, 80% had scoliosis and 83% had cardiomyopathy, including one 
case of severe angina at only nine years of age (Anheim et al., 2012). 
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Another deletion was found in what is so far the only systematic study of 
exonic FXN deletions, carried out in the Norwegian population. The project 
contacted not only the three Norwegian laboratories that perform FXN gene 
testing, but also all of the 22 public hospitals of Norway that contain a 
paediatric and/or neurology unit, patient support organisations and the 
national centre for rare diagnoses. In all, 27 patients had genetically 
confirmed FRDA with homozygous GAA expansions, and a further four had 
clinical ataxia and one GAA expansion. Of these four, one was 
heterozygous for a point mutation, and another had a large deletion (of the 
remaining two, one had a mutation in the related OPA1 gene and the other 
remains without genetic diagnosis). The deletion was identical to the first 
ever FXN exonic deletion described by Zühlke et al, of 2776 base pairs 
around exon 5a. The patient had a relatively typical FRDA phenotype, 
including an age at onset of 7 with presenting symptoms of unsteadiness 
and gradual progression towards wheelchair use, cardiac symptoms, 
scoliosis, but no diabetes mellitus (Wedding et al., 2015).  
 
A final case affected a patient from among a cohort of 41 FRDA patients, 
who had very early onset FRDA with hypertrophic cardiomyopathy, rapidly 
progressive gait instability and severe scoliosis, due to a complete exonic 
deletion of all exons from 1 to 5b. Although ‘exquisitely rare’, tests for FRDA 
exonic deletions are indicated by this study to be more appropriate in FRDA 
cases where the patient is of a particularly severe and early onset clinical 
phenotype (Hoffman-Zacharska et al., 2016). 
 
Where a FXN exonic deletion is suspected, the MLPA test is recommended 
among relatives of that individual, to avoid a routine genetic test showing a 
single normal-sized GAA expansion being falsely interpreted as two normal 
sized expansions. Indeed, most patients with normal-sized alleles only have 
a single small band on the long-range PCR gel electrophoresis due to the 
small size of the triplet repeat, making misinterpretation potentially more 
common than when testing expanded alleles. Carrier status for the exonic 
deletion would be of great relevance to an individual’s genetic counseling, 
indicating that their partner should also be tested for FRDA carrier status. 
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Conclusion 
Out of the very small number of FXN exonic deletions that have so far been 
described, almost all of the patients display a classical if severe FRDA 
clinical presentation. However, the number of cases studied is too few to 
consider the clinical phenotype fully characterized, and no systematic 
studies of their prevalence in a population have been performed. Oddly, the 
only exception to the phenotypic trend is the van den Ouweland case, where 
the patient, despite having a complete deletion of their FXN gene, had very 
slow disease progression, although alongside other unusual symptoms not 
usually observed in FRDA such as chorea.  
 
In clinical diagnosis studies, GAA expansions are sized with the long-range 
PCR method by gel electrophoresis. It is interesting to note that when only 
a single band is visible on the gel corresponding to a pathological GAA 
expansion and there is no band corresponding to a normal sized GAA 
expansion, it is assumed by most diagnostic laboratories that the patient 
has two, equal-sized GAA expansions. Although this interpretation is very 
likely given the rarity of exonic deletions, it must be remembered that this 
result is by no means a confirmation that the patient indeed has two, equal-
sized GAA expansions and it is possible that several cases of compound 
heterozygotes with large deletions are being missed. Correct results could 
have important implications for genetic counseling, as well as better 
understanding the underlying pathological mechanisms of FRDA. For 
example, in the case of the UK EFACTS cohort, the Université Libre de 
Bruxelles reported 15 of 147 patients for whom GAA sizing data was 
available as having equally sized pathological GAA expansions. Although 
the considerations made in this section are of relevance to these patients, 
they remain unscreened for exonic deletions in the FXN gene. 
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1.7 Justification for Current Study 
 
FRDA is a highly complex, multisystem disorder, in which neurological signs 
are first observed, but the patient usually dies from cardiac complications. 
The crucial discovery of its genetic basis allowed FRDA research to directly 
investigate the underlying disease mechanisms and generate cellular and 
animal models of great usefulness. Further understanding of both FRDA 
molecular genetics and disease pathophysiology is of great importance, 
especially as at present there is no treatment available for FRDA.  
 
I carried out two studies on FRDA, one with a translational scientific 
approach using molecular genetics techniques, and the other with a more 
basic approach using cell imaging techniques. In the translational study, an 
unprecedented 2000 ataxia patients were screened for the FRDA mutation 
to identify its percentage in an idiopathic late onset ataxia cohort. These 
patients are not routinely screened for FRDA as it is a paediatric disease: 
however, recently the FRDA mutation has been found in late onset ataxia 
patients. The results will improve the ataxia guidelines for genetic testing, 
making them more evidence-based. Correct diagnosis would also vastly 
improve patient care and genetic counselling.  
 
In the basic science study, experiments were carried out in two separate 
FRDA cellular model populations, one atrial mouse adult (HL-1) and one 
ventricular rat neonatal line (H9c2). They modelled FRDA via knockdown of 
the frataxin gene using siRNA, and key results in these cells were confirmed 
using YG8R primary cells. These cells were used to test the novel 
hypothesis of Ca2+ signaling dysfunction in conjunction with dysregulation 
of iron and ROS levels in FRDA, never previously studied in FRDA model 
heart cells. These mechanisms act through a great variety of bioenergetic 
pathways, mostly associated with ISC biogenesis and cellular and 
mitochondrial iron dynamics. Any potential clinical therapy, unless acting 
further upstream at the level of genetic or epigenetic repair of the mutation 
itself (no easy feat in a triplet repeat disorder), must address the multiple 
physiological pathways associated with FRDA if it is to be successful.  The 
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primary aims of my study, subdivided into two separate sections for the 
FRDA genetics and physiological studies respectively, can be outlined thus: 
 
 
 
 
 
 
Aims: 
 
Genetic Study: 
1. To determine whether any of the cases of atypical FRDA are 
being missed by clinicians, due to the current clinical basis for 
FRDA referral. 
2. To develop our understanding of the genotype-phenotype 
relationship in FRDA. 
 
Physiological Study: 
1. To explore the pathophysiology of cardiac cells in cellular and 
animal models of FRDA and gain insight into whether there is 
any effect on Ca2+ homeostasis in these models. 
2. To investigate whether any variation in Ca2+ homeostasis may 
be linked to more well-established elements of FRDA 
pathophysiology, and whether any therapeutic avenue may be 
opened by new findings. 
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Chapter 2 : Methods 
 
2.1 Genetic Screening Study of Ataxia 
Patients 
 
2.1.1 Case Ascertainment 
 
Case Ascertainment and Sample Preparation 
The Neurogenetics Department of the National Hospital for Neurology and 
Neurosurgery (NHNN), a tertiary referral centre for inherited neurological 
diseases, has on its database samples received from neurological centres 
across the UK, including from EFACTS (see Chapter 1). This database was 
screened for two cohorts from among patients presenting with ataxia. One 
cohort was made from patients whose clinicians had requested FXN gene 
testing to observe for FRDA positivity. The other cohort of patients was 
comprised of those for whom FXN gene testing had not been requested by 
their clinician, and for whom, despite having been referred to hospital for 
spinocerebellar ataxia (SCA) testing, no clear genetic cause had been 
found. In the latter cohort, testing for GAA expansions was also carried out 
in the Neurogenetic Department of the NHNN using previously established 
techniques (Campuzano et al., 1996; Potdar & Raghu, 2013; Warner et al., 
1996). Patient DNA is extracted in the NHNN using standard procedures 
and stored indefinitely at -80°C. All patients signed informed consent for 
genetic testing. The study was reviewed and approved by the UCL Joint 
Research Office. 
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2.1.2 Triplet-Primed Polymerase Chain Reaction 
 
Need for Molecular Diagnosis of Friedreich’s Ataxia 
Polymerase chain reaction (PCR) is a simple and efficient technique that 
uses primers to amplify a desired region of DNA. Primers are short stretches 
of DNA designed to be complementary to specific DNA regions flanking the 
region of interest. These primers bind to those flanking regions and allow 
DNA polymerase to fill in the centre of the region with free nucleotides over 
a number of denaturation-synthesis cycles, vastly amplifying the 
concentration of that DNA region of interest. This product can then be 
analyzed by, for example, agarose gel electrophoresis. 
 
Triplet-Repeat Primed PCR  
The ultimate function of carrying out PCR experiments on the DNA of our 
2000 patients was to test for pathological GAA expansions in each allele, 
which would allow for the diagnosis of FRDA. A two-stage PCR process was 
carried out, beginning with triplet-primed repeat PCR (TP-PCR). TP-PCR, a 
fast and robust technique, was ideal to apply en masse to the 2000 patient 
samples. However, it was necessarily a primary screening method, as it only 
answered the question of whether ataxia patients have the pathological 
GAA expansion in either allele (Fig. 6). Thus, any samples positive at the 
TP-PCR stage moved on to the next, more labour-intensive round of long 
range PCR testing. This allowed us to distinguish between FRDA expansion 
homozygous and heterozygous individuals, and fully test for FRDA 
positivity.  
 
A study by Ciotti et al. showed 100% concordance between results obtained 
by TP-PCR and those by Southern Blot analysis and confirmed the TP-PCR 
method to be robust, fast and highly reproducible (Ciotti et al., 2004; 
Muthuswamy et al., 2013). TP-PCR detects GAA expansion using a set of 
three primers: FATP-P1, FATP-P3, and FATP-P4. P1 is a fluorescently 
labelled locus-specific primer that complements a section of DNA flanking 
the 5’ end of the GAA sequence. P3 and P4 are reverse primers sharing a 
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common 5’ sequence. P4 contains a sequence complementary to the 3’ end 
of the repeat and binds to multiple sites within the repeat: its limited quantity 
means it runs out in the first cycles. The P3 primer amplifies from the end 
of the amplification products produced by the P4 primer. The P4 primer 
binds to multiple sites, so that products of many different sizes are 
produced, giving a characteristic trace when these undergo fragment size 
analysis by capillary electrophoresis (ABI-3730 fragment analyser, Applied 
Biosystems, ThermoFisher Scientific). The primer sequences used were: 
 
FATP-P1: 5′-GCTGGGATTACAGGCGCGCGA-3′  
FATP-P3: 5′- TACGCATCCCAGTTTGAGACG-3′ 
FATP-P4: 5′-6-FAM 
TACGCATCCCAGTTTGAGACGGAAGAAGAAGAAGAAGAAGAA-3′ 
 
The desired samples of patient DNA were aliquoted, and DNA quality and 
concentration were determined using a NanoDrop ND-1000 
spectrophotometer (ThermoScientific, Wilmington, DE, USA), using no less 
than 150 μg of genomic DNA per patient sample. A stock plate of the DNA 
samples was made up to be tested, and the plate was incubated at 55°C for 
two hours to ensure DNA homogeneity. 
 
Then, the three primers were all resuspended in TE to 100 μM, and aliquots 
were made in TE at the following concentrations: FATP-P1 at 10 μM, and a 
mix containing FATP-P3 at 10 μM and FATP-P4 at 1 μM. Following this, a 
master mix was made containing 10 μL Amplitaq Gold 360 Master Mix 
(Applied Biosystems, ThermoFisher Scientific), 2 μL GC Enhancer (Applied 
Biosystems, ThermoFisher Scientific), 4 μL H2O, 1 μL of the FATP-P3 
primer (10 μM) and 1 μL of the primer mix FATP-P1 (10 μM) with FATP-P4 
(1 μM) for each sample being analysed plus 10% for pipetting errors. This 
master mix was then centrifuged and added to the appropriate number of 
wells, of a 96-well plate, accounting for positive, negative and water 
controls. 2 μL of each DNA sample was taken from the stock plate and 
added to the appropriate wells. The resulting 20 μL solution was run on the 
following PCR program: an initial denaturation stage of 95°C for 10 minutes 
and then 35 cycles of 95°C for 1 minute, 58°C for 1 minute and 72°C for 1 
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minute. This was followed by a final extension stage of 72°C for 7 minutes, 
and then the samples were cooled to 4°C until ready to analyse. 
 
After the PCR was completed, the capillary electrophoresis was carried out. 
A new master mix was made containing 12 μL Hi-Di formamide (Applied 
Biosystems, ThermoFisher Scientific) and 0.3 μL LIZ500 size standard 
(Applied Biosystems, ThermoFisher Scientific) per sample. The master mix 
was vortexed after adding the size standard, added to the appropriate 
number of wells in a new 96-well plate and 1 μL of PCR product for each 
sample was added to each of the wells. The plate was then heat-sealed, 
and the samples were heated to 95°C for 3 minutes on the thermocycler, 
and then rapidly cooled on ice for three minutes before transfer to the 
fragment analyser. Once the data was obtained, it was analysed using 
GeneMarker v2.2.0 (Soft Genetics, PA, USA), which generates a plot 
graphic for each sample. 
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Figure 6: TP-PCR results visualized by capillary electrophoresis, showing that TP-
PCR does not distinguish between FRDA carriers and FRDA positives. 
A) Negative TP-PCR result, indicative of a normal GAA expansion. B) Positive TP-PCR 
result. This patient was later shown to be an FRDA positive by Long Range PCR. C) 
Positive TP-PCR Result. This patient was later revealed to be an FRDA carrier by Long 
Range PCR. 
 
 
 71 
 
 
 
2.1.3 Long Range PCR 
 
The second stage of the two-stage PCR process, following TP-PCR, was 
long range PCR, which asked the crucial final research question: do the 
patients positive at the TP-PCR stage have the FRDA pathological GAA 
repeat in both alleles or only one? Conventional PCR cannot produce 
fragments any larger than 3-4 kilobases (kb), as the Taq DNA polymerase 
error rate eventually stalls the lengthening of the DNA strand and leads to 
polymerase dissociation.  
 
The long range PCR technique introduces a proofreading enzyme in 
tandem with the polymerase, which removes any misplaced bases and 
allows continuous amplification of the DNA strand up to 22 kb. This is ideal 
for amplification allowing for accurate sizing of the large FRDA GAA 
repeats. It has been used in several studies determining the relationship 
between the molecular and clinical phenotypes in FRDA. The GAA-R and 
GAA-F primers are those originally described by Campuzano and his 
colleagues in 1996 in their paper on the genetic basis for FRDA 
(Campuzano et al., 1996). The primer sequences used were: 
 
GAAF: 5’- GGG ATT GGT TGC CAG TGC TTA AAA GTT AG-3’  
GAAR: 5’-GAT CTA AGG ACC ATC ATG GCC ACA CTT GCC-3’ 
 
The accurate analysis of expansion size by long PCR originally linked the 
intronic homozygous GAA expansions in patients to the autosomal 
recessive mode of inheritance in FRDA, confirming this expansion mutation 
as the cause of disease (Campuzano et al., 1996; Lamont et al., 1997). It 
also allowed for the discovery that there is an inverse correlation between 
expanded repeat length and age at onset, and FRDA patients with diabetes 
or cardiomyopathy had larger expansions (Filla et al., 1996). Most relevantly 
for our study, a further study amplified the GAA expansion mutation in both 
healthy individuals and patients and showed that by observing the bands 
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after agarose gel electrophoresis, one could distinguish successfully 
between normal, heterozygous and homozygous alleles (Kocheva et al., 
2008). Thus, the long range PCR protocol has been put forward as a genetic 
screening method to distinguish between FRDA patients and carriers. 
 
The desired samples of patient DNA were aliquoted, and DNA quality and 
concentration were determined using a NanoDrop ND-1000 
spectrophotometer (ThermoScientific, Wilmington, DE, USA). A stock plate 
of the DNA samples was made up to be tested, and the plate was incubated 
at 55°C for two hours to ensure DNA homogeneity. The two primers were 
all resuspended in TE to 100 μM, and a single aliquot was made at in TE 
incorporating both primers at the following concentrations: GAA-F at 5 μM 
and GAA-R at 5 μM The first of two master mixes was then made, (i) 
consisting of 2.5 μL of dATP, dTTP, dCTP and dGTP (Applied Biosystems, 
ThermoFisher Scientific) each of 100 mM concentration, 1 μL of the 5 μM 
GAA-F and 5 μM GAA-R primer mix, and 14 μL of H2O per sample plus 10% 
for pipetting errors.  1 μL DMSO was added if necessary at the expense of 
H2O to improve PCR amplification. 25 μL of master mix (i) was added to 
each well, followed by 1 μL of normalized DNA (DNA diluted x10 in H2O). 
The plate was then centrifuged.  
 
At this point, the second master mix was made, (ii) consisting of 5 μL of 
Expand Long Template Buffer 3 with 27.5 mM MgCl2 and detergents 10x 
concentrated (Sigma-Aldrich), 0.75 μL Expand Long Template Enzyme Mix 
(Sigma-Aldrich), an enzyme mix that contains thermostable Taq DNA 
Polymerase and a thermostable DNA polymerase with proofreading activity, 
and 18.75 μL H2O per sample plus 10% for pipetting errors, and then kept 
on ice. The original mixture of master mix (i) and the DNA was subjected to 
a ‘hot-start’ PCR to reduce non-specific annealing and amplification. It was 
placed in the PCR machine once the temperature had reached 90°C, and 
only then was 24 μL of master mix (ii) added to each well quickly. The PCR 
programme proceeded as follows: an initial denaturation stage of 94°C for 
7 minutes, then 10 cycles of 94°C for 10 seconds, 62°C for 30 seconds and 
68°C for 3 minutes, and then 20 further cycles of 94°C for 10 seconds, 62°C 
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for 30 seconds and 68°C for 3 minutes with 20 second increments every 
cycle. This was followed by a final extension stage of 68°C for 10 minutes, 
and then the samples were cooled to 4°C until ready to analyse. 
 
Following conclusion of the PCR, 10 μL of the 50 μL PCR product per 
sample was run on a 2% agarose minigel (2% was chosen to enhance the 
resolution of the DNA fragments) using a 1 Kb Plus ladder (Invitrogen, 
ThermoFisher Scientific) as a standard. The results were checked on the 
Gene Genius gel documentation system and recorded as a paper 
photograph after approximately 1, 2 and 3 hours at suitable exposure times. 
The gel electrophoresis allowed visualization of the expansion size of the 
PCR product. To calculate the number of GAA repeats, the required formula 
was allele size = (number of base pairs-457)/3. This is because the 
synthesised PCR products contain flanking sequences totalling 457 base 
pairs in addition to the GAA trinucleotide repeat expansion. Normal alleles 
run at approximately 500 base pairs, whereas affected alleles run at 
approximately 720 base pairs or above. 
 
Capillary electrophoresis was also carried out as a confirmatory mechanism 
for the success of the original PCR. A new master mix was made containing 
12 μL Hi-Di formamide (Applied Biosystems, ThermoFisher Scientific) and 
0.3 μL ROX500 size standard (Applied Biosystems, ThermoFisher 
Scientific) per sample. The master mix was vortexed after adding the size 
standard, added to the appropriate number of wells in a new 96-well plate 
and 1 μL of PCR product for each sample was added to each of the wells. 
The plate was then heat-sealed, and the samples were heated to 95°C for 
3 minutes on the thermocycler, and then rapidly cooled on ice for three 
minutes before transfer to the fragment analyser. Once the data was 
obtained, it was analysed using GeneMarker v2.2.0 (Soft Genetics, PA, 
USA), which generates a plot graphic for each sample. 
 
 
The individuals who were determined experimentally to be either 
homozygous for the GAA expansion were thereby confirmed as having 
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FRDA, and their clinical details were subsequently gathered to examine the 
correlation between genotype and phenotype for each patient and the 
nature of any atypical presentations of FRDA. If the presence of at least one 
GAA expansion was detected, the samples were forwarded for point 
mutation and exonic deletion testing to determine whether they could be 
compound heterozygous FRDA patients. 
 
 
 
 
 
2.1.4 Point Mutation Screening and Large Deletion 
Screening 
 
Known cases of compound heterozygotes with point mutations were 
collected from the databases of the Neurogenetic Department of the NHNN 
and the European Friedreich’s Ataxia Consortium for Translational Studies 
(EFACTS) registry. Relevant clinical data were gathered from patients’ 
notes and the EFACTS registry. Whilst testing for repeat expansions was 
carried out in the Neurogenetics laboratory of NHNN (as described in the 
TP-PCR and Long range PCR methods section), sequencing for point 
mutations was undertaken in the Merseyside and Chesire Regional 
Molecular Genetics laboratory, Liverpool Women’s Hospital, Liverpool, UK 
and the Université Libre de Bruxelles (Dr Myriam Rai & Prof. Massimo 
Pandolfo). In both laboratories, a previously published technique was made 
use of using the following primers  (Pandolfo, 2006): 
 
Exon 1:  5’-AGC ACC CAG CGC TGG AGG-3’  (forward) 
5’-CCG CGG CTG TTC CCG G-3’  (reverse) 
Exon 2:  5’-AGT AAC GTA CTT CTT AAC TTT GGC-3’  (forward) 
5’-AGA GGA AGA TAC CTA TCA CGT G-3’  (reverse) 
Exon 3:  5’-AAA ATG GAA GCA TTT GGT AAT CA-3’  (forward) 
5’-AGT GAA CTA AAA TTC TTA GAG GG-3’  (reverse) 
Exon 4:  5’-AAG CAA TGA TGA CAA AGT GCT AAC-3’  (forward) 
5’-TGG TCC ACA ATG TCA CAT TTC GG-3’  (reverse) 
Exon 5a:  5’-CTG AAG GGC TGT GCT GTG GA-3’  (forward) 
5’-TGT CCT TAC AAA CGG GGC T-3’  (reverse) 
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The technique involves a screening of exons 1 to 5a, covering the entire 
coding region of the most commonly expressed FXN transcript. It can also 
detect the pathogenic mutations in the promoter region, alternative exon 5b, 
the untranslated exon 6, the 3’-untranslated region, cryptic splice site 
mutations and somatic mosaicism. 
 
 
 
2.1.5 Large Deletion Screening 
 
Large deletions were detected using the multiplex ligation probe 
amplification (MLPA) technique, which has been used previously for the 
detection of exonic deletions (Anheim et al., 2012; Deutsch et al., 2010; van 
den Ouweland et al., 2012).  The General Protocol issued by the 
manufacturer was followed (MRC-Holland, Amsterdam, Netherlands; 
version MDP-v002, 23.1.2012). The commercially available SALSA MLPA 
P136-B2 Recessive Ataxias Probemix was used (MRC-Holland, 
Amsterdam, Netherlands; lot 0511), which contains probes against the five 
coding exons in the FXN gene, but no probe for the non-coding exon 6. The 
probemix also contains probes against the nine exons of the APTX gene 
and the 26 exons of the SETX gene. 
 
The probemix contains probes against nine reference exons from unrelated 
genes on different chromosomes, which act as a quality control mechanism. 
Patients are assumed to have no exonic deletions in any of these exons, or 
any point mutations at the site of probe binding: if they do, this will become 
apparent at the data analysis stage. The probemix also contains internal 
quality control fragments, the ‘QDX2 control fragment set’. Among these is 
a 92-nucleotide control probe very similar to the other MLPA probes, used 
by the software as a comparison to other control fragments. Additionally, 
there are four ‘Q-fragments’, oligonucleotides containing both PCR primer 
sequences in a single molecule and therefore not dependent on the 
amplification of target DNA during the PCR process (see below).  These are 
present in extremely low concentrations so that if enough target DNA is 
used, these Q-fragments are out-competed by the amplicons of MLPA 
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probes. Thus, if insufficient DNA has been used or if the ligation reaction 
failed, this is indicated to us by the height of the Q-fragments peaks being 
over one-third that of the 92-nucleotide probe on the software. There are 
two further ‘D-fragments’ from among this set of internal quality control 
fragments, which detect sequences within CpG islands, which are known to 
be harder to denature, and are usually located near mRNA transcription 
start locations in exon 1 of FXN. If the height of these peaks is less than 
40% than that of the 92-nucleotide control probe, this is evidence that DNA 
denaturation was incomplete. This can lead to unreliable data for the probes 
detecting sequences in or within 5 kb from the CpG islands. Finally, there 
are probes that detect sequences within the X and Y chromosome that 
identify the gender of the sample and allow for a general identification of 
incorrect sample use.  
 
 
Table 1: Probes in MRC-Holland SALSA MLPA P316-B2 Recessive 
Ataxias Probemix. 
FXN 
Exon 
SALSA 
MLPA 
Probe 
Length 
(nt) 
Ligation 
Site 
Start-
End 
Distance 
to next 
Probe 
Left (5') Probe- 
Right (3’) 
Probe 
1 10891-
L11561 
234 43nt before 
exon 1 
70840233-
70840293 
10.9 kb 5’:CAGCAAGACAGC
AGCTCCCAAGT 
3’: 
TCCTCCTGTTTAGAA
TTTTAGAAGCGGCG
GGCCACCAG 
2 10893-
L11563 
208 463-464 70851166-
70851235 
6.7 kb 5’:CAGAGTGTCTATT
TGATGAATTTGAGG
AAATCT 
3’: 
GGAACTTTGGGCCA
CCCAGGGTAAGATA
AAACACCTT 
3 10894-
L13901 
258 517-518 70857878-
70857950 
11.9 kb 5’:CTCTCTAGATGAG
ACCACCTATGAAAG
ACTAGCA 
3’: 
GAGGAAACGCTGGA
CTCTTTAGCAGAGT
TTTTTGAAGACCT 
4 14129-
L15733 
472 24nt after 
exon 4 
70869764-
70869842 
8.3 kb 5’:CCATCCAGGTATG
TAGGTATGTTCAGA
AGTCA 
3’: 
ACATATGTAATTCTT
AAAGACTTCCGAAA
TGTGACATTGTGGA
CCAT 
5 10895-
L11565 
154 1448-
1449b 
70878073-
70878130 
- 5’:TGGCCTGCACTG
GGTTGTCCA 
3’: 
GGGAGACCTAGTGC
TGTTTCTCCCACATA
TTCACATA 
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Table based on MRC-Holland Product Descriptions v8 (7.3.12) & v11 (10.12.15). 
 
 
Table 2: QDX2 control fragments in MRC-Holland SALSA MLPA P316-
B2 Recessive Ataxias probemix. 
Length 
(nt) 
Name Gene 
Chromosomal 
Location 
64 64nt Q-fragment - - 
70 70nt Q-fragment - - 
76 76nt Q-fragment - - 
82 82nt Q-fragment - - 
88 88nt D-fragment CARM1 19p13.2 
92 92nt control fragment IL1B 2q13 
96 96nt D-fragment JPH3 16q24.2 
100 100nt X-fragment AMOT Xq23 
105 105nt Y-fragment UTY Yq11.221 
Table based on MRC-Holland Product Description v8 (7.3.12). 
 
 
 
 
 
DNA quality and concentration were determined using a NanoDrop ND-
1000 spectrophotometer (ThermoScientific, Wilmington, DE, USA), using 
no less than 150 μg of genomic DNA per patient sample. On day 1, for each 
sample, 5 μL of DNA solution in Tris-EDTA buffer (TE) was denatured at 
98°C for 5 minutes and cooled to 25°C on a thermocycler (Applied 
Biosystems Gene Amp PCR System 9700, ThermoFisher Scientific, 
Waltham, MA, USA). Next, a hybridization master mix was prepared 
containing 1.5 μL of MLPA buffer and 1.5 μL of probemix for each reaction, 
and 3 μL of this mastermix was added to each 5 μL denatured DNA sample. 
The new samples were then hybridized through incubation for 1 minute at 
95°C and then for 16-20 hours at 60°C of the thermocycler. On day 2, a 
ligase mastermix was prepared with 25 μL of distilled water, 3 μL of ligase 
buffer A, 3 μL of ligase buffer B and 1 μL of ligase-65 enzyme for each 
sample. The thermocycler temperature was lowered to 54°C, and 32 μL of 
ligase mastermix was added to each hybridised sample. The sample was 
ligated by incubation at 54°C for 15 minutes, and the enzyme inactivated by 
heating to 98°C for 5 minutes before cooling to 20°C. Following this, the 
‘one-tube PCR’ protocol was followed. A polymerase mastermix was 
prepared containing 7.5 μL distilled water, 2 μL carboxyfluorescein-labelled 
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(6-FAM) SALSA PCR primer and 0.5 μL SALSA polymerase for each 
sample. 10 μL of this polymerase mastermix was added to each sample, 
and the whole 50 μL solution subjected to the following PCR programme: 
35 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 60 
seconds. The samples were then held at 72°C for another 20 minutes, and 
then cooled to 15°C (see Table 3). 
 
On day 3, fragment size analysis was performed by capillary electrophoresis 
(ABI-3730 fragment analyser, Applied Biosystems, ThermoFisher 
Scientific). For this process, 0.2 μL GeneScan 500LIZ dye size standard 
(Applied Biosystems) and 9 μL Hi-Di formamide (Applied Biosystems) were 
added to 1 μL of each PCR product. The samples were heated to 80°C for 
2 minutes on the thermocycler, and then rapidly cooled on ice for three 
minutes before transfer to the fragment analyser. Once the data was 
obtained, it was analysed using Coffalyser software (MRC-Holland) and 
GeneMarker v2.2.0 (Soft Genetics, PA, USA), which generates an EDQ or 
peak ratio for each probe using the negative control. 
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Table 3: Thermocycler Program for MLPA Reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table based on MRC-Holland Product Description v8 (7.3.12). 
 
 
 
 
 
 
 
 
 
 
 
Stage Temperature Time 
DNA Denaturation 98°C 5 minutes 
 25°C Pause 
Hybridization 95°C 1 minute 
 60°C Pause 
Ligation 54°C Pause 
 54°C 15 minutes 
 98°C 5 minutes 
 20°C Pause 
PCR Reaction 95°C 30 seconds 
 60°C 30 seconds 
 72°C 60 seconds 
 72°C 20 minutes 
 15°C Pause 
35 cycles 
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2.2 Physiology of Ca2+ in 
Cardiomyocytes in Friedreich’s Ataxia  
 
2.2.1 Cell Culture 
Two immortal cardiomyocyte cell lines were employed for Ca2+ imaging 
analysis and other physiological measurements. HL-1 cells are an atrial 
murine adult line, first developed by Dr William Claycomb (Claycomb et al., 
1998) (a generous donation from the lab of Professor Sean Davidson, 
Hatter Institute, UCL). This was the first cell line developed that can maintain 
the contractile activity of the cardiomyocytes in vitro. HL-1 cardiomyocytes 
can be observed to contract, with this possibility more frequent at higher 
confluency. They can also be frozen using DMSO as a cryoprotectant, and 
also recovered from frozen stocks. The medium supported cell growth, 
maintaining the cells in a medium in which they could survive, grow and 
divide. Flasks or plates where the cells were to be plated were first pre-
plated with the cell adhesive proteins gelatin and fibronectin in preparation 
for HL-1 plating. For passaging, 0.25% trypsin-EDTA was used to detach 
the cells from the surface of the flask. H9c2 cells (ATCC) were also used to 
corroborate data from the HL-1 cell line. These are immortalized ventricular 
neonatal rat myoblasts.  
 
Preparation of Complete Claycomb Medium 
Claycomb medium requires several supplements in order to nourish the HL-
1 cells properly (FBS and L-Glutamine) as well as to maintain a 
differentiated phenotype in the cells and to stimulate their beating 
(Claycomb et al., 1998). They must be wrapped in aluminium foil as the 
ascorbic acid in the norepinephrine stock is light-sensitive. All supplements 
should be heated to 37°C. The Claycomb medium must incorporate the 
following reagents before being added to cells: Foetal Bovine Serum (FBS) 
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at 10% (Invitrogen), penicillin at 100 U/mL (Sigma Aldrich), streptomycin at 
100 μg/mL (Sigma Aldrich), norepinephrine at 0.1 mM and L-glutamine at 2 
mM. When referring to Claycomb medium during this methods section, this 
shall refer to complete Claycomb medium unless otherwise stated. 
Norepinephrine stock was made up to a 10mM concentration using ascorbic 
acid. Firstly, 25 mL of 30 mM ascorbic acid was made by adding 0.1475 g 
of ascorbic acid to 25 mL of cell culture grade distilled water. This mixture 
was covered in foil as ascorbic acid is light sensitive. Then, 80 mg of 
norepinephrine was added to the 25 mL of 30 mM ascorbic acid in a fume 
hood, taking the necessary precautions due to the toxicity and volatility of 
norepinephrine.  This was then filter-sterilised using a 0.22 μm acrodisc 
syringe filter in the sterile hood, and aliquoted in 5 mL volumes for addition 
to the Claycomb medium (or stored at -20°C). The Claycomb medium itself 
was stored at 4°C and covered in aluminium foil due to the strong light-
sensitivity of the medium. 
 
Passaging of HL-1/H9c2 Cells 
HL-1/H9C2 cells were always handled under conditions of the utmost 
sterility. They were first plated into two T25 tissue culture flasks and 
maintained at 37°C and at 5% CO2 in a humidified incubator for ideal cell 
growth conditions. Upon reaching 90-100% confluence, one of these flasks 
was split 1:2 into one T75 flask that was again split 1:3 into further T75 flasks 
(as many as required based on the experiments to be carried out) to 
become the ‘working’ set of cells. The other T25 flask was split 1:3 into a 
single T75 flask. Once the cells in this T75 flask were confluent, they were 
split into two T75 flasks, whose cells were frozen in liquid nitrogen upon 
reaching confluency for storage purposes (see separate ‘freezing HL-
1/H9c2 cells’ section in methods). 
Before plating the cells into flasks, these flasks must be coated with a pre-
plating solution containing 0.02% gelatin and 5 μg/mL fibronectin (3 mL/T75 
flask; 1 mL/T25 or 3 cm2 dish/well) in tissue-culture grade H2O. The solution 
must be autoclaved after the addition of gelatin for full dissolution of the 
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gelatin, after which the fibronectin is added in sterile conditions. The pre-
plating solution must also be filter-sterilised prior to use in pre-plating, using 
a 0.22 μm acrodisc syringe filter in the sterile hood. The pre-plated flasks 
were incubated for at least two hours in the incubator. No pre-plating stage 
was required for the H9c2 cells, which were maintained in DMEM containing 
10% FBS and 2mM L-glutamine. The T75 flask containing the HL-1/H9c2 
cells to be passaged was first rinsed with 2 mL of 0.25% trypsin-EDTA 
(Sigma Aldrich), without pipetting directly over the surface of the cells. After 
removing this, 3 mL of the 0.25% trypsin-EDTA was added and the flask 
was left for 3 minutes inside the incubator, to harvest the cells.  The 0.25% 
trypsin-EDTA detaches the cells from the surface of the flask. If the cells 
remained attached to the flask, the flask was lightly rapped on the benchtop, 
or the 3 mL of 0.25% trypsin-EDTA was removed and replaced with another 
3 mL and incubated for 3 minutes as before: however, these procedures 
were kept to a minimum to avoid cell deterioration. As soon as possible 
following confirmation of cell detachment, the 3 mL 0.25% trypsin-EDTA 
containing the detached cells was collected and placed in a 15 mL falcon 
tube containing 3 mL of complete Claycomb medium (always pre-heated to 
37°C before use). This inactivates the activity of trypsin, which if left active 
for too long can lead to cell deterioration and death. The tube containing 6 
mL of solution was centrifuged at 700 rpm for 5 minutes.  
 
Meanwhile, the pre-plating solution was removed from the T75 flasks that 
were due to be plated. After the centrifugation the cells formed into a pellet: 
the supernatant was removed, and the pellet was fully resuspended in 6 mL 
of incomplete Claycomb medium. 100 μL of this suspension was taken and 
added to a hemocytometer, along with 400 μL of 0.4% Trypan Blue, and the 
cells were counted. Following this, 12-13 mL of fresh complete Claycomb 
medium was added to each T75 flask due to be plated, followed by 2 mL of 
the cell suspension to achieve a 1:3 cell passage. A passage between 1:2 
and 1:5 could also be performed depending upon experimental timing: any 
thinner than 1:5 was considered too thinly spread to reach full cell 
confluence. Alternately if the cells were being prepared for experiments, 
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they were plated in appropriate volumes onto 25mm glass coverslips stored 
within a 6 multi-well plate. 
 
 
Isolation of Neonatal Cardiomyocytes 
In order to carry out Ca2+ imaging experiments on primary cells, these had 
to be obtained by isolation of mouse neonatal cardiomyocytes from 6-day 
old YG8R and Y47R mice (Jackson Laboratories; this study was carried out 
in accordance with the recommendations of the Animal (Scientific 
Procedures) Act 1986, or ASPA). The protocol was approved by the UCL 
Animal Welfare and Ethical Review Body (AWERB). Mouse pups were 
obtained from mating couples of a YG8R/Y47R mouse colony. The YG8R 
is a mouse model that contains a human FXN YAC incorporating 190+90 
GAA repeats on a mouse Fxn null background, recapitulating the FRDA 
progressive disease phenotype observed in humans (Al-Mahdawi et al., 
2006; Pook et al., 2001). In order to isolate these cells they underwent 
several digestion cycles in a buffer containing collagenase, which breaks 
down the connective tissue in muscle cells, in a method previously 
described by Stephanou et al. (Stephanou et al., 1998). A two-step 
procedure is carried out, involving enzyme digestion followed by mechanical 
agitation of the ventricular tissue, and finally purification of the 
cardiomyocyte population. Neonatal cardiomyocytes are generally isolated 
from mice that are 4-6 days old. A number of hearts can be digested 
simultaneously to increase the myocyte yield. Mouse pups were 
decapitated, following which their hearts were excised and the cells 
dispersed in an isolation buffer. 
 
 
Table 4: Isolation Buffer 
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 Adjusted to pH 7.35 and filter-sterilised.  
Table 5: Digestion Buffer 
Digestion Buffer Volume required 
Isolation Buffer 100 mL 
Collagenase type II 
(≈250units/mg) 
60 mg 
Penicillin/Streptomycin 1 mL 
Must be prepared fresh during each experiment. 
When the pups were culled, their hearts were first rinsed in 70% EtOH and 
then isolated in a dish of isolation buffer, after which they were finely cut into 
small pieces. Meanwhile, the enzymatic digestion buffer containing 
collagenase type II enzyme (Worthington) and pancreatin was prepared, 
oxygenated for half an hour and filter-sterilised. The solution containing the 
finely chopped heart tissue for each mouse was then transferred to a 25 
cm2 flask containing 3 mL of digestion buffer enzyme solution and left to 
settle for 1-2 minutes. This digestion buffer was then slowly discarded, 
taking special care not to discard any of the heart tissue, and 3 mL of fresh 
digestion buffer was added. The flask was then kept at 37°C for 15 minutes. 
Following this, the flask was gently shaken, and the digestion buffer again 
discarded. The digestion at 37°C for 15 minutes was then repeated, after 
which the supernatant enzyme solution incorporating cardiomyocytes (and 
other cell types) was removed from the remaining chunks of tissue and 
suspended in 2 mL of FBS each. A fresh 3 mL of digestion buffer was then 
added to the tissue, and this procedure was repeated three times, until three 
5 mL samples of cardiomyocyte-containing enzyme solution from each 
mouse heart have been collected (thus per pup, around 15 mL of digestion 
buffer is required).  
Isolation Buffer Required 
concentration (mM) 
Mw Volume added to 
500 mL solution (g) 
NaCl 116 58.44 3.4 
HEPES 20 238.30 2.38 
NaH2PO4 0.77 141.96 0.06 
Glucose 5.5 180.16 0.5 
KCl 5.4 5.4 0.2 
MgSO4 0.4 0.4 0.05 
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The collected enzyme solutions were then centrifuged at 1000 rpm for 5 
minutes, the supernatant discarded, and the cardiomyocyte fraction re-
suspended in 2 mL plating medium with a syringe needle, after which the 
cells were plated using one well of a 6-well plate per cardiomyocyte fraction 
re-suspended in 2 mL of plating medium (15% FBS and 1% 
penicillin/streptomycin in DMEM+GlutaMAX medium). Thus, the cells from 
two hearts plated a 6-well plate, with each heart occupying three wells each. 
The 6-well plates contained 25 mm coverslips in each well (to allow for later 
analysis of the cells) and had been pre-plated with autoclaved and filter-
sterilised 0.01% gelatin in PBS at 37°C for one hour in the incubator, after 
which the gelatin solution was removed, and the wells were ready for 
plating. The cells were left in plating medium overnight to attach to the 
surface, and the next day the medium was replaced with maintenance 
medium (1% FBS and 1% penicillin/streptomycin in DMEM+GlutaMAX 
medium). 
 
 
2.2.2 Transfection of HL-1/H9c2 Cardiomyocytes 
Transfection is the process of introducing foreign genetic materials into a 
eukaryotic cell in a non-viral manner. RNA interference (RNAi) is a 
technique whereby RNA is inserted into a cell to down-regulate the 
production of a specific protein by blocking translation, in this case frataxin. 
With effective introduction of an small interfering RNA (siRNA) construct, a 
single protein in a cell can be ‘silenced’, as the siRNA destroys the mRNA 
encoding that protein. As a good FRDA model requires a frataxin protein 
knockdown and not a full knockout, use of a small siRNA targeted to frataxin 
mRNA of 20-25 base pairs in length with no vector is ideal. siRNA is at first 
double-stranded, with 2 nucleotides on each 3’ overhang. Once it enters the 
cell however, it can be denatured by helicase, and then the sense and anti-
sense siRNA strands and bound by the RISC (RNA-induced silencing 
complex)-related proteins. In the cells, the RISC complex containing the 
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anti-sense strand (which is the strand required to pair with the mRNA) uses 
the siRNA as a template for recognizing complementary mRNA. In this way, 
only specific mRNAs (such as frataxin) are selected for silencing by this 
method. If even one nucleotide on the siRNA does not correspond to the 
mRNA, the siRNA may not bind. Conversely, as few as 11 contiguous 
nucleotide matches with an unrelated mRNA can lead to off-target silencing. 
The active RISC complex is recycled and goes onto destroy other mRNA 
strands in the cell.  
 
In the study, Lipofectamine 2000 was used as a transfection reagent. The 
lipofectamine reagent contains lipid subunits, which can form liposomes 
(the synthetic equivalent of the phospholipid bilayer of cell membranes) in 
an aqueous environment, which entrap nucleic acids. Transfection 
efficiency is increased due to the fact that the positive surface charge of the 
liposomes mediates the interaction of the negatively charged nucleic acid 
molecules and the cell membrane. This overcomes the electrostatic 
repulsion of the cell membrane and allows for the fusion of the liposome-
nucleic acid transfection complex with the negatively charged cell 
membrane. The transfection complex is thought to enter the cell by 
endocytosis. 
 
YFP-tagged plasmid DNA (pcDNA3-YFP) was co-transfected alongside the 
siRNA to act as a marker of cell transfection. This plasmid vector allows the 
cell to express YFP-tagged DNA using its own machinery. While the site of 
action for transfected RNA is in the cytoplasm, the DNA must be transported 
to the nucleus for effective transfection. There, the DNA is either transiently 
expressed for a short period of time or become incorporated into genomic 
DNA where the change induced is passed on to cells as they divide. In this 
case, the YFP-tagged DNA acts as a transiently expressed fluorescent 
marker that confirms cell transfection, and results in high expression levels 
that persist for 48 hours when the DNA is transfected.  
 
The simultaneous transfection of cells with two unrelated, separate nucleic 
acid molecules carried out is known as a co-transfection. Theoretically, if 
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the cell takes up the siRNA construct, it is very likely to have taken up the 
YFP-DNA as well, and therefore YFP fluorescence can be used as a 
determination of successful co-transfection. There is a very small chance a 
transfected cell will express only the YFP-DNA plasmid and not the siRNA 
construct: however, if the experiment is repeated enough times, this chance 
will not be statistically significant. To knock-down frataxin mRNA in HL-
1/H9c2 cardiomyocytes, a co-transfection of FXN-siRNA and YFP-tagged 
plasmid DNA was performed. Mm_Fxn_1 FlexiTube siRNA was used as the 
predesigned siRNA against mouse frataxin (SI01007139, Qiagen) in HL-1 
cells, and Rat_Fxn FlexiTube siRNA (SI02902557, Qiagen) was used in 
H9c2 cells. This interferes with the expression of frataxin by targeting a short 
sequence around 450bp into the mouse FXN mRNA transcript from the 5’ 
end (Gene accession no. NM_008044). For the negative control (siRNA-
scrambled), AllStars Negative Control siRNA (1027418, Qiagen) was used 
for both cells.  
 
100,000 HL-1/H9c2 cells were seeded per 35 mm well in a 6-well plate. On 
the next day, into each of the 6 wells went the following concentrations of 
siRNA and YFP-DNA (pcDNA3-YFP): 30 nM siRNA and 10 μg/mL YFP-
DNA. To this end, solutions ‘A1’ and ‘B1’ were prepared in separate 
Eppendorf tubes. The negative control siRNA was used in the case of A1, 
and Mm_Fxn_1 FlexiTube siRNA in the case of B1, both of which were 
diluted to a 100 μM stock and then into 10 μM aliquots stored at -20°C 
before addition to the solutions. Each solution contained 9 μL siRNA from 
these aliquots, 15 μg (3.75 μL) YFP-DNA and 1.5 mL incomplete Claycomb 
medium. The solutions ‘A2’ and ‘B2’ were also made in separate Eppendorf 
tubes, each containing 30 μL Lipofectamine 2000 and 1.5 mL incomplete 
Claycomb medium.  
 
After incubating these solutions separately for 5 minutes at room 
temperature, solution KD1 was combined with KD2 and solution NC1 was 
combined with NC2. The resulting ‘Solution A’ and ‘Solution B’ were mixed 
gently and incubated at room temperature for 20-30 minutes to allow DNA-
liposome complexes to form. Prior to adding the transfection mix to the cells, 
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they were rinsed once with phosphate buffered saline (PBS) to remove any 
FBS, which inhibits the transfection process. Following this, 1 mL each of 
Solution A was added to three wells of the 6-well plate, and 1 mL each of 
Solution B was added to the other three and these were clearly labelled. 
The cells were incubated at 37°C for three hours (no more than this due to 
toxicity of the Lipofectamine 2000), and then the transfection mix was 
removed from the cells and replaced by fresh, complete Claycomb medium 
to allow the newly transfected cells to continue growing. 
 
Transfection Efficiency 
The transfection efficiency was calculated in HL-1 cells by measuring the 
amount of YFP-cells, which we used as a marker of successful co-
transfection. Among cells transfected with siRNA control, 1946 out of 5772 
cells were transfected with YFP, giving a transfection efficiency of 
33.7±3.6%. Among cells transfected with FXN-siRNA, 1360 out of 4705 
cells were transfected with YFP, giving a transfection efficiency of 
28.9±3.6%. No significant difference was found between the two cell 
populations (Fig. 7). Transfection efficiency in H9c2 cells was observed to 
be of a very similar amount (data not shown). 
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Figure 7: Transfection Efficiency in HL-1 Cells.  
Transfection efficiency was measured at 34±4% in cells transfected with the scrambled 
siRNA, and 29±4% in cells transfected with the FXN-siRNA. There was no significant 
difference in transfection efficiency between the two groups. 
 
2.2.3 Fluorescence Imaging 
 
Basics of Fluorescence  
Certain atoms or molecules can be excited at a certain wavelength of light 
specific to that atom/molecule, after which they emit light at a specific 
emission wavelength. This is known as luminescence, and fluorescence is 
a subcategory of luminescence where light is emitted from the 
atoms/molecules 10-8 s or less after absorption of light by the 
atoms/molecules. Compounds that emit fluorescence are known as 
fluorophores. Specifically, a molecule absorbing light causes its electron to 
move from the electronic ground state into an excited state. Fluorescence 
is caused by an electron returning to the electronic ground state, emitting a 
photon. This light can be detected by an epifluorescence microscope. The 
microscope is engineered for optimal fluorescence signal detection, and 
therefore excites the fluorophore at wavelengths very close to or at its 
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absorption peak, minimises the background signal, and detects as much 
fluorescence emission as possible. 
 
 
CCD Microscopy 
Digital cameras are now used in fluorescence microscopy that incorporate 
a CCD photon detector, which allows for the transformation of light intensity 
information into information coded by localised electric charge that varies 
with changes in the light intensity. The detector is an integrated circuit 
etched onto a silicon surface forming light-sensitive elements called pixels. 
Photons incident on this surface generate charge that can be read by 
electronics, which can be quickly converted into a fluorescence intensity 
value for the corresponding location. Thus, the light signal is converted into 
quantitative, usable data based on its intensity in arbitrary units. The data 
of light patterns falling on the device is quantified digitally, allowing it to be 
reconstructed and displayed on a computer monitor. The capability for 
fluorescence imaging of a monochromatic CCD camera is tested by 
optimisation of the gain, offset and exposure time. CCDs have the highest 
light sensitivity of any light detection technique available. They can produce 
images with one input event, and therefore are ideal for picking up 
fluorescence events that change at speed (such as a change in Ca2+ levels 
in a cardiomyocyte), in a way that a confocal microscope is unable to do 
due to the decreased signal intensity that it exchanges for increased optical 
resolution.  
 
 
Confocal Microscopy 
The confocal microscope builds upon fluorescence microscopy techniques 
by using an optical imaging technique that improves optical resolution by 
adding a spatial pinhole at the confocal plane of the lens to eliminate out-
of-focus light (see Fig. 8). As only light produced by fluorescence very close 
to the focal plane is detected, the optical resolution of the image is much 
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better than that of wide-field microscopes like the CCD camera, allowing for 
the observation of finer detail. However, the increased resolution is at the 
price of decreased signal intensity, so longer exposures are required. The 
confocal microscope illuminates a specimen using a point laser source, 
unlike the CCD camera which uses a light detection technique. Unlike the 
CCD camera, it enables three-dimensional reconstruction of an object from 
the superimposition of sets of images obtained at different depths, a process 
known as optical sectioning where the object is scanned in the x and y 
direction as well as the z-direction along the optical axis. The light signal is 
in this case converted by photomultiplier tubes (PMTs) into quantitative 
electrical signals based on light intensity in arbitrary units, which is then 
digitised and displayed as an image on a monitor for further analysis. 
 
 
Figure 8: Confocal Microscope. Image in public domain. 
 
Ca2+ Imaging 
Once the cells were ready, the cells were analysed using the Fura-2-AM 
dye to measure Ca2+ levels and their fluctuation following addition of 
caffeine and thapsigargin. Fura-2-AM is a ratiometric UV-light excitable dye, 
which emits light when excited at 340 nm in Ca2+-bound form and at 380 nm 
in Ca2+-unbound form. The acetoxymethyl (AM) form is useful for 
noninvasive intracellular loading. Fluorescence measurements were 
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obtained using a cooled charge-coupled device (CCD) camera 
(Hamamatsu, Orca ER).  
 
Cytosolic [Ca2+] ([Ca2+]c) was observed in single cells using excitation light 
from a Xenon arc lamp, with the beam passing sequentially through 10 nm 
band pass filters centred at 340 nm and 380 nm placed inside a computer-
controlled filter wheel. Emitted fluorescence light was reflected via a 510 nm 
long-pass filter to the CCD camera and digitised to 12-bit resolution (Digital 
Pixel Ltd, UK). All imaging data was analysed using Andor software (Belfast, 
UK). 
 
To measure [Ca2+]c in transfected HL-1/H9c2 cells or primary mouse 
cardiomyocytes, the cells plated on 25 mm diameter coverslips in 6-well 
plates were first loaded for 30 minutes in the cell incubator with 5 µM Fura-
2-AM in 1 mL of HEPES-buffered salt solution (HBSS), so that the cells 
could take up the fluorophore.  Incubation in the dark is crucial as Fura-2-
AM is light-sensitive. Before adding the coverslips to the coverslip plates, 
the plates were washed for 5 minutes each in ethanol and H2O and dried 
thoroughly with a tissue. Meanwhile, the coverslips were transferred from 
the sterile incubator two at a time to maintain healthy cell conditions for as 
long as possible before the experiment.  
 
The Claycomb medium was removed and the cells were rinsed with 1 mL 
of HBSS, and then washed again in 1 mL of HBSS for 3-5 minutes, following 
which this was removed and another 1 mL of HBSS was added. Then one 
coverslip was removed with sharp tweezers and added to the coverslip ring, 
which was carefully sealed and the appropriate amount of HBSS (i.e. the 
correct amount so that any solutions added later in the experiment 
containing precise concentrations of drugs would add up to a full total of 500 
μL) was added as the recording medium. The CCD camera was turned on, 
beginning with turning on the computer and then progressively switching on 
the filter wheel and the monochromator, the noise of the filter wheel 
indicating that the camera was switched ‘on’ and the experiment could 
proceed. The Omega program was activated on the desktop.  
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When using the 40x objective, a drop of oil was added to the objective 
before placing the coverslip upon it; when using the 20x objective, no oil 
was added (using the 20x objective includes more cells in the field of vision 
but at the cost of a lower exactitude of measurement). Before the coverslip 
was placed on the objective and into the plateholder, the underside of the 
objective was cleaned with ethanol and dried with tissue. For measuring the 
intensity of the Fura-2-AM dye, a protocol was developed on the Omega 
software incorporating the 340 nm and 380 nm objective options in order to 
excite electrons alternately at 340 nm and 380 nm, allowing for a ratiometric 
measurement between the two Fura-2-AM intensities. The appropriate filter 
wheel was also selected for picking up emitted light, which was filter wheel 
2, which picks up the light emission of Fura-2-AM at a wavelength of 510 
nm.  
 
In the case of HL-1 and H9c2 cells, successful transfection was marked by 
co-transfection of YFP-tagged plasmid DNA, and therefore only cells 
showing successful YFP-DNA co-transfection were selected for analysis in 
the experiment. Thus, the Omega software was also used in this case to 
create a 472 nm light wavelength of excitation (adjusting the available 490 
nm objective option) in order to excite electrons at the appropriate 
wavelength for YFP, and thus provide an image of YFP-DNA fluorescence 
that could then be used for selecting which cells to analyse during the Ca2+ 
imaging. The appropriate filter wheel was also selected for picking up 
emitted light, which was filter wheel 4, collecting the emission with the 525-
536 nm band pass filter.  
 
Before beginning the visualization of the cells using the Omega program, 
the microscope light path was turned on and the microscope was adjusted 
to ‘optical’ mode. An appropriate cluster of cells to measure was found by 
microscope observation. Then, the microscope light path was turned off and 
the microscope adjusted to ‘fluorescence’ mode, and the live imaging option 
was selected on the Omega program. The pixel binning was set to the ‘4x4’ 
setting. The focus, gain (amplification applied to the photon detection 
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system), offset (the threshold that defines the lowest intensity of brightness 
displayed) and exposure time were adjusted to produce an image of YFP-
DNA fluorescence (if using HL-1 or H9c2 cells), and then of the Fura-2-AM 
fluorescence in the cells, that was crisp yet unsaturated at the 472 nm, 340 
nm and 380 nm wavelengths. Once an appropriate image was established, 
appropriate regions of interest were set and the analysis was run, ensuring 
that the traces were measured as ratios of excitation between 340:380 nm, 
and not measured separately.  
 
Caffeine-based experiments 
Caffeine is a non-selective adenosine receptor antagonist that activates 
release of Ca2+ from intracellular stores and can be used to assess SR Ca2+ 
content in skeletal or cardiac muscle fibres (Endo & Thorens, 1975; Fabiato 
& Fabiato, 1975). The caffeine was used to elicit release of Ca2+ from SR 
stores and compare the amplitude and peak shape of the ensuing Ca2+ 
spike, our first step in the search for indications of any change in Ca2+ 
homeostasis. Once a [Ca2+]c baseline was established for the cell, 10 mM 
caffeine was added at a single interval using pre-prepared 50 mM or 100 
mM aliquots of caffeine and the increase in [Ca2+]c following activation of 
the ryanodine receptors on the SR. Images were collected and digitised at 
the fastest intervals possible based on the time exposure of the images, 
with a minimum of 1 second intervals.  
 
Thapsigargin-based experiments 
Thapsigargin, a potent inhibitor of the SERCA pump (Rogers et al., 1995), 
was also used to assess SR Ca2+ content. In order to measure the effect of 
thapsigargin on the SERCA pump accurately, thapsigargin had to be added 
to the cells in a Ca2+-free solution, instead of in regular HBSS solution. The 
Ca2+-free recording medium was made using the following concentrations:  
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Table 6: Ca2+-free Medium. 
Constituents of 
Ca2+-free 
medium 
Required 
concentration (M) 
NaCl 2 
KCl 1 
MgSO4 1 
KH2PO4 1 
D-Glucose 1 
HEPES 1 
EGTA 0.5 
N.B. The EGTA must be calibrated at pH 8.01, so instead of a volume of 50 mL a volume 
of 200 mL was used (with 38.04g of EGTA), so as to allow enough volume for pH 
calibration. 
 
Ca2+-free 
medium 
Stock 
concentration 
(M) 
Final 
concentration 
(mM) 
NaCl 2 156 
KCl 1 3 
MgSO4 1 2 
KH2PO4 1 1.25 
D-Glucose - 10 
HEPES 1 10 
EGTA 0.5 0.5 
 
The Ca2+-free medium was then filter-sterilised and either used immediately 
in experiments using thapsigargin, or frozen at -20°C for later use. Before 
analysis with the cells bathed in HBSS in the coverslip dish under the CCD 
camera, the HBSS was replaced with 300 μL Ca2+-free recording medium, 
after which the experiment was run on the camera and the Ca2 baseline 
observed for 2 minutes. Then, thapsigargin pre-diluted in 200 μL Ca2+-free 
recording medium (to aid admixture) at an amount achieving a final 
concentration in the 500 μL of medium of 2 μM thapsigargin, was added to 
the coverslip, and the effect on Ca2+ levels recorded. 
 
To calculate the fluorescence, following normalisation against the baseline 
value, the highest ratiometric (340/380) Fura-2 fluorescence value obtained 
during the peak was subtracted by the final value of the baseline 
fluorescence before peak onset. In an additional measurement, the 
experiments using thapsigargin to inhibit the SERCA pump were carried out 
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having preincubated the cells in 10 µM dantrolene for 2 hours, and then 
proceeding as usual. Dantrolene inhibits the ryanodine receptors, and thus 
its use in combination with thapsigargin helps distinguish whether the 
effects of the frataxin knockdown are causing damage to the ryanodine 
receptors themselves. 
 
 
 
Measurements of ROS production 
The cells were also analysed for other physiological factors in addition to 
Ca2+ levels in order to find potential links between any findings regarding 
Ca2+ levels and other physiological events known to occur in FRDA. Using 
the CCD camera (as described in the Ca2+ imaging section), 
dihydroethidium (Het; 5 µM; Thermo scientific), a superoxide indicator that 
exhibits blue fluorescence in the cytosol until oxidized where it intercalates 
within the cell’s DNA and stains the nucleus a bright fluorescent red, was 
added in HBSS (Sigma) just before the start of the experiment to the HL-
1/H9c2 cells and remained in the solution for the duration of the experiment. 
The dye was used ratiometrically to measure cytosolic superoxide levels, 
as the dye was excited in unoxidized form at 364 nm (blue fluorescence) 
and in oxidized form at 543 nm (red fluorescence), and emitted fluorescence 
was collected using the dual band filter. Data was collected every 5 seconds 
using the ratio 543/364nm. This was then normalised through averaging the 
first 10 ratiometric values and dividing each value by this baseline. The rate 
of fluorescent units/second was calculated to allow for a comparison 
between the disease and control cell groups. Mitochondrial ROS was 
calculated following addition of 1 μM CM-H2Xros (Thermo scientific) 20 
minutes before beginning the experiment. 
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Measurement of NAD(P)H Autofluorescence  
The autofluorescence of NAD(P)H (or NADH and NADPH together) was 
imaged in cardiomyocyte cultures using the cooled CCD camera. The 
setting up of the experiment regarding transfer and preparation of cells for 
analysis using the CCD camera is as described in the Ca2+ imaging section. 
The autofluorescence that these pyridine nucleotides emit in their reduced 
forms was excited at 360 nm, with the emission collected by the 525-536 
nm band pass filter. After the transfected cells had been selected for by 
testing for YFP, cells were exposed to first the uncoupling agent carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 1 µM), to stimulate 
respiration and achieve maximum NADH oxidation, and then to NaCN (1 
mM), to inhibit respiration and achieve maximum NADH reduction. This was 
done in order to measure the full range of the autofluorescence signal, in 
relation to the full mitochondrial NADH pool, and thus to allow for 
normalisation of the data (Abeti et al, 2011). The following formula was used 
to normalise the NADH autofluorescence measurements:  
ΔFnormalised = (F - Ffccp) / (Fcn - Ffccp) 
 
 
Measurement of Mitochondrial Membrane Potential (Δψm) 
Tetramethyl rhodamine, methyl ester (TMRM) is a cationic, cell-permeant 
red-orange fluorescent dye readily sequestered by active mitochondria. It 
was used to estimate the dynamic signal Δψm in HL-1/H9c2 cell 
mitochondria, and to observe the fluctuations in the membrane potential 
when caffeine was added. FCCP, which is an uncoupling agent that disrupts 
ATP synthesis, was added at the end to fully dissipate the Δψm. In order to 
measure small fluctuations in Δψm, de-quenching mode was used. The cells 
were incubated for 20 minutes with 500 nM TMRM, and then prepared in a 
coverslip chamber and imaged using the cooled CCD camera (as described 
in the Ca2+ imaging section). The dye must be kept continuously in solution 
at 500 nM, as otherwise it will wash out of the cells immediately. The cells 
were observed in 300 µl of HBSS medium. After the transfected cells had 
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been selected for by testing for YFP-DNA expression, the TMRM was 
visualised using an excitation wavelength of 560 nm with a long pass filter 
using the 810 Zeiss confocal microscope. Depolarisation was indicated by 
an increase of Δψm. Once the experiment had begun and a TMRM baseline 
value established among the cells selected, 10 mM caffeine was added, 
and 1 µM FCCP was added after a 10-minute interval from the start to 
complete the experiment. 
 
 
 
Immunofluorescence 
Immunofluorescence techniques were used to visualize the frataxin mRNA 
knockdown achieved by the HL-1/H9c2 cells siRNA transfection. To do this, 
a Zeiss 810 UV-vis confocal laser scanning microscope (CLSM) was used 
to obtain the images. Immunofluorescence is a semi-quantitative method 
that uses the specificity of antibodies to their antigen to target fluorescent 
dyes to specific molecular targets within the cell, thereby allowing 
visualization of the target molecule throughout the sample. It is an example 
of immunostaining (using antibodies to stain proteins). In this experiment, 
the unlabelled primary antibody specifically binds the target molecule, and 
the secondary antibody carrying the fluorophore recognizes the primary 
antibody and binds to it. Secondary antibodies must be against the host 
species of the primary antibody being used. 
Following transfection of the cells in 6-well plates as described above, the 
Claycomb medium was removed by aspiration and the coverslips were 
washed twice in PBS 1x. The wash buffer was aspirated, and the cells fixed 
by addition of 4% paraformaldehyde (PFA). The PFA was prepared in PBS 
at 60°C and in 1 M NaOH in order to dissolve the paraformaldehyde.  The 
cells were incubated in PFA for 10-15 minutes, after which the PFA was 
removed by aspiration and the cells washed thoroughly three times (for 5, 
10 and 5 minutes) with PBS 1x. After the last wash was aspirated, the cells 
were permeabilised by addition of 0.1% Triton X-100 in PBS 1x and 
incubation for 30 minutes at room temperature. After this detergent solution 
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was removed by aspiration, the coverslips were again washed in PBS 1x 
three times as before. After the last wash was aspirated, blocking solution 
made from 3% bovine serum albumin (BSA) and 10% goat serum in 0.1% 
Triton X-100 in PBS 1x was added, and the cells were incubated in this 
solution for 1 hour at room temperature. After the blocking solution was 
aspirated, the primary antibody solution was added to the coverslip. The 
primary antibody used was the mouse monoclonal anti-frataxin antibody 
[17A11] ab113691 (Abcam) at a concentration of 1 μg/mL for 
immunofluorescence. The primary antibody was provided at 1 mg/mL and 
was therefore diluted 1:1000 in 3% BSA and 10% goat serum in 0.1% Triton 
X-100 in PBS 1x, using enough solution to cover the entire coverslip (25-50 
μL).  
 
The cells with the primary antibody applied were incubated at room 
temperature for 1 hour (keeping the lid on the 6-well plate to avoid 
evaporation) or overnight in a humidified chamber at 4°C. The specificity of 
the immunoreactions was controlled by adding buffer rather than primary 
antibodies in a control coverslip(s), which did not result in immunostaining.  
Following this, the coverslips were washed three times in PBS 1x, then 
drained and applied with the secondary antibody. The secondary reagent 
used was Alexa Fluor 568 goat anti-mouse IgG (A-11004, Thermo Fisher 
Scientific), diluted 1:1000 for one hour beforehand in 3% BSA and 10% goat 
serum in 0.1% Triton X-100 in PBS 1x. The coverslips were incubated for a 
minimum of 45 minutes in darkness, after which the coverslips were washed 
three times in PBS 1x. On the final wash in PBS, 300 nM DAPI was added 
for 5 minutes in order to stain the nuclei to allow for their detection, and the 
cells were incubated at room temperature in the dark for 2-5 minutes. The 
cells were washed three times in PBS 1x again. Then, a drop of mounting 
medium was placed on a microscope slide and the coverslip was placed 
upon the drop, cell side down. The coverslip was sealed and the cells were 
wrapped in foil and kept at 4°C until ready for viewing with the confocal 
microscope. Confocal images were obtained using a Zeiss 810 UV-vis 
CLSM equipped with a META detection system and a 40x oil immersion 
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objective. Illumination intensity was kept as low as possible to avoid 
phototoxicity and the pinhole was set to give an optical slice of 2 µm. 
 
 
2.2.4 DNA Analysis of YG8R/Y47R/WT mice 
Mice pups were obtained from mating couples of a YG8R/Y47R mouse 
colony. In order to genotype these pups or any mice of interest from the 
colony that could be used in matings, a sample had to be obtained from 
them and analysed by PCR methods. Briefly, PCRs were carried out in a 25 
μL volume containing 200-500 ng of genomic DNA from the mice, 2.5 pmol 
of each primer, and the Extract-N-Amp tissue PCR kit (Sigma-Aldrich).  
Genomic DNA was isolated from ear or tail biopsies of mice. PCR analysis 
was carried out using GAA-F and GAA-R primers (Campuzano et al., 1996). 
DNA extraction was performed as follows: each ear/tail was first placed in 
a 0.5 mL Eppendorf tube, and 100 μL of Extraction solution was added, as 
well as 25 μL of tissue preparation solution, and the solution was mixed by 
pipetting. The sample was then incubated at room temperature for 10 
minutes, after which it was incubated at 95°C for three minutes on a heat 
block. Then, 100 μL of Neutralisation solution B was added to the sample, 
which was then mixed by vortexing and centrifuged for 5-10 seconds. All 
the solutions were from the Extract-N-Amp tissue PCR mix. These DNA 
extractions from mouse tails or ears were either used immediately in a PCR 
experiment or stored at 4°C for later use. Meanwhile, the following PCR mix 
was prepared on ice: 
 
 
Table 7: PCR Mastermix for DNA Analysis of YG8R/Y47R Mice. 
PCR mastermix reagents 
Volume per sample 
(μL) 
Extract-N-Amp Polymerase 12 
PCR-grade dH2O 8 
GAA-F (from 100μM stock) 0.5 
 101 
GAA-R (from 100μM stock) 0.5 
 
The primers used were those from the original Campuzano paper that 
details them (Campuzano et al., 1996): 
GAAF: 5’- GGG ATT GGT TGC CAG TGC TTA AAA GTT AG-3’  
GAAR: 5’-GAT CTA AGG ACC ATC ATG GCC ACA CTT GCC-3’ 
 
The PCR mastermix was prepared for n+1 samples, with each sample 
prepared in duplicate and including positive controls for the three transgenic 
genotypes Y47R, YG8R and Y47R/YG8R and an H2O control. 21 μL was 
then added to the pre-labelled 250 μL Fischer PCR tubes, and 4 μL of the 
appropriate DNA extraction mix was added to each. The tubes were quickly 
agitated and centrifuged, and then added to the PCR machine using the 
following PCR amplification cycle: 
Table 8: PCR Cycles for DNA Analysis of YG8R/Y47R Mice. 
Cycles Stage Temp Time 
1 cycle denaturation 94°C 3 minutes 
10 cycles denaturation 94°C 10 seconds 
 annealing 62°C 30 seconds 
 elongation 68°C 3 minutes 
20 cycles denaturation 94°C 10 seconds 
 annealing 62°C 30 seconds 
 elongation 68°C 3 minutes + 20 second 
increments per cycle 
1 cycle  68°C 10 minutes 
  4°C pause 
 
Following completion of the PCR reaction, 10 μL of PCR product was added 
to a 1.5% agarose gel made using 1xTBE, using 5 mL of Invitrogen 1kb 
ladder, and gel electrophoresis was performed. The gel was run at 80V for 
1 hour in the large tanks after which the gel was checked, and then for a 
further 2 hours and 20 minutes in order to size the bands. In the smaller 
minigel trays the gel was run at 40V for 40 minutes to 1 hour. Band sizes 
are 457 base pairs + 3x the GAA repeat number of the sample. 
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2.2.5 Statistical Analysis 
Data were generated from a minimum of three independent experiments 
(three sets of three coverslips). Statistical analysis was carried out with the 
OriginPro 2015 software (OriginLab Corporation). The data is expressed in 
the form mean ± standard error of the mean (SEM). 
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Chapter 3 : Genetic Screening 
Study of Ataxia Patients for 
Friedreich’s Ataxia 
 
3.1 Introduction 
FRDA is a complex, multisystem disorder that displays varying rates of 
progression in patients. This divergence in progression has been addressed 
in several case studies. Through comparing the age at onset, timespan 
between age at onset and first use of wheelchair and first onset of various 
common symptoms such as dysarthria and lower limb and upper limb 
weakness, these studies developed a clearer understanding of FRDA 
progression (Harding, 1981; Schols et al., 1997). These studies provided 
evidence for a general timescale for FRDA from age at onset to death. 
However, the amount of variation in age at onset as well as rate of 
progression was high enough to elicit studies into the frequency and nature 
of atypical forms of FRDA, such as late-onset or very-late onset FRDA 
(LOFA/VLOFA), as well as a potential genetic basis for their occurrence. 
 
The discovery of the genetic basis for Friedreich’s ataxia (Campuzano et 
al., 1996) crucially allowed for a full clinical description of atypical cases of 
the disease. Many of these had previously been misdiagnosed due to being 
outside the established clinical diagnostic criteria (Durr et al., 1996; Filla et 
al., 2000; Geoffroy et al., 1976; Harding, 1981; Schols et al., 1997). These 
cases had a less severe disease phenotype, involving a later onset of 
disease, milder or absent neurological symptoms, slower progression and 
an absence of non-neurological symptoms (Bhidayasiri et al., 2005; 
Coppola et al., 1999; De Michele et al., 1994; Gellera et al., 1997; 
Klockgether et al., 1993; Montermini et al., 1997; Ragno et al., 1997). 
Indeed, onset can rarely even be in a very late age range after 50, making 
misdiagnosis more probable for these patients (Berciano et al., 2005; 
Galimanis et al., 2008). Patients with an age at onset after 50 are 
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characterized as VLOFA, whereas patients with an age at onset between 
25 and 50 are characterized as LOFA. 
 
There is a well-established correlation between the rate of 
progression/severity of FRDA and the size of the GAA1 allele, with very 
small sizes below 100 GAA repeats often responsible for atypical FRDA 
(Schols et al., 1997; Sharma et al., 2002). Atypical FRDA can also present 
due to compound heterozygosity. This can involve a point mutation in one 
FXN allele alongside the GAA expansion in the other (Campuzano et al., 
1996; Cossee et al., 1999; Gellera et al., 2007), with atypical symptoms 
particularly common in cases involving the p.G130V missense mutation 
(Bidichandani et al., 1997; Cossee et al., 1999; Forrest et al., 1998). Very 
rarely an exonic deletion is present instead of a point mutation, which has 
also been shown to lead to an unusual presentation of FRDA in one case 
(van den Ouweland et al., 2012).  
 
Thus, it is crucial for clinicians to understand the difference between 
classical FRDA and LOFA/VLOFA, in order to correctly diagnose FRDA 
even when it presents atypically. This chapter concerns a study I carried out 
regarding the frequency of atypical FRDA cases in the disease, in order to 
understand to what extent FRDA cases were being missed by clinicians. 
Specifically, a consecutive series of 2000 ataxic patients who lacked a 
genetic diagnosis after having been referred for the major spinocerebellar 
ataxias (SCA1, 2, 3, 6, 12 and 17) and who had not been originally referred 
for a FRDA test, presumably as their symptoms were atypical for the 
disease, were screened for FRDA. This chapter details this study and 
places it in the context of: 
1. Previous studies on FRDA disease progression and on atypical 
FRDA, including late-onset/very-late onset Friedreich’s Ataxia and 
the influence of GAA expansion size and compound heterozygosity 
on patient phenotype. 
2. A previous study by Dr M.H. Parkinson, which studied genotype-
phenotype correlation in 1768 patients from the same database as 
the 2000 patients in my study, but who had already been referred for 
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FRDA testing by their clinicians, and thus presumably had symptoms 
that fit the diagnostic criteria for FRDA. 
 
 
3.2 Results 
 
3.2.1 Genetic Analysis 
A consecutive series of 2000 patients from the UK who 1) presented with 
ataxia, 2) lacked a genetic diagnosis after having been tested for the major 
spinocerebellar ataxias (SCA1, 2, 3, 6, 12 and 17), and 3) had not been 
referred for FRDA testing, were tested for FRDA using DNA samples from 
the patients that had been taken between the years 1996 and 2013. The 
DNA from all relevant patients was obtained from the NHNN Department of 
Neurogenetics.  The vast majority of neurogenetics labs test for the 
presence of pathological GAA expansions by the two-stage molecular 
diagnostic process of 1) triplet-primed PCR and 2) long-range PCR. Using 
this two-stage PCR process, 2000 cases were screened for FRDA in the 
laboratory. If two GAA expansions are discovered after stage 2, a genetic 
diagnosis of FRDA can be made. Twenty cases tested positive at the TP-
PCR stage, which confirmed the presence of a FXN GAA triplet repeat 
expansion in at least one allele for each sample (refer to Methods, section 
1.2). At the long PCR stage, 3 cases were shown to have triplet repeat 
expansions in both alleles and were thus newly diagnosed as being FRDA-
positive (0.15% of cases; Fig. 10). The number of pathological GAA 
expansions for each allele in the three FRDA-positive patients determined 
following long-range PCR are given in Table 10. The intermediate zone 
between ‘normal’ and ‘pathologically’ expanded repeats as classified and 
used in the Neurogenetics laboratory of the NHNN is between 35 and 89 
GAA repeats. In all three patients, the number of GAA repeats in each allele 
is over the threshold and thus pathological for FRDA. However, although 
individuals affected with FRDA commonly have GAA expansion sizes 
between 600 and   900 GAA repeats (Campuzano et al., 1996; Entezam et 
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al., 2017; Epplen et al., 1997), the number of GAA repeats is lower for the 
GAA1 allele of each of the three patients. Patient 3 has a GAA expansion 
size that is very close to the upper threshold for the non-pathological 
intermediate zone in FRDA: 100 GAA repeats in each allele. Patient 1 has 
170 repeats in GAA1 and 550 repeats in GAA2, respectively. Such a small 
amount of GAA repeats indicates a likely late-onset, very slowly progressive 
disease course, particularly in patient 3. Patient 2, on the other hand, has 
two divergent pathological GAA expansions of 420 and around 2000 GAA 
repeats (for the larger amounts, it becomes difficult to set an exact 
measurement based on the gel reading).  Although the GAA1 allele is still 
well below the usual amount of 600-900 GAA repeats in FRDA patients, the 
larger size of the GAA2 allele indicates a potential earlier age at onset and 
faster course of disease compared to patient 1 and patient 3, respectively. 
The allele sizes of all three patients indicate late-onset atypical FRDA with 
its accompanying phenotype of slower progression and more variable 
symptoms, where patients usually have between 100 and 500 repeats in 
the GAA1 allele (Bhidayasiri et al., 2005; Durr et al., 1996; Schols et al., 
1997). Furthermore, for patient 3, the number of GAA repeats is 
indistinguishable in each allele, as shown by the presence of only a single 
band on the gel indicating pathological GAA expansion, and no 
corresponding control band (Fig. 10). There is an extremely small chance 
that this patient could be compound heterozygous for a single pathological 
GAA expansion and a large deletion, although this has never been 
discovered in a FRDA patient. Nevertheless, it is standard laboratory 
procedure to assume the far more likely scenario that this single band 
comprises the DNA from two pathological GAA expansions, and not screen 
this patient for exonic deletions. These first conclusions drawn from the 
genetic data are placed in the context of clinical data in Section 3.3, where 
a full genotype-phenotype correlation is performed on the three FRDA-
positive patients discovered in this study. 
 
Of the other 17 cases that tested positive at the triplet-primed PCR stage 
and were subsequently tested by long range PCR, a further 12 cases were 
shown to have a pathological GAA repeat expansion in only one allele, while 
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in the other 5, no result was attainable using this process due most likely to 
DNA degradation (Fig. 10). These samples were thus referred for further 
testing for compound heterozygosity status by searching for possible FXN 
point mutations and exonic deletions. If only one expansion is found in an 
individual with ataxic symptoms, the DNA is first put through sequence 
analysis to test for pathological point mutations.  The samples were sent off 
for external sequence analysis at Royal Liverpool University Hospital and 
all returned negative for any of the relevant FRDA point mutations. 
 
 
Figure 9: Long-range FXN PCR Example Photo. 
Lane 20 = FRDA patient. Lane 21 = no DNA control. Lanes 22/23 = Negative (GAA-/-) 
controls. Lanes 24/25 = Carriers (GAA+/-). Lane 26 = Positive control (GAA+/+). 1kb size 
ladder (Promega, Madison, WI, USA) with equivalent GAA sizes. To calculate the number 
of GAA repeats, the required formula was allele size = (number of base pairs-457)/3. The 
reasoning behind this calculation is that the synthesised PCR products contain flanking 
sequences totalling 457 base pairs in addition to the GAA trinucleotide repeat expansion. 
Normal alleles run at approximately 500 base pairs, whereas affected alleles run at 
approximately 720 base pairs or above. Gel courtesy of Dr Robyn Labrum and Dr Ese 
Mudanohwo, also used in M. H. Parkinson thesis.   
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Figure 10. Long Range PCR: FRDA Positive and Carrier Data. 
A) The FRDA-positive data for patients 1, 2 and 3 obtained by Long-range PCR, visualized 
on a 2% agarose gel following electrophoresis, with GAA sizes indicated. B), C), D) 10 of 
the 12 FRDA carriers displayed in lanes 21, 23, 24, 25, 32, 37, 38, 41, 42 and 46. 1kb size 
ladder (Promega, Madison, WI, USA) with equivalent GAA sizes was used. 
 
 
 
 
3.2.2 MLPA Testing 
The multiplex ligation-dependent probe amplification (MLPA) process 
measures gene dosage and allows identification of FRDA patients 
incorporating large deletions in the FXN gene (Deutsch et al., 2010). As well 
as the 12 patients to be screened, a negative control used by the NHNN 
laboratory was used that was clinically confirmed as lacking pathological 
GAA expansions and thus being FRDA-negative.  The MLPA GeneMapper 
software uses this negative control to calculate an ‘Exon Dosage Quotient’ 
(EDQ) score for the disease exons by creating peaks based on the patient 
sample and control sample exon size, and then comparing the ratio (Fig. 11 
 
D 
14 GAA 
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& Fig. 12). A non-DNA containing control containing TE buffer was also 
included to test for contamination by extraneous DNA of any of the reactions 
during the experiment. The MLPA reaction ‘failed’ for the TE control, 
indicating no contamination of the MLPA reaction reagents. In the MLPA 
results, an EDQ of 1±0.25 shows no evidence of exon deletion or duplication 
in any of the five exons that the MLPA reaction is designed to study. A result 
of 0.5±0.25 shows heterozygous deletion, while a result of 0±0.25 shows 
homozygous deletion. Conversely, a result of 1.5±0.25 shows heterozygous 
duplication, and a result of 2±0.25 shows homozygous duplication. In theory 
an exon triplication could also occur, but this has never yet been observed 
in any FRDA patient.  
 
For all 12 GAA+/- cases discovered by the previous two-stage PCR 
process, the EDQ score for exons 1 to 5 were all within the 1±0.25 range, 
indicating that exon deletion or duplication at each of the probe sites was 
absent (Table 9). Using GAA+/- patient 8 as an example, Figure 11 shows 
the signal intensity of peaks for each of the probes for this patient in blue 
and for the negative control in red for comparison, with the five FXN exon 
probes labelled.  The ratio of blue to red peaks generates the EDQ. As can 
be observed, they are all of approximately equal height, and so the EDQ 
ratios are all in the 0.75-1.25 range. Figure 12 shows the EDQs for GAA+/- 
patient 8 with the disease probes in green and the reference probes in blue, 
and the five FXN exon probes again labelled. All the values can be clearly 
seen to be within the 0.75 to 1.25 ‘normal’ range, indicating the absence of 
exonic deletions or duplications in the FXN gene.  
 
As none of the 12 GAA+/- individuals were positive for any point mutations 
or exonic deletions in the FXN gene, they were confirmed as FRDA carriers. 
The carrier rate was calculated at 0.6%, or 1 in 167, in the full cohort. A 
large variation has previously been seen in carrier frequency, with which the 
carrier frequency of this study is broadly compatible (Cossee et al., 1997; 
Epplen et al., 1997; Filla et al., 1992; Harding & Zilkha, 1981; Romeo et al., 
1983). Finally, the other 5 cases remaining that also tested positive at the 
triplet-primed PCR stage showed no result after either gel or capillary 
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electrophoresis at the long-range PCR stage, due to probable degraded or 
low-quality DNA.  
 
Table 9: FXN Exon Dosage Quotients (EDQ) for 12 GAA+/- samples 
and controls. 
Sam-
ple 
Pre-test 
status 
EDQ 
Exon 1 
EDQ 
Exon 2 
EDQ 
Exon 3 
EDQ 
Exon 4 
EDQ 
Exon 5 
1 GAA +/- 0.954 0.998 0.996 0.882 1.067 
2 GAA +/- 0.897 1.093 0.943 1.051 0.969 
3 GAA +/- 0.998 0.919 1.057 1.164 0.920 
4 GAA +/- 1.013 1.000 1.024 0.975 1.047 
5 GAA +/- 1.057 0.997 0.967 0.864 1.008 
6 GAA +/- 0.923 1.085 1.052 1.073 1.027 
7 GAA +/- 0.885 0.995 0.964 0.998 1.017 
8 GAA +/- 0.981 0.984 1.015 0.909 1.068 
9 GAA +/- 0.967 0.982 0.937 1.027 1.014 
10 GAA +/- 1.103 1.010 0.943 0.820 1.001 
11 GAA +/- 1.150 1.053 0.968 0.924 0.962 
12 GAA +/- 1.251 1.121 1.029 1.130 0.933 
13 GAA -/- 1.000 1.000 1.000 1.000 1.000 
14 TE 
control 
- - - - - 
15 GAA +/+ 1.108 1.086 1.004 0.893 0.985 
16 GAA +/+ 1.162 1.113 1.174 1.138 0.968 
17 GAA +/+ 0.908 1.087 1.062 1.126 1.051 
Mean±
SD All GAA 
+/- 
1.006±
0.093 
1.020±
0.060 
0.991±
0.045 
0.985±
0.108 
1.003±
0.046 
Range 0.885-
1.150 
0.919-
1.121 
0.937-
1.057 
0.820-
1.164 
0.920-
1.068 
Mean±
SD All 
values 
1.015±
0.095 
1.033±
0.060 
1.008±
0.062 
0.998±
0.108 
1.002±
0.042 
Range 0.992-
1.151 
0.919-
1.121 
0.937-
1.174 
0.820-
1.164 
0.920-
1.068 
GAA +/- one GAA expansion (symptomatic carrier) 
GAA -/- no GAA expansions (negative control) 
GAA +/+ two GAA expansions (known FRDA patient reported as having two identically 
sized expansions) 
TE=Tris-EDTA buffer (no DNA control) 
SD=standard deviation 
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Figure 11: Peak height comparison chart for patient 8. 
Chart generated by GeneMarker software. Blue peaks = patient samples; red peaks = 
control samples. 64-82 peaks=Q-fragments; 88-105 peaks=D,X,Y & 92bt control 
fragments; 128-481 peaks=FXN, SETX, APTX & 9 control genes including FXN peaks at 
154, 208, 234, 258 & 472. The ratio of the red peaks:blue peaks was used to calculate the 
peak ratios (EDQ) in Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Peak ratios (EDQ) for patient 8. 
Chart generated by GeneMarker software. Peak ratio (EDQ) for disease (green) and 
reference (blue) probes. The five FXN gene probes are highlighted (154, 208, 234, 258 & 
472nt). The remainder are for SETX and APTX. All values are within the upper and lower 
limits of normal, indicating no evidence for deletions or duplications of any FXN exon. 
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Table 10: General summary of FRDA-positive cases from ataxic 
patient screening study. 
 
3.2.3 Clinical Features 
Three patients out of the cohort of 2000 patients screened were confirmed 
through the two-stage PCR process as being positive for FRDA via the most 
common homozygous recessive genotype. A further twelve were confirmed 
via additional point mutation and exonic deletion testing as having a FRDA 
carrier status (Fig. 13). The clinical features of all FRDA-positive patients 
that have been derived from available medical notes and clinic letters are 
summarised in Table 10 and detailed more fully in Table 11 and Table 12 
respectively. The mean±SD age at onset for the three patients was 
43.3±16.1 (range 25 to 55). The incompleteness of patient data for all three 
patients does not allow for a complete clinical description, but there are 
many interesting clinical findings that provide an understanding of the 
reason for the original misdiagnoses. 
 
Very Late-onset Patient 1: Intrafamilial Variability 
Patient 1, a right-handed male, had a very slowly progressive gait and 
truncal ataxia, with mild dysarthria and retained reflexes. He swayed to 
either side and was positive for the Romberg test. However, his fine motor 
functions were still intact, and he had no numbness, weakness, or 
Patient 
no. 
Age 
at 
Onset 
Expansion 
size, allele 
1 
Expansion 
size, allele 
2 
Symptoms summary 
1 50 170 550 
Cerebellar ataxia, very slowly 
progressive gait and truncal ataxia, 
mild dysarthria, impaired balance 
2 25 420 2000 
Progressive gait ataxia, impaired 
balance, paresthesias in hands and 
feet, areflexia, reduced vibration 
and joint position sense, mild 
dysarthria, blackouts 
3 55 100 100 
Progressive gait ataxia, brisk lower 
limb reflexes, extensor plantars, 
dysarthria, reduced vibration sense 
 115 
impairment of the visual, auditory or any other neurological system. His 
records showed no reports of any non-neurological symptoms or wheelchair 
use. Thus, his symptoms were almost exclusively cerebellar in nature, 
unlike the usual FRDA combination of cerebellar and sensory ataxia. There 
was no family medical history of note, with one fascinating exception. It is 
speculated in patient 1’s clinical notes that his elder brother had been 
tentatively diagnosed with multiple sclerosis in his mid-20s. Over the next 
10 to 15 years his brother’s fine motor function deteriorated, and he was 
eventually confined to a wheelchair. Over another 15 years, his ability to 
move deteriorated further, and he died in his 60s. He was not excessively 
rigid, nor did he have dysarthria or any significant problems with any 
neurological systems. The FRDA diagnosis of patient 1 greatly increases 
the probability that his brother is also a FRDA case, given also the slowly 
progressive nature of his disease and the lack of any previous family history. 
However, a potential FRDA re-diagnosis is unfortunately not possible as 
DNA is not available from the brother. If the brother was to be retrospectively 
interpreted as FRDA-positive, the intrafamilial variability of age at onset of 
25 years would indicate instability of the FRDA expansion mutation and 
great intrafamilial clinical heterogeneity in FRDA.  
 
Patient 2: Borderline LOFA case 
Patient 2, a right-handed female patient, was referred for a progressive 
neuropathy at age 27. The patient’s predominantly insidious symptoms had 
onset in her early 20s and had worsened from age 25. In addition, her past 
medical history was positive for blackouts from age 17. On referral she had 
a wide-based ataxic gait, impairment of balance, mild dysarthria and 
gradually progressive numbness and paresthesia in her hands and feet. 
However, she had normal eye movement and cranial nerves on 
examination. Her Romberg’s test was positive, and she had areflexia, 
reduced joint position sense in her knees and elbows and bilateral finger-
nose incoordination. She was confined to a wheelchair in her early 30s. 
Although the comparatively earlier onset points to a genetic cause of 
neuropathy, she had no significant past medical family history of note: only 
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one maternal uncle was diagnosed with multiple sclerosis in his 20s and 
died at 31. A sural nerve biopsy was carried out that showed no clear 
evidence of inflammatory change in the nerve itself. Thus, the relatively mild 
sensory deficit was thought to be not severe enough to cause her ataxia. 
Her MRI scan was normal. Thus, the patient showed progressive sensory 
neuropathy and a mix of sensory and cerebellar ataxia.  
 
Very Late-onset Patient 3: A Clinical Conundrum  
Patient 3, a male, presented with late onset cerebellar ataxia at 55 years of 
age. He had progressive balance problems, slurred speech, incoordination 
and dysphagia. As he was a heavy drinker, regularly consuming up to 100 
units of alcohol a week for 30 years of his life, it was suggested that his 
cerebellar syndrome was all alcohol-related, and undeniably his alcohol 
intake will have contributed to his condition. However, on cutting his alcohol 
intake drastically, his physical signs continued to progress gradually with 
age, which can occur in alcoholic cerebellar degeneration but may also 
imply possible alternative explanations for his disease. He had high blood 
pressure and pleural calcification on chest radiograph. On examination he 
presented with cerebellar dysarthria, nystagmus, finger-nose and heel-shin 
ataxia and an ataxic broad-based gait. He had pyramidal signs and reduced 
vibration sense in the legs, as well as brisk lower limb reflexes and upgoing 
plantars. His power and reflexes were otherwise normal, and his records 
showed no reports of any non-neurological symptoms or wheelchair use. 
 
 
3.2.4 Comparison of Clinical Data 
Two of the three FRDA positive cases had VLOFA, with ages of onset of 55 
(Patient 3) and 50 (Patient 1) respectively. Neither patient showed any 
ancestral history of ataxia, indicative of a recessive condition.  The results 
from the long-range PCR for the two VLOFA patients indicate the GAA1 
expansion sizes in both alleles were extremely close to the mimimum 
diagnostic threshold for FRDA (Patient 1, 170 GAA repeats; Patient 3, 100 
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GAA repeats), which may well account for the extremely late onset of 
disease in the two patients (Table 10). Both male, they presented with gait 
ataxia, as is common in both classical and late-onset FRDA (Bhidayasiri et 
al., 2005; Gellera et al., 1997). As expected, they had an extremely slow 
disease progression and showed symptoms of mild dysarthria. Overall, 
patient 3 showed the less benign phenotype of the two patients, presenting 
with pyramidal signs and reduced vibration sense in the legs, upgoing 
plantars and nystagmus, which were all either absent or unreported in 
patient 1. Both showed an absence of several symptoms expected in FRDA, 
such as all the non-neurological symptoms, pes cavus and sensory 
neuropathy. Although subtle sensory neuropathy is usually present in 
VLOFA (Berciano et al., 2005; Lhatoo et al., 2001), it may not have been 
picked up clinically due to misdiagnosis. Spastic tetraparesis is often 
observed in VLOFA (Berciano et al., 2002; Labauge, 2002; Lhatoo et al., 
2001), but patient 3 shows brisk reflexes only in the lower limbs, while in 
patient 1 even the fine motor functions are still intact. Surprisingly, the 
symptoms of patient 1 indicate a pure cerebellar ataxia rather than the 
typical mix of cerebellar and sensory ataxia in FRDA, which may go some 
way to explain the misdiagnosis of this patient. Patient 3 has symptoms 
which may appear more indicative of FRDA at first glance, but his original 
diagnosis of pure alcohol-induced ataxia due to his lifestyle, although 
partially correct, was evidently responsible for his FRDA not being 
diagnosed for many years.  
In the case of patient 2, a threshold LOFA patient with onset in her early to 
mid-twenties, the long-range PCR gave FXN GAA expansion sizes of 
around 420 repeats in the smaller allele and somewhere between 1500-
2500 repeats in the larger allele. This would increase the probability of a 
more severe phenotype and an earlier age of onset, as is indeed the case 
in the results. As the smaller GAA1 allele accounts for 62.9% of age at onset 
variation and the larger GAA2 allele accounts for 15.6% of the variation in 
LOFA patients (Lecocq et al., 2016), the expanded allele of 420 GAA 
repeats is probably more relevant phenotypically than the allele with the 
larger pathological expansion. This patient displayed areflexia and reduced 
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joint position sense in knees and elbows, unlike the two VLOFA patients, 
and was confined to a wheelchair in her early 30s. Her presenting symptom 
was also a progressive neuropathy accompanied by blackouts, although it 
was later concluded that her sensory deficit was too mild to be the cause of 
her ataxia. This patient conforms to a general LOFA milder phenotype with 
more variable symptoms, and it is possible that the unusual presenting 
features for FRDA including the blackouts may have initially misled 
clinicians. 
 
 
Figure 13: Flowchart summary of genetic results in 2000-patient two-stage PCR 
study. 
GAA+/+ two GAA expansions; GAA+/- one GAA expansion; GAA-/- no GAA expansions. 
MLPA = multiplex ligand-dependent probe amplification.  
 
3.2.5 FRDA Carrier Clinical Details 
Clinical details were obtained for 9 out of 12 FRDA carriers, who were all 
originally referred for idiopathic ataxia. As none of these patients were 
compound heterozygous for an FRDA point mutation or exonic deletion, 
they are not FRDA-positive or expected to have FRDA-like symptoms 
(Andermann et al., 1976; Harding, 1981). I provide their clinical details for 
the purpose of comparing their phenotype with the FRDA-positive patients, 
GAA +/+  n=3
GAA +  n=20 GAA - n=1980
FXN point mutation = 0
GAA +/- n=12
Symptomatic heterozygote 
(no point mutation) = 12
MLPA
Degraded DNA  n=5
Long PCR n=20
TP-PCR  n=2000
Friedreich’s 
ataxia n=3
No Friedreich’s ataxia
No exonic deletion = 12Exonic deletion = 0
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and better understanding the potential clinical difficulty in diagnosis and 
selecting which patients to refer for FRDA testing among the thousands of 
patients referred with ataxic symptoms to diagnostic clinics in the UK. 
Patient 1, a female, had eye movement disorder and dizziness, triggered by 
a virus. Her age of onset for these symptoms was 32. 
Patient 2, a female, developed a cerebellar syndrome with some episodic 
features and severe nystagmus after she had suffered renal failure during 
an acute illness at age 50. She also had a mild gait ataxia, although her eye 
movement abnormality was more severe than her ataxia. It was uncertain 
whether her episodic ataxia had a progressive course. It is also unknown 
whether her renal symptoms could have had a neurological basis. 
Patient 3, a female, presented with severe dysphagia. She experienced falls 
beginning at age 65, and her very late onset ataxia was slowly progressive. 
Her symptoms included a cerebellar atrophy consistent with progressive 
supra-nuclear palsy, dysarthria, extended neck, visual hallucinations, 
horizontal nystagmus and bradykinesia. 
Patient 4, a left-handed male, had spastic paraplegia, possibly hereditary. 
His mother had a progressive gait disturbance. 
Patient 5, a male, had a progressive alteration in sensation in both feet from 
age 48. His hands also became less sensitive in making fine movements, 
and he was diagnosed with a painful sensory neuropathy of uncertain 
cause. Following further analysis, he was diagnosed with small fibre 
neuropathy, with possible corticospinal tract features. He had non-sustained 
left horizontal nystagmus, but brisk reflexes and a lack of cerebellar ataxia. 
He also had a slowly progressive dysfunction of thermal perception. He had 
no family history of neurological disease. 
Patient 6, a male, had partial epilepsy and secondary generalisation 
cerebral and cerebellar atrophy. He experienced his first seizure age 19, 
and thereafter suffered from complex partial and secondary generalised 
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seizures, at the rate of around 15 per year. He had an ataxic, broad-based 
gait. 
Patient 7, a female, was diagnosed at age 25 with oscillopsia and finger-
nose ataxia. She veered to the right when walking and had the sensation of 
vertigo on awakening. At age 50, she was diagnosed with 
temporomandibular joint disturbance, nystagmus, bilateral extensor plantar 
responses, dizzy spells, poor balance, severe depression, mild cerebellar 
signs on examination, and increasingly poor vision. It was felt likely that the 
patient had demyelination of the vertebral column, commonly the first 
episode in multiple sclerosis. This patient was indeed later diagnosed with 
multiple sclerosis. 
Patient 8, a female, presented with impaired mobility and became 
wheelchair bound. This patient was later diagnosed with multiple sclerosis. 
Patient 9, a left-handed female, developed seizures from age 2, consisting 
of absence-like attacks of a few seconds. Her conditioned worsened, and 
at 19 she had cryptogenic partial epilepsy as well as learning disability. Her 
epilepsy involved complex partial seizures, secondary generalised tonic-
clonic seizures and regular daily absences. Her EEG displayed epileptiform 
activity. 
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Table 11: Clinical features of FRDA-positive cases from ataxic patient screening study, Part 1. 
Y = Yes; N = No; N/R = No Result; UL = Upper Limb; LL = Lower Limb 
 
 
 
 
 
 
 
 
Table 12: Clinical features of FRDA-positive cases from ataxic patient screening study, Part 2. 
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3.2.6 Comparison to FRDA-referred Cohort Study* 
* I thank Dr Michael Parkinson for gathering the genetic data from patients 
referred for FRDA, and Dr Hector Garcia and Ms Katarina Manso for 
gathering the comparative clinical data on patients from this cohort. 
The data gathered in this study were compared to a previously gathered 
cohort of 1768 genetically undiagnosed ataxia patients who, contrary to the 
2000 I tested, had already been referred for a FRDA test (M. Parkinson, 
unpublished data). These 1768 patients underwent a genetic screening for 
FRDA at the NHNN between 2003 and 2013. 196 cases (11.1%) were 
shown to have homozygous pathological GAA expansions within the FXN 
gene and were therefore classified as FRDA-positive. Of the 40 which were 
found to carry a single pathological expansion, 11 were found to have 
pathological point mutations associated with FRDA after sequencing, 
increasing the number confirmed as FRDA-positive to 207 (11.7%).  
 
This proportion of FRDA-positive cases is, as expected, far higher than in 
my study, as patients referred for FRDA are more likely to have typical 
symptoms of the disease. Among the other 29 cases, inspection of clinical 
records revealed that 9 were asymptomatic carriers, most likely referred for 
predictive clinical testing or partner testing in order to inform reproductive 
choices. The other 20 cases were symptomatic carriers, and thus subjected 
to an MLPA test in order to determine whether any cases were compound 
heterozygous for an exonic deletion. 18 were not positive for exonic 
deletions, while there was no DNA available for the other two patients. Thus, 
29 patients of the cohort were confirmed after the appropriate genetic tests 
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to be FRDA carriers, a carrier rate of 1.6%. This is considerably higher than 
the carrier rate in my study, although both are within the normal range based 
on previous studies (Cossee et al., 1997; Epplen et al., 1997; Filla et al., 
1992; Harding & Zilkha, 1981; Romeo et al., 1983). Figure 14 details the 
flowchart for these 1768 patients and the diagnostic pathway through which 
FRDA patients and carriers are identified by the NHNN Neurogenetics 
department. Figure 15 gives the combined flowchart for my own study and 
the M. H. Parkinson study, and Figure 16 shows the respective proportions 
of FRDA positives and carriers discovered in my study and in M.H. 
Parkinson’s study in pie chart form. 
 
The clinical features for 106 of the 207 FRDA-positive cases from this cohort 
are given in full in Tables 13-16. These were derived in 80 cases from the 
EFACTS assessment (Tables 13-14), whereas in another 26 cases, 
information was derived from the available or traceable medical notes and 
clinic letters (Tables 15-16). In general, the 80 EFACTS patients are more 
completely clinically characterized than the other 26, although it was also 
not always possible to obtain the entirety of FRDA-relevant clinical data from 
each patient even in the EFACTS cohort. Although the number of FRDA 
positives in my study is too few to make a meaningful statistical analysis 
with the clinical data from the referred samples in the M.H. Parkinson study, 
there does still appear to be a trend to toward increased disease severity 
and a more ‘classical FRDA’ phenotype with the samples referred for FRDA. 
The mean±SD age at onset for the 103 referred patients for which data was 
available was 14.3±10.5 (range 1 to 51), corresponding to the typical age at 
onset of FRDA. This was significantly younger than the mean±SD age at 
onset for the 3 FRDA positive patients from my study, which was 43.3±16.1 
(range 25 to 55) and indicative of LOFA/VLOFA.   
 
The proportion of patients from the samples referred for FRDA with the 
presence of certain key clinical characteristics for which data were available 
were catalogued in Table 17. Almost all of these patients for whom data is 
available present with areflexia (96.2%), vibrational sensory loss (99%) and 
dysarthria (92.4%). All three FRDA-positive patients not originally referred 
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for FRDA also had dysarthria, which is very common even in LOFA/VLOFA 
patients. However, only 1 in 3 showed any signs of areflexia and 2 in 3 
showed vibrational sensory loss, indicative of the less severe phenotype 
and greater variability of symptoms in delayed-onset FRDA. Similarly, 
although 81.6% of patients from the Parkinson study had symptoms of 
square wave jerks and 57.3% showed signs of nystagmus, the only eye 
movement deficits reported among the FRDA positives in my study was 
nystagmus in 1 patient out of 3. Similarly, paresis and extensor plantars 
were observed in the lower limbs of only 1 in 3 patients from my study, but 
in 88.7% and 73.8% of patients in the Parkinson study, respectively.  
 
There was also no mention of any non-neurological signs in the 3 FRDA-
positive patients from my study, whereas 56.7% of FRDA-positive patients 
in the other study had cardiomyopathy and 9.5% had diabetes. Only one 
patient in my study became wheelchair-bound, compared to 67.9% of those 
in the other study. Overall, the three FRDA-positive cases not originally 
referred for FRDA display had a significantly later age of onset and an 
overall less severe ataxia phenotype than the cohort of 106 FRDA-positive 
cases that were clinically referred for an FRDA test and for which clinical 
data were available. The small size of the GAA1 expansions in the three 
FRDA-positive patients from my study is most likely the cause of the later 
age at onset and the less severe phenotype. The implications of the data 
from both studies will be considered together in the discussion. 
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Figure 14: Flowchart summary of genetic results in M.H. Parkinson study. 
GAA+/+ two GAA expansions; GAA+/- one GAA expansion; GAA-/- no GAA expansions. 
MLPA = multiplex ligand-dependent probe amplification. With thanks to Dr M.H. Parkinson 
for the figure. 
 
 
Figure 15: Flowchart summary of genetic results in both 2000-patient two-stage 
PCR study and M. H. Parkinson study combined. 
GAA+/+ two GAA expansions; GAA+/- one GAA expansion; GAA-/- no GAA expansions. 
MLPA = multiplex ligand-dependent probe amplification.  
 
 
FRDA tests ordered 
n=1768
GAA +/+  n=196 GAA +/- n=40 GAA -/- n=1532
FXN point 
mutation n=11
Carrier  n=29Friedreich’s 
ataxia 
n=207
No Friedreich’s 
ataxia
Symptomatic 
heterozygote 
(no pt mut)  
n=20
Asymptomatic 
carrier  n=9
MLPA  n=18
No exonic 
deletion  n=16
No DNA  n=2
MLPA failed  n=2
FRDA tests ordered 
n=3768
GAA +/+  n=199 GAA +/- n=52 GAA -/- n=3517
FXN point 
mutation n=11
Carrier  n=41Friedreich’s 
ataxia 
n=210
No Friedreich’s 
ataxia
Symptomatic 
heterozygote 
(no pt mut)  
n=32
Asymptomatic 
carrier  n=9
MLPA  n=30
No exonic
deletion  n=28
No DNA  n=2
MLPA failed  n=2
Carrier rate 41/3768
1.1% or 1/92
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Figure 16: Proportion of FRDA positives, carriers, no result and negatives among 
screened cohorts of A) ataxia patients not referred for FRDA, and B) ataxia patients 
referred for FRDA (M.H. Parkinson).
A 
B 
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Table 13: Clinical features of EFACTS FRDA patients from M.H. Parkinson study, Part 1. 
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1 Unsteadiness (unable to ice skate) Y Increased N N Y N Y Y Y N Y Y Y 
2 Unsteadiness, clumsiness Y Increased N Y Y Y Y Y Y Y Y Y Y 
3 Unsteadiness (extreme reaction to alcohol) Y Normal N N Y Y Y Y Y Y Y Y Y 
4 Hand tremors, leg pains Y Increased N Y Y Y Y Y N N/R Y Y Y 
5 Unsteadiness, falls Y Normal Y Y Y Y Y Y Y Y Y Y Y 
6 Unsteadiness, clumsiness Y Decreased Y Y Y Y Y Y N N Y Y Y 
7 Unsteadiness Y Normal Y Y Y Y Y Y Y N Y Y Y 
8 Unsteadiness, altered sensation in both legs, scoliosis Y Normal N Y Y Y Y Y Y Y Y Y N 
9 Unsteadiness Y Increased N Y Y Y Y Y Y N Y Y Y 
10 Unsteadiness Y Normal N Y Y Y Y Y N Y Y Y Y 
11 Unsteadiness Y Normal N Y Y Y Y Y N N/R Y Y Y 
12 Shaky hands, poor handwriting, falls Y Increased Y Y Y Y Y Y Y Y Y Y Y 
13 Scoliosis. Unsteadiness Y Normal Y N Y Y Y Y Y Y Y Y Y 
14 Falls Y Increased Y Y Y Y Y Y Y Y Y Y Y 
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15 Unsteadiness Y Normal Y N Y N Y Y Y Y Y Y Y 
16 Unsteadiness Y Increased N Y Y Y Y Y Y N Y Y Y 
17 Clumsiness (in playing football and guitar) Y Increased Y N Y N Y Y Y Y Y Y Y 
18 Unsteadiness, falls Y Increased Y Y Y Y Y Y N Y Y Y Y 
19 Unsteadiness Y Normal N Y Y Y Y Y Y Y Y Y Y 
20 Clumsiness (bumping into things) Y Increased Y N Y N Y Y Y Y Y Y Y 
21 Unsteadiness Y Increased N N Y N N N Y N Y Y Y 
22 Unsteadiness, falls Y Increased N Y Y Y Y Y Y N Y Y Y 
23 Unsteadiness, clumsiness Y Increased Y N Y N N N Y N Y Y Y 
24 Unsteadiness Y Increased Y N Y N Y Y Y N Y Y N 
25 Unsteadiness (especially with gymnastics) Y Increased Y Y Y Y Y Y Y Y Y Y Y 
26 Unsteadiness Y Normal N Y Y Y Y Y Y N Y Y Y 
27 Unsteadiness Y Increased N Y Y Y Y Y N Y Y Y N 
28 Unsteadiness, dysarthria Y Increased N N Y N Y Y Y N Y Y Y 
29 Scoliosis Y Increased Y N Y N Y Y Y Y Y Y N 
30 Unsteadiness Y Increased N Y Y Y Y Y N Y Y Y Y 
31 Unsteadiness Y Normal Y N Y N Y Y Y Y Y Y N 
32 Unsteadiness, falls Y Increased N/R Y Y Y Y Y Y N/R N/R Y N 
33 Unsteadiness Y Normal N/R N Y N Y Y N N/R N/R Y N 
34 Unsteadiness Y Normal N Y Y Y Y Y N Y Y Y Y 
35 Falls, clumsiness with handwriting Y Normal N N N N Y Y N N Y N N 
36 Scoliosis Y Increased Y N Y N Y Y N Y Y Y Y 
37 Unsteadiness Y Increased Y Y N Y Y N Y N Y Y Y 
38 Unsteadiness Y Normal Y N Y N Y Y Y N Y Y Y 
39 Unsteadiness Y Increased N Y Y Y Y Y Y Y Y Y Y 
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40 Unsteadiness Y Normal Y Y Y Y Y Y Y N Y Y Y 
41 Unsteadiness Y Increased N N Y N Y Y Y Y Y Y Y 
42 Unsteadiness, falls Y Normal N Y Y Y Y Y Y Y Y Y Y 
43 Falls Y Increased N N Y N Y Y Y N Y N Y 
44 Unsteadiness Y Normal N Y Y Y Y Y Y Y Y Y Y 
45 Unsteadiness. Fatigue on prolongued walking Y Increased Y N Y N Y Y Y Y Y Y Y 
46 Unsteadiness Y Normal N Y Y Y Y Y Y N Y Y N 
47 Unsteadiness Y Normal Y Y Y Y Y Y N Y Y Y Y 
48 Unsteadiness, falls Y Increased N N Y N Y Y Y N Y Y Y 
49 Clumsiness Y Increased N Y Y Y Y Y N Y Y Y Y 
50 Scoliosis. Unsteadiness Y Increased Y Y Y Y Y Y Y Y Y Y Y 
51 Unsteadiness Y Increased Y Y Y Y Y Y Y Y Y Y Y 
52 Unsteadiness Y Normal N N N N Y Y Y Y Y N N 
53 Unsteadiness Y Normal N Y Y Y Y Y Y N/R Y Y Y 
54 Unsteadiness Y Normal N N Y N Y Y Y Y Y N Y 
55 Unsteadiness Y Increased N Y Y Y Y Y N Y Y Y Y 
56 Unsteadiness Y Increased N Y Y Y Y Y N N/R Y Y Y 
57 Unsteadiness Y Increased N Y Y Y Y Y Y Y Y Y Y 
58 Unsteadiness. Cardiomyopathy Y Increased N Y Y Y Y Y Y Y Y Y Y 
59 Clumsiness Y Normal N N N N Y Y Y Y Y N Y 
60 Scoliosis Y Increased N Y Y Y Y Y Y Y Y N Y 
61 Unsteadiness Y Increased Y Y Y Y Y Y Y N Y Y Y 
62 Unsteadiness Y Normal N N Y N Y Y Y Y Y Y Y 
63 Cardiomyopathy Y Normal N Y Y Y Y Y Y Y Y Y Y 
64 Unsteadiness Y Normal N/R Y Y Y Y Y N N/R Y Y Y 
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65 Unsteadiness, falls Y Increased N Y Y Y Y N N N Y Y N 
66 Falls Y Increased N Y Y Y Y Y Y N/R Y Y Y 
67 Unsteadiness Y Normal N/R N Y N Y Y N N/R Y Y Y 
68 Clumsiness Y Increased N Y N N Y N Y N Y Y N 
69 Scoliosis Y Normal N Y Y Y Y Y Y Y Y Y N 
70 Unsteadiness Y Increased N N N N N N N N/R Y Y Y 
71 Clumsiness Y Normal N Y Y Y Y Y Y Y Y N N 
72 Unsteadiness Y Increased N N N N Y Y Y N/R Y Y N 
73 Unsteadiness Y Increased N Y Y Y Y Y Y N Y Y N 
74 Falls Y Normal N/R N N N Y Y Y N/R Y Y Y 
75 Unsteadiness. Falls Y Normal N N N N Y Y N N Y Y N 
76 Falls Y Increased Y Y Y Y Y Y Y N/R Y Y N 
77 Unsteadiness Y Normal N N N N N/R N/R N/R N/R N/R Y N 
78 Unsteadiness Y Normal N N N N Y Y N N/R Y N N 
79 Unsteadiness Y Increased N Y Y Y Y Y Y N/R Y Y Y 
80 Unsteadiness Y Increased N Y Y Y Y Y Y Y Y Y Y 
N.B. With thanks to Ms Katarina Manso and Dr Hector Garcia for the phenotypic data gathered on all the FRDA-positive patients from the Parkinson study in Tables 13-16. 
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Table 14: Clinical Features of EFACTS FRDA Patients from M. H. Parkinson Study, Part 2. 
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1 N Y Y N Y N N Y PC N Y (Palpitations) Normal 
LVH, T inverted in 
inferolateral leads 
Y N 
2 Y Y Y N Y Y Y Y TE N 
Y (Ventricular 
tachycardia, AF, ICD) 
Hypertrophy, small left 
ventricular cavity with 
normal wall thickness with 
longitudinal dysfunction 
Inferolateral T wave 
changes 
Y  Y  
3 Y Y Y N Y N Y N N N Y 
Normal LV size and function, 
mild diastolic dysfunction, 
mildly dilated LA size 
T wave inversion I, II, aVF, 
V3-V6 
Y N 
4 N Y Y N Y N/R Y Y TE N Y Mild concentric hypertrophy LVH Y  N 
5 Y Y Y Y Y N/R Y Y PC N Y 
Mild hypertrophic 
cardiomyopathy 
Dyspnoea Y  Y  
6 N Y Y Y Y N Y Y N N Y (Vasovagal syncope) 
Hypertrophic 
cardiomyopathy 
LVH N Y  
7 N Y Y Y Y N N Y N N Y 
Concentric LVH, mild 
diastolic dysfunction 
T wave inversion II, III, aVF, 
V5, V6), dyspnoea 
N N 
8 Y Y Y Y Y N N Y PC N N Normal 
Repolarization 
abnormalities, LVH 
N N 
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9 N Y Y Y Y N Y Y PC N Y (Paroxysmal AF) Mild concentric LVH 
T wave inversions in leads 
V3-V6, I, II, III, aVL, aVF 
Y  N 
10 Y Y Y Y Y Y Y Y PC N Y (AF, ICD) 
Moderately dilated LV and 
RV, severe systolic 
dysfunction 
Abnormal (ventricular paced 
rhythm, tachycardia). 
Y N 
11 N Y Y N Y Y Y Y N N Y 
LV moderate concentric 
hypertrophy, low-normal 
systolic function 
T wave inversion in the 
inferolateral leads, 
incomplete RBBB 
Y  Y  
12 Y Y Y Y Y Y Y Y PC N N Normal Normal N Y  
13 Y Y Y Y Y N/R N Y PC N N Normal Normal Y Y 
14 Y Y Y Y Y Y N Y 
PC & 
TE 
N Y LVH 
Widespread T-wave 
inversion (I-III, aVF, V1-V6) 
Y  N 
15 Y Y Y Y Y N Y N PC N N N/R N/R N N 
16 N Y Y Y Y N N Y 
PC & 
TE 
N Y Concentric LVH Repolarization abnormalities Y Y  
17 Y Y Y N Y N N N 
PC & 
TE 
N N Normal 
T wave inversion in I, II, 
aVL, V4-V6 
N Y 
18 Y Y Y Y Y N Y Y PC N Y (AF) Mild concentric hypertrophy 
T wave inversion all leads, 
right axis deviation 
Y  N 
19 Y Y Y Y Y N Y Y PC Y Y (AF) 
Left ventricular hypertrophy 
with severely impaired 
systolic function, severe 
tricuspid regurgitation 
T wave inversions in the 
precordial leads, right axis 
deviation 
Y  N 
20 Y Y Y Y Y Y Y Y PC N N Normal Lateral T wave changes Y Y 
21 N Y Y Y Y N N Y PC N N Normal Normal Y N 
22 N Y Y Y Y N N Y PC N Y N/R N/R N N 
23 N Y Y Y Y N N N N N N Normal Repolarization abnormalities Y N 
24 N Y Y Y Y N N N N N N Normal 
T wave inversion in I, II, 
aVL, V5, V6, LV hypertrophy 
Y N 
25 Y Y Y Y Y N Y Y 
PC & 
TE 
N Y 
Mild hypertrophic 
cardiomyopathy 
N/R Y N 
26 N Y Y Y Y N Y Y TE N N Normal Normal Y N  
27 Y Y Y Y Y Y Y Y PC N N N/R N/R Y N 
28 N Y Y N Y N N Y N N Y 
Hypertrophic 
cardiomyopathy 
Repolarization abnormalities Y N 
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29 Y Y Y Y Y N Y Y PC N Y Mild concentric LVH 
Negative T waves in the 
inferior and the lateral leads 
N N 
30 Y Y Y Y N Y Y Y PC N Y N/R 
T wave inversion in II, III, 
aVF, V6 
N N 
31 Y Y Y Y Y N N N N N N N/R N/R N N 
32 N/R Y Y N Y N N Y PC N Y N/R N/R N N 
33 N/R Y Y N Y N N Y N N N N/R N/R N N 
34 Y Y Y Y Y N Y N PC N N Normal Flattened T waves N N 
35 N Y Y Y Y N N N N N 
Y (AF, Myocardial 
ischaemia) 
Hypertrophic 
cardiomyopathy 
T wave inversion N N 
36 Y Y Y Y Y N N Y PC N Y Mild septal hypertrophy 
T wave inversion in 
inferolateral leads 
Y N 
37 N Y Y N Y N N Y N N N Normal Normal Y N 
38 N Y Y N Y N N N N N N Normal Normal Y N 
39 Y Y Y N Y N N Y N N N N/R 
T wave inversion I, aVL, V3-
V6 
Y N 
40 N Y Y N Y Y N N N N Y LVH 
Non-specific T wave 
flattening inferolaterally 
Y N 
41 Y Y Y N Y N N Y PC N Y 
Mild concentric LV 
hypertrophy 
T wave inversion in I, II, 
aVL, V5, V6 
N N 
42 Y Y Y N Y N Y Y PC N 
Y (intermittent atrial 
tachyarrhythmia) 
Hypertrophic 
cardiomyopathy 
Repolarization 
abnormalities, Hypertrophy 
Y N 
43 N Y Y Y Y N N Y PC N N Normal Normal Y N 
44 Y Y Y N Y N Y Y PC N Y LVH N/R N N 
45 Y Y Y N Y N N Y N N Y Mild concentric LVH Normal Y N 
46 N Y Y N Y N N Y PC N N Normal Normal N N 
47 Y Y Y Y Y N Y Y PC N Y 
Hypokinetic basal postero-
inferior wall, left atrial size 
mildly dilated 
Inferolateral T wave 
inversion, Inferioposterior Q-
waves 
Y N 
48 N Y Y N Y N N Y PC N Y (Permanent AF) 
Dilated LV/RV with severe 
systolic dysfunction, thinning 
of basal, posterior and 
inferior wall 
AF, T-wave inversion Y N 
49 Y Y Y Y Y Y Y Y PC N N Normal T negative wave V4-V6 Y  N 
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50 Y Y Y Y Y N N Y PC N Y N/R N/R Y Y  
51 Y Y Y Y Y N N Y N N N Normal 
Non-specific T wave 
flattening 
Y N 
52 Y Y Y N N N N N N Y N N/R N/R N N 
53 N Y Y Y N N Y Y PC N Y Ventricular hypertrophy N/R Y N 
54 Y Y Y Y Y N Y N N N N Normal Normal Y N 
55 Y Y Y Y Y Y Y N PC N N Normal Flat T wave in lateral leads Y N 
56 N Y Y Y Y N/R Y Y PC N Y (Paroxysmal AF) Normal Repolarization abnormalities Y N 
57 Y Y Y N Y Y N Y PC N Y (Paroxysmal AF) Mild LVH 
Negative T waves in the 
anterolateral leads 
Y N 
58 Y Y Y Y Y Y Y Y PC Y 
Y (Previous 
myomectomy, AF) 
Hypertrophic 
Cardiomyopathy, 
Hypokinetic lateral wall 
Q waves V1-V3 Y  N 
59 Y Y Y N N N N N N N Y Mild LVH Repolarization abnormalities N N 
60 Y Y Y N Y N N Y PC Y Y (Paroxysmal AF) Mild hypertrophy 
T wave inversion in II, III, 
aVF, V3-V6 
Y  N 
61 N Y Y Y N N Y N PC N N Normal 
T wave inversion in leads II, 
III, aVF, V3-V6 
Y N 
62 Y Y Y N Y N N N N N N Normal Repolarization changes N N 
63 Y Y Y N Y N Y Y PC N N Normal N/R N N 
64 N/R Y Y Y Y N N Y PC N Y 
Mild concentric LVH, 
moderate mid-ventricular 
obstruction, Mid/apical LV 
cavity obliteration 
Negative T waves I, II, III, 
aVF, V4-V6 
N N 
65 N Y Y Y N N N N N N Y N/A Hypertrophy N N 
66 N/R Y Y N Y N Y N N N Y LV basal septal hypertrophy 
Slow R wave progression, T-
wave abnormalities 
Y N 
67 N/R Y Y N Y N N Y N Y N Normal Normal Y N 
68 N Y Y Y Y N Y Y PC N Y LVH 
Repolarization 
abnormalities,  hypertrophy 
N N 
69 Y Y Y N Y N Y Y PC N N N/R N/R N N 
70 N/R Y Y N N N N N N N N Normal 
Mild repolarization 
abnormalities 
Y N 
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71 Y Y Y N N N N N PC N N Normal Normal N N 
72 N/R Y Y N Y N N Y N N N N/R N/R Y  N 
73 N Y Y N Y Y N Y PC N 
Y (Supraventricular 
tachycardia) 
Apical hypertrophy 
Small inverted T waves 
laterally 
Y N 
74 N/R Y Y 
N/
A 
N/
A 
Y Y Y N N Y (Paroxysmal AF) Impaired LV systolic function LVH N N 
75 N Y Y Y Y N N N N N N N T wave inversion V3-V6 Y N 
76 N/R Y Y N Y N N Y PC Y 
Y (Intracardiac 
thrombus) 
N/R N/R Y N 
77 N/R Y Y N N N N Y PC N N N/R N/R N N 
78 N/R Y Y N Y N N N N N N Normal N/R N N 
79 N/R Y Y N Y N N Y PC N Y Normal Inverted T wave laterally Y N 
80 Y Y Y Y Y N Y Y PC N Y Mild concentric LVH 
T wave inversion in most of 
the leads 
N N 
N/A = Not Applicable; LVH = Left Ventricular Hypertrophy; PC = Pes Cavus; TE = Talipes Equinovarus; AF = Atrial Fibrillation; ICD = Implantable Cardioverter Defibrillator; LV/RV = Left/Right 
Ventricular; LA/RA = Left/Right Atrial; aVL/aVR = Augmented Vector Left/Right; RBBB = Right Bundle Branch Block; V1-V6 = Types of Electrodes in ECG 
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Table 15: Clinical features of non-EFACTS FRDA patients from M.H. Parkinson study, Part 1. 
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1 Clumsiness, poor balance Y N/R N/R Y Y N/R Y Y Y N/R N/R Y N 
2 Poor coordination, unsteadiness Y N/R Y N/R Y N/R Y Y Y N/R Y Y N/R 
3 Unsteadiness Y Increased N/R Y Y N/R Y Y Y N/R Y Y Y 
4 Falls, unsteadiness Y Normal N/R Y Y Y Y Y Y N Y Y N 
5 Unsteadiness, clumsiness Y Normal Y N Y N Y Y N N N Y N 
6 Unsteadiness, incoordination UL Y Increased Y Y Y Y Y Y Y Y Y Y Y 
7 Unsteadiness Y Increased Y N Y N Y Y Y Y Y Y N 
8 Unsteadiness Y Normal N Y N Y Y Y N N Y Y N/R 
9 Clumsiness of both arms Y Normal Y Y Y Y Y Y Y Y Y Y Y 
10 Clumsiness Y N/R N N N N Y Y Y N/R N/R Y N 
11 Unsteadiness Y Normal N Y Y Y Y Y N Y Y Y Y 
12 Unsteadiness, clumsiness Y Increased N Y Y Y Y Y Y Y Y Y Y 
13 Unsteadiness Y Decreased N N N N N Y N N Y Y Y 
14 Unsteadiness, clumsiness Y N/R Y Y Y N Y Y Y N Y Y N 
15 Clumsiness Y N/R Y N Y N/R Y Y Y Y Y Y Y 
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16 Unsteadiness Y N/R N Y Y Y Y Y N N/R Y Y Y 
17 Clumsiness, repeated falls Y Increased N Y Y Y Y Y Y Y Y Y Y 
18 Unsteadiness Y Normal Y N Y N N N Y Y Y Y Y 
19 Unsteadiness, falls Y Normal N Y Y Y Y Y Y Y Y Y Y 
20 Unsteadiness Y Increased Y Y Y Y Y Y Y Y Y Y Y 
21 Unsteadiness, fatigue Y Normal Y Y Y Y Y Y Y Y Y Y Y 
22 Unsteadiness Y Normal N N N N Y Y Y Y Y Y Y 
23 Unsteadiness Y N/R Y N Y N Y Y N N/R N/R N/R N/R 
24 Unsteadiness Y Increased Y Y Y Y Y Y Y N/R Y Y N 
25 N/R Y N/R N Y Y Y N/R N/R N/R N/R N/R Y N/R 
26 N/R Y Normal N N Y N N Y N/R Y Y Y N 
 
 
Table 16: Clinical features of non-EFACTS FRDA patients from M.H. Parkinson study, Part 2. 
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1 N/R N/A N/R N/R N/R Y Y Y Y N 
Y (Congestive failure, 
AF) 
N/A N/A Y Y 
2 N/R Y Y Y Y N/R N/R Y N/R N 
Y (Biventricular 
hypertrophy, AF) 
N/A N/A N/R N/R 
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3 N Y Y N Y Y N/R Y Y Y 
Y (Dilated 
myocardiopathy, AF) 
Wall thinning N/A Y N 
4 N Y Y N Y N N/R N/R N/R N N/R N/A Axonal sensory neuropathy Y N 
5 N Y Y N N N N/R Y N/R N Y LV thickening N/A N/R N/R 
6 Y Y Y N N Y Y Y Y Y N N/A Sensory neuropathy Y N/R 
7 Y Y Y N N N N N N N N Normal 
Symmetrical sensory axonal 
neuropathy 
Y Y  
8 Y Y Y N N N N/R N/R N/R N N N/A Sensory neuropathy N/R N/R 
9 Y Y Y Y Y N N N/R N/R N Y (Palpitations) LVH Sensory axonal neuropathy Y N 
10 N/R Y Y N N N N/R N/R N N Y N/R N/A N/R N/R 
11 Y Y Y Y Y N/R N Y N N Y (Faint episodes x3) 
LVH, mild diastolic 
dysfunction 
N/A N N 
12 Y Y Y Y N Y N Y N Y 
Y (Recurrent chest 
pain) 
LVH, apex wall thickening Sensory neuropathy Y N 
13 N Y Y Y Y N N N N N N N/A 
Sensory/motor axonal 
neuropathy 
Y N 
14 N Y Y N N Y Y Y N/R N N N/A N/A N N 
15 Y Y Y Y Y Y N/R Y N/R N Y (Palpitations) 
Mild hypertrophic 
cardiomyopathy 
N/A Y Y 
16 N Y Y Y N N Y Y N Y N N/A N/A N Y  
17 Y Y Y Y Y N N/R N/R N/R N/R N N/A 
Sensory axonal neuropathy 
(absent radial and sural 
SAN) 
Y N 
18 Y Y Y Y Y N N Y N N Y (Dyspnoea) N/R N/A Y N 
19 Y Y Y Y Y N/R N Y Y N Y (Palpitations) Mild concentric LVH N/A Y  N 
20 Y Y Y Y Y N/R N Y N N Y (Dyspnoea) Normal N/A Y  N 
21 Y Y Y Y Y Y N Y Y N N N/R N/A Y  Y 
22 Y Y Y Y N N N Y N/R N N Normal N/A Y N 
23 N/R Y N/R N/R N/R N N Y N/R N Y 
Mild, asymmetric septal 
hypertrophy morphology 
N/A N/R Y 
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24 N Y Y Y Y Y Y Y N N Y 
Concentric LVH with some 
apical non-compaction 
N/A N/R N 
25 N/R Y Y Y Y N/R N/R N/R N/R N N/R N/A N/A N/R N/R 
26 Y Y Y Y N N/R N/R N/R N/R N N Normal N/A N Y  
 140 
Table 17: Clinical Features in FRDA Patients, M. H. Parkinson Study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.7 Results Summary 
We carried out a study of a consecutive series of 2000 ataxia patients 
lacking a genetic basis for their symptoms following referral for all the major 
SCAs, and who had not been referred for an FRDA test, presumably as 
their symptoms were atypical for the disease. This was the largest study of 
its kind ever done. Out of 2000 patient DNA samples tested, only three 
were identified as having two pathological GAA expansions and thus as 
being FRDA-positive, accounting for 0.15% of our population (Fig. 13). 
Clinical information showed atypical phenotypes for all three FRDA-
positive cases, two of which were very-late onset. The FRDA-positive 
results, although too few to analyse in any statistical fashion, are consistent 
with previous reports, which show that the size of the pathological GAA 
expansion is inversely correlated with age at onset and positively 
correlated with severity of symptoms in FRDA. The three FRDA-positive 
Feature 
FRDA 
patients     
  No. % n 
Paresis 94 88.7 106 
Spasticity 54 55.1 98 
Areflexia 100 96.2 104 
Extensor plantars 76 73.8 103 
Vibrational sensory 
loss 98 99 99 
Square wave jerks 84 81.6 103 
Nystagmus 59 57.3 103 
Diabetes 10 9.5 105 
Cardiomyopathy 59 56.7 104 
Dysarthria 97 92.4 105 
Dysphagia 74 72.5 102 
Wheelchair-bound 72 67.9 106 
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patients display atypical symptoms, consistent with the greater variety of 
symptoms seen in LOFA/VLOFA. 
 
My study also located 12 patients with the pathological GAA expansion in 
only one allele (Fig. 13). No point mutations and no exonic deletions were 
discovered among the 12 individuals with only one pathological GAA 
expansion. Thus, these 12 were confirmed as FRDA gene carriers, all of 
which were symptomatic for separate ataxic disorders. This gives a carrier 
rate of 0.6%, or 1/167. All available clinical information is detailed in the 
following results section and explored in the discussion.  
 
This study complemented a previous one by Dr M.H. Parkinson, which 
collected the clinical data of 1768 undiagnosed ataxia patients who had 
been referred for an FRDA test (Fig. 14). Among those that had been 
referred, 207 (11.7%) tested positive for FRDA. The carrier rate in this 
population was of 1.6%, or 1 in 63, within the expected limits of carrier 
frequency (Cossee et al., 1997; Epplen et al., 1997; Filla et al., 1992; 
Harding & Zilkha, 1981; Romeo et al., 1983). 11 FRDA patients were 
compound heterozygotes with rare point mutations: the proportion of these 
among the FRDA–positive cases was 5.3%, which is above the expected 
amount (M.H. Parkinson, unpublished data). When combined with the 
previous data, this gave from a total of 3768 patients screened an FRDA 
positive rate of 5.6% (210/3768) and a carrier rate of 1.1% (41/3768; Fig. 
15). A comparison of clinical data in these respective studies indicated that 
phenotypes of FRDA-positive patients who had been referred for an FRDA 
test by their consultants were more in line with classical FRDA than those 
who had not been referred (Tables 13-17).  
 
Overall, the study indicates that although the probability that a FRDA case 
is missed during the consultant referral and genetic testing process is 
extremely low, it can occur, adding important clinical data on atypical 
FRDA. Despite this, in general an ataxic patient who displays symptoms 
atypical for FRDA is indicated by this study to be extremely unlikely to have 
FRDA. This therefore reinforces the current diagnostic model in which the 
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FRDA test is only carried out upon consultant referral, making it more 
evidence-based. 
 
 
 
 
3.3 Discussion 
Since the discovery of the genetic basis for FRDA in 1996, natural history 
studies have been performed on large cohorts of genetically confirmed 
FRDA patients that provide the frequencies of clinical features. These have 
been of vital importance in further understanding the underlying molecular 
pathology, planning interventional clinical trials, and providing prognostic 
information for the patients (Delatycki et al., 1999; Durr et al., 1996; 
McCabe et al., 2000; Schols et al., 1997). Some of these studies also 
showed that the original diagnostic criteria proposed by Geoffroy and 
Harding before the FRDA gene was discovered proved to be inadequate 
for up to a quarter of genetically diagnosed FRDA patients (Durr et al., 
1996; Filla et al., 2000; Schols et al., 1997). The criteria typically excluded 
atypical cases presenting with very early or late onset FRDA, retained 
reflexes and very slow or limited disease progression (Geoffroy et al., 1976; 
Harding, 1981). The literature describes specific cases of atypical FRDA in 
its main, often overlapping forms of LOFA/VLOFA and FRDA with retained 
reflexes (Coppola et al., 1999; Klockgether et al., 1996; Parkinson et al., 
2013; Verma & Gupta, 2012). However, no systematic study has ever been 
carried out on a cohort of ataxic patients to determine the frequency of 
FRDA cases among patients not originally referred for FRDA. This is 
particularly relevant clinically as atypical FRDA patients not picked up by 
consultants may never be diagnosed, and thus not receive the medical 
care appropriate to them in the present or the future.  
 
The aim of the work described in this chapter was therefore to provide a 
thorough genetic and clinical assessment of atypical, late-onset FRDA 
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patients discovered through the largest screening to date of individuals 
presenting with ataxia not originally referred for FRDA by their consultants, 
and also compare the data with a previous study of FRDA frequency in 
ataxia cases who were originally referred for FRDA, which was also the 
largest study to date of its kind (M.H. Parkinson, unpublished data). The 
specific objective of the genetic assessment was to assess the frequency 
of FRDA among a 2000-strong consecutive series of SCA-negative ataxic 
patients that were not referred for a FRDA test across a 17-year period 
(1996-2013), presumably as they had a clinical history that did not induce 
clinicians to consider an FRDA screening necessary. 
 
The rate of FRDA-positive cases in my cohort was 0.15% (Fig. 13). This 
indicates that although the probability that a FRDA case is missed during 
the consultant referral and genetic testing process is extremely low, it can 
occur. Despite this, it is clear that an ataxic patient who displays symptoms 
atypical for FRDA is evidently extremely unlikely to have FRDA. When 
compared to the Parkinson study, the frequency of FRDA-positives is as 
expected far higher among ataxic patients referred for FRDA, at 11.7% 
(Fig. 14). The extreme comparative paucity of FRDA cases in the 
diagnostic results from my genetic study indicates that a patient with FRDA 
tends to have a phenotype that is very consistent and diagnosable. Despite 
our knowledge of LOFA/VLOFA and the phenotypic variability in the 
disease, 50% of which is accounted for by the GAA expansion size (in 
particular GAA1; Filla et al., 1996), which can undergo intergenerational 
instability as well as somatic mosaicism (Monros et al., 1997; Pandolfo & 
Pastore, 2009), it appears from this study that our understanding of the 
clinical variability of FRDA and its atypical forms is strong enough to allow 
for correct diagnosis in almost all cases presenting with ataxia. These 
findings, alongside the expected highly atypical nature of the disease 
exhibited by the very few FRDA-positive patients discovered in my study, 
reinforce the current diagnostic model where the FRDA test is only carried 
out upon consultant referral. The alternative, testing all patients presenting 
with ataxia for FRDA, is not cost-effective or time-effective given the 
scarcity of FRDA-positive cases. 
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Furthermore, 12 GAA+/- individuals were also discovered out of the cohort 
of 2000 ataxic patients, none of which tested positive for compound 
heterozygosity point mutations or exonic deletions and thus were 
confirmed as FRDA carriers. In the Parkinson study, one of the largest ever 
performed to systematically screen a consecutive series of ataxia patients 
for FXN point mutations and exonic FXN deletions, the prevalence of FXN 
point mutations among FRDA patients referred for an FRDA screening has 
been calculated as 5.3% (11 out of 207; M.H. Parkinson, unpublished 
data), which is approximately the same as when the two studies are 
compared (11 out of 210). Comparatively, the point mutation rate per 
patient was 4.3% (11 out of 258) in a previous study (Campuzano et al., 
1996) and 3.5% (25 out of 719) in another (Cossee et al., 1999). Thus, 
pathological GAA expansions are present in approximately 97-98% of 
chromosomes from FRDA patients studied. The absence of FXN point 
mutations discovered in the 2000-patient cohort, particularly given the 
eventual finding of only three positive FRDA cases, is completely 
consistent with previous data. This is despite the fact that atypical 
presentation of FRDA is sometimes accounted for by compound 
heterozygosity with point mutations (Parkinson et al., 2013), in particular 
the p. G130V mutation that leads to a late-onset, atypically mild disease 
phenotype (Bidichandani et al., 1997; Cossee et al., 1999; Forrest et al., 
1998). Thus, despite the negative results for FRDA point mutations in this 
study, previous evidence supports testing for FRDA point mutations in 
atypical FRDA cases.  
 
Ataxic patients have been referred to major tertiary referral centres for 
neurogenetics specialising in hereditary ataxia across the world for 
decades. However, the MLPA test for exonic deletions is only requested in 
very specific cases due to its perceived rarity. Compound heterozygosity 
with exonic deletions has been found in 11 confirmed cases, two from the 
USA and nine from western Europe. The majority of previous described 
FRDA cases with exonic deletions in the FXN gene have been discovered 
through a convergence of suspected FRDA with inconclusive genetic data 
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(van den Ouweland et al., 2012; Zuhlke et al., 2004). Additional findings of 
these mutations in FRDA patients would indicate that GAA+/- symptomatic 
individuals should be more regularly tested for exonic deletions. However, 
given the absence of FRDA-associated exonic deletions in the very large 
cohorts of both my study and the Parkinson study, the current 
understanding that compound heterozygous FRDA patients with an exonic 
deletion are extremely rare is retained. The results add to the bulk of 
evidence regarding whether testing for exonic deletions is indicated in 
FRDA patients. They reinforce the current diagnostic screening method for 
ataxia patients, where the MLPA test for exonic deletions is not offered 
routinely but only in cases where a single pathological GAA mutation or 
FRDA-associated point mutation is found in an individual who also exhibits 
clear clinical symptoms of FRDA.   
 
There is an extremely small chance that FRDA patients with exonic 
deletions may not have been detected due to a small deletion preventing 
the binding of one or both of the GAA primers to the GAA repeat, or a large 
deletion to one of the splice sites. Ideally in future, alternative techniques 
to assess the exact breakpoints of a deletion should be adopted in addition 
to the MLPA technique, which could also be revised to provide more 
coverage to the larger exons 1 and 5b. However, given the complete 
absence of cases of exonic deletions thus far in individuals from the UK 
who present with compound heterozygote FRDA, and given also the more 
severe FRDA phenotype that usually occurs in cases of FRDA compound 
heterozygotes with exonic deletion (Brigatti et al., 2012; Deutsch et al., 
2010), a mistake in the data is extremely unlikely, certainly among the 8 
FRDA carriers for which clinical data was successfully retrieved. There is 
only one discovered case of FRDA with exonic deletion where the patient 
had an atypical mild FRDA phenotype that slowly progressed over 30 years 
(van den Ouweland et al., 2012), which is not enough to be able to draw 
any diagnostic conclusions. Frataxin protein or mRNA levels could also be 
measured in future to help guide further genetic testing. 
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The 12 FRDA carriers confirmed in my cohort gave a carrier rate of 0.6% 
or 1 in 167 (Fig. 13). The earlier Parkinson study to which our study is 
compared in this chapter has a carrier rate of 1.6% which is equivalent to 
1 in 63 (M.H. Parkinson, unpublished data; Fig. 14). When combined 
together, these studies give an overall carrier rate of 1.1% (Fig. 15). No 
systematic study of FRDA carrier rate has been carried out in the UK, 
although Harding & Zilkha estimated it at approximately 1 in 110 (Harding 
& Zilkha, 1981). However, all studies produced prior to 1996 rely on clinical, 
not genetic diagnoses, making them potentially less accurate. Previous 
European studies range from a higher frequency of 1 in 85 in France 
(Cossee et al., 1997) and between 1 in 60 and 1 in 90 in Germany (Epplen 
et al., 1997), to a lower frequency of 1/191 in the Piedmont region of 
northern Italy (Leone et al., 1990) and 1 in 196 in the entire population of 
Norway (Wedding et al., 2015). A large variation can be seen in carrier 
frequency between studies, with which the carrier frequency of this study 
is broadly compatible. An interesting further study would be to update the 
understanding of different carrier rates among different European 
populations. The considerably greater carrier frequency in the Parkinson 
cohort compared to my cohort may be partially explained by the fact that it 
included 9 asymptomatic carriers who were probably referred for predictive 
clinical testing for potential presymptomatic FRDA, or else they were 
partners tested to inform reproductive choices. The present samples are 
not representative of the UK population as a whole, and thus cannot be 
considered as a full epidemiological study: however, this is the largest 
study of its kind carried out so far, using patient data from across the 
country. 
 
The clinical features of the three FRDA-positive patients are too small a 
sample size to statistically analyse. However, they are consistent with the 
size of the pathological GAA expansion being inversely correlated with age 
at onset and positively correlated with severity of symptoms in FRDA (Durr 
et al., 1996; Filla et al., 1996; Montermini et al., 1997; Rajagopalan et al., 
2010). The symptoms of especially patient 1 and patient 3 have a 
LOFA/VLOFA symptom characterization that conforms fully with their 
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extremely small GAA expansion sizes (Tables 11-12). The average age at 
onset of FRDA in the three patients is typical for LOFA (and tending 
towards VLOFA), while the average age at onset for the patients in the 
Parkinson study conforms fully with typical age at onset in classical FRDA 
(Durr et al., 1996; Filla et al., 1990; Harding, 1981; Reetz et al., 2015), 
meaning that considered together (Fig. 15) they have a phenotype very 
characteristic of classical FRDA.  
 
The absence of non-neurological symptoms in any of the three FRDA-
positive patients may be explained by these symptoms being far less 
common in late-onset FRDA (De Michele et al., 1996; Durr et al., 1996; 
Filla et al., 1996; Gellera et al., 1997). They all have dysarthria, which often 
presents later in LOFA cases. Its presence on disease presentation may 
be explained by the VLOFA status of the patients. In classical FRDA 
patients, dysarthria tends to exhibit prior to pyramidal weakness, which 
itself presents before loss of vibrational or joint position sense and muscle 
weakness (Harding, 1981), but the FRDA-positive patients in the 2000-
patient study were clinically assessed so late that it is difficult to build a 
clear picture of disease progression from case notes. Indeed, the whole 
topic of disease progression has proved difficult to study in the three FRDA-
positives and therefore its role in the Parkinson study is also not analysed 
in this chapter. Retrospective analyses of case histories of this kind 
necessarily aim for quantity of patients, as the clinical data are often not 
consistently and completely available. 
 
The paucity of FRDA-positives from my cohort of 2000 ataxic patients 
suggests that the clinical symptoms of the FRDA-positives are likely to be 
extremely atypical for FRDA. The extremely small size of the GAA1 repeat 
expansion in patients 1 and 3 is entirely consistent with this hypothesis 
(Tables 11-12). Although both patients have VLOFA, the phenotype is only 
particularly unusual for FRDA in patient 1, who displays an even milder 
phenotype, lacking even the nystagmus and pyramidal signs present in 
patient 3 despite having a marginally larger GAA1 expansion size. 
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Nevertheless, there are understandable and interesting reasons for why 
patients 2 and 3 may not have been referred by their consultant on referral.  
 
In the case of patient 3, it is quite clear that his very high alcohol intake is 
crucially responsible for creating diagnostic confusion, as well as likely 
worsening his ataxic symptoms. Aside from the alcohol intake, he displays 
symptoms fairly typical for LOFA/VLOFA such as dysarthria, nystagmus, 
finger-nose ataxia, gait ataxia, pyramidal signs and reduced vibration 
sense in the legs, whilst retaining power and reflexes and lacking any 
confirmed sign the non-neurological features of FRDA, meaning it is quite 
likely he would have been correctly diagnosed had it not been for the 
alcohol abuse.  
 
In the case of patient 2, the GAA expansion sizes are smaller but still in the 
expected LOFA range, and the more phenotypically relevant GAA1 size 
(420 repeats; Lecocq et al., 2016) is considerably smaller than the GAA2 
size (c. 2000 repeats). This genotype provides a slightly more severe 
phenotype, with a borderline classical/LOFA age at onset of around 25 
(although the clinical notes indicate it may have been in her early twenties) 
and additional symptoms not seen in patients 1 and 2 such as areflexia 
and confinement to wheelchair in her early thirties. Her symptoms were not 
unduly atypical for FRDA/LOFA. However, her presenting symptoms of 
neuropathy and blackouts were highly unusual for FRDA and her sensory 
ataxia was not severe. Both of these findings may have hindered a correct 
diagnosis of FRDA. The lack of clinical distinction between LOFA and 
VLOFA claimed recently (Lecocq et al., 2016) cannot be appropriately 
studied here due to the small sample size available. 
 
The clinical symptoms of the elder brother of patient 3, originally diagnosed 
as multiple sclerosis, may also be radically reinterpreted following this 
study. The elder brother experienced a progressive loss of motor function 
and confinement to a wheelchair, passing away in his 60s. Although 
dysarthria or specific neurological symptoms are not reported, the very 
benign nature and progression of the FRDA-like symptoms in his brother 
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increases the possibility that the original patient diagnosis of multiple 
sclerosis was mistaken. His lack of previous family history is characteristic 
of autosomal recessive disease and indicates a possible missed FRDA 
diagnosis, although this does not itself preclude the original multiple 
sclerosis diagnosis. The FRDA diagnosis of patient 3 allows us to re-
interpret the clinical data in a new light in both the patient and his brother. 
The symptoms in both siblings are / would be unusual for FRDA. If the elder 
brother of patient 3 is indeed FRDA positive, this would indicate a strong 
intrafamilial variability in age at onset of 25 years. As the largest FRDA 
phenotype study to date showed an only 40% correlation between GAA 
expansion and severity of clinical symptoms (Reetz et al., 2015), such 
variability would not be inconsistent with FRDA literature. Other factors 
affecting FRDA phenotype might involve somatic mosaicism, expansion 
interruptions, intergenerational instability of the FRDA expansion (Monros 
et al., 1997) or other genetic and environmental elements (Pandolfo & 
Pastore, 2009). Further study of intrafamilial cases may shed greater light 
on the clinical heterogeneity of FRDA and its complex, multisystemic 
nature. 
 
The Parkinson study of FRDA frequency in patients clinically referred for 
FRDA, unlike my study, reveals a cohort of FRDA patients with a clinical 
spectrum typical of classical FRDA (Tables 13-17). For example, the 
frequency of symptoms such as areflexia, extensor plantars, dysarthria, 
dysphagia and vibrational sensory loss all conform to previous large case 
series studies carried out on FRDA patients (Delatycki et al., 1999; 
Harding, 1981). Square wave jerks are found more frequently than 
nystagmus, as in previous literature (Durr et al., 1996; Harding, 1981; 
Schols et al., 1997). The previous data concerning non-neurological 
features such as cardiomyopathy and diabetes are not precise enough to 
establish a comparison with the data in this study, and data for GAA repeat 
size in each allele was not consistently available for the Parkinson study. 
However, it may be reasonably assumed, based on their classical FRDA 
symptoms and age at onset, that the majority of FRDA patients detected in 
the Parkinson study had a considerably higher number of GAA repeats 
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than those of the three FRDA patients detected in the more recent study. 
Thus, the clinical symptoms in both patient cohorts presented in this 
chapter further bear out the original implications of the genetic findings, 
which were that the FRDA patient phenotype is very consistent and 
diagnosable, with a natural phenotypic variation that is well accounted for 
by the genotypic-phenotypic characterization of LOFA/VLOFA. 
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Chapter 4 : Reduced Ca2+ Levels 
in Cardiomyocytes in Friedreich’s 
Ataxia Models 
 
 
4.1 Introduction 
 
Frataxin is a mitochondrial protein involved in the biogenesis of iron-
sulphur clusters (ISCs). It has been shown to be involved in various 
physiological functions such as response to oxidative stress (Abeti et al., 
2016; Babcock et al., 1997; Condo et al., 2007; Gakh et al., 2006; O’Neill 
et al., 2005) and most recently, regulation of cellular Ca2+ homeostasis 
(Bolinches-Amoros et al., 2014; Molla et al., 2017; Abeti et al, 2018). The 
reduction of frataxin in FRDA patient biopsies has been associated with 
intracellular iron deposits (Lamarche et al., 1980; Sanchez-Casis et al., 
1976), mitochondrial dysfunction associated with a deficit in ISC-containing 
enzymes involved in mitochondrial respiration (Rotig et al., 1997) and 
oxidative damage (Bradley et al., 2004; Emond et al., 2000; Schulz et al., 
2000). It has been proposed that the modifications in iron metabolism are 
themselves the cause of the inhibition of mitochondrial respiration and the 
promotion of ROS generation that lead to the physiological dysfunctions 
described (review: Pandolfo & Pastore, 2009).  
 
Frataxin deficiency has been shown to lead to mitochondrial dysfunction 
with iron accumulation and hypersensitivity to oxidative damage in mice 
(Abeti et al., 2016; Abeti et al., 2015; Al-Mahdawi et al., 2006; Ristow et al., 
2003), yeast (Babcock et al., 1997; Karthikeyan et al., 2003), 
Caenorhabditis elegans (Vazquez-Manrique et al., 2006) and Drosophila 
melanogaster (Llorens et al., 2007). Frataxin has been shown to interact 
physically with components of the ISC assembly complex (Stemmler et al., 
2010) and also specifically with complex II of the electron transport chain 
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(ETC; Gonzalez-Cabo et al., 2005), directly associating frataxin with 
mitochondrial structure, function and bioenergetics (Lodi et al., 1999; 
Ristow et al., 2000). Frataxin has also been proposed to protect the cell 
against oxidative damage (Gakh et al., 2006; O’Neill et al., 2005), which 
has itself been linked to the mitochondrial iron overload that results from 
frataxin deficiency (Babcock et al., 1997; Cavadini et al., 2000; Karthikeyan 
et al., 2002).  
  
The effect of oxidative stress on Ca2+ homeostasis is well-established 
(Ermak & Davies, 2002).  Although Ca2+ regulation is strongly linked with 
mitochondrial function in the cell, few studies of FRDA have explored this 
link. Stable frataxin deficiency in dorsal root ganglia (DRG) neurons has 
been shown to lead to mitochondrial failure, in association with oxidative 
stress and Ca2+ dysregulation (Mincheva-Tasheva et al., 2014; Molla et al., 
2017). It is also known that frataxin expression levels directly correlate with 
mitochondrial buffer Ca2+ capacity (a marker of mitochondrial function), 
which increases with frataxin overexpression in 3T3-L1 adipocytes (Ristow 
et al., 2000) and decreases with frataxin downregulation in SH-SY5Y 
human neuroblastoma cells (Bolinches-Amoros et al., 2014).  
 
The effects on Ca2+ homeostasis by the oxidative stress generated through 
iron overload in cardiomyocytes is also of great interest for clarifying the 
pathophysiological mechanism of FRDA cardiomyocytes. The early 
embryonic lethality that results from total frataxin knockout in mouse 
models occurs without significant mitochondrial iron accumulation during 
embryonic resorption (Cossee et al., 2000), and this accumulation has 
been shown to occur after onset of FRDA pathology in frataxin-deficient 
neuronal and cardiac murine cell lines (Puccio et al., 2001). This suggests 
that a subtle increase in redox-active mitochondrial iron is more likely to 
play a key role in FRDA pathogenesis than a general mitochondrial iron 
accumulation. Studies of other diseases such as hereditary haemolytic 
anaemia and other iron-overload conditions associate iron-induced 
oxidative stress with imbalanced Ca2+ handling, which can lead to 
arrhythmias and sudden death as have also been observed in FRDA. In 
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these studies on other iron-overload conditions, the oxidative stress has 
been linked with lower peak systolic Ca2+ levels, higher diastolic Ca2+ 
levels, as well as slowed rates of Ca2+ relaxation (Oudit et al., 2006; 
Schwartz et al., 2002). Due to the overlap in key symptoms between FRDA 
and some of these other iron-overload conditions, an investigation into 
Ca2+ signaling in FRDA heart cells could shed light on certain unknown 
aspects of FRDA pathophysiology (Isaya, 2014).  
 
In cardiomyocytes, most Ca2+ influx occurs via voltage-gated L-type Ca2+ 
channels. Although many of the FRDA neuronal-based studies cited above 
observe Ca2+ channel function in the plasma membrane, in FRDA 
cardiomyocyte pathology the role of the SR as the key dynamic Ca2+ store 
could also be of great relevance. Cardiac-specific ryanodine receptors 
(RYR2) on the SR surface allow for release of Ca2+ from SR stores 
regulated by Ca2+-induced Ca2+-release (CICR), where this Ca2+ release is 
stimulated by the presence of Ca2+ itself. This event is a crucial part of the 
cyclical process causing cardiac muscle contraction, as the released Ca2+ 
then binds to the C domain of troponin (Ramay et al., 2010), highlighting 
the fundamental role of Ca2+ signaling and homeostasis in cardiac 
excitation-contraction coupling. Mitochondria are crucial for regulating local 
interorganellar Ca2+ communication and ROS levels and form tightly linked 
microdomains with the RYR2, which indicates that they are highly likely to 
be affected by an SR pathology (Csordas et al., 2006; Garcia-Perez et al., 
2008).  
 
Oxidative damage could specifically affect Ca2+ levels in FRDA 
cardiomyocytes via oxidation-sensitive Cys residues on the RYR2 or the 
sarcoplasmic reticulum Ca2+ ATPase (SERCA) pumps (Adachi et al., 2004; 
Cherednichenko et al., 2004; Goldhaber & Qayyum, 2000; Sharov et al., 
2006; Ying et al., 2008; Zima & Mazurek, 2016). For example, the oxidative 
damage could potentiate the RYR2, leading to an increased probability and 
duration of RYR2 channel opening, and thereby causing an increased Ca2+ 
leak from the SR (Zima & Mazurek, 2016).  
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4.2 Results 
 
*With great thanks to Dr R. Abeti for obtaining the data on 
mitochondrial energy imbalance, as well as the H9c2 cell caffeine 
response and H9c2 immunofluorescence data. 
 
4.2.1 Fxn-siRNA-induced Knockdown  
The focus of the work described in the present chapter was to investigate 
the role of Ca2+ in cardiomyocytes to elucidate FRDA pathophysiology. To 
do so I employed two cardiac cell lines to conduct my experiments. HL-1 
and H9c2 are the only available cell lines that can substitute primary 
cardiomyocytes as disease models. HL-1 cells are adult atrial murine 
cardiomyocytes, while H9c2 cells are neonatal ventricular cardiomyocytes 
from rats. I modelled FRDA in these cells via siRNA-induced knockdown 
of frataxin. One neonatal line and one adult line were used, which allowed 
for insight into FRDA pathophysiology at different stages of cardiac 
development. I also used neonatal heart cells from the YG8R FRDA mouse 
model to confirm findings made in the cell lines. 
 
YFP was co-transfected alongside the siRNA to provide a fluorescent 
marker of successful transfection, and therefore of frataxin mRNA 
knockdown (Fig. 17 A-B). I co-transfected one set of cells with YFP-DNA 
and scrambled siRNA as my control cells, and another set of cells with 
YFP-DNA and mouse Fxn-siRNA. The efficiency of transfection was 
assessed by immunofluorescence using an antibody against frataxin 
protein. The fluorescence parameters are indicated in Fig. 17 A-B. Cells in 
all experiments were selected if, in addition to Fura-2 fluorescence, they 
also emitted YFP fluorescence, which confirmed their transfected status. 
In order to observe if siRNA transfection against Fxn had achieved 
knockdown, I calculated the relative fluorescence level of frataxin in the 
transfected cells in the FXN-siRNA group when the frataxin fluorescence 
in the siRNA-scrambled group was set at 100%. The results showed a 
significant 40 % decrease in frataxin expression in Fxn-siRNA HL-1 cells 
when compared to control cells (Fig. 17 C) and a significant 70% 
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decrease in frataxin expression in Fxn-siRNA H9c2 cells compared to 
control cells (Fig. 17 D; H9c2 data in collaboration with Dr R. Abeti).    
 
  
 
 
 
 
 
YFP YFP FxnFxn
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Figure 17: Immunofluorescence Experiments on HL-1 and H9c2 cells: knock-down 
of endogenous frataxin in cardiac cell lines using siRNA. 
A) A comparison between siRNA-scrambled-transfected and Fxn-siRNA-transfected HL-
1 cells. The top left images show YFP fluorescence in green in siRNA-scrambled cells, 
and cells labelled with Fxn antibody showing with red fluorescence. The bottom left 
images show DAPI labelling the nuclei in blue, and the merged image. The top right 
images show YFP fluorescence in siRNA-transfected cells, with the equivalent Fxn 
antibody fluorescence being very low. The bottom right images show DAPI labelling the 
nuclei in blue, and the merged image. B) A comparison between siRNA-scrambled-
transfected and Fxn-siRNA-transfected H9c2 cells. The top left images show YFP 
fluorescence in green in siRNA-scrambled cells, and cells labelled with Fxn antibody 
showing red fluorescence. The bottom left images show DAPI labelling the nuclei in blue, 
and the merged image. The top right images show YFP fluorescence in siRNA-transfected 
cells, with the equivalent Fxn antibody fluorescence being very low. The bottom right 
images show DAPI labelling the nuclei in blue, and the merged image. C) Frataxin 
immunofluorescence levels in HL-1 cardiomyocytes in cells transfected with the siRNA-
scrambled and transfected with Fxn-siRNA. The histogram shows the quantified red 
fluorescence from both groups of cells. When the anti-frataxin fluorescence level of the 
control cells was set at 100%, the frataxin level of the cells transfected with Fxn-siRNA 
(n= 3 independent experiments) was 60±5%, a significant decrease compared to control 
cells (***p<0.001). SEM was used to calculate the error. D) Frataxin immunofluorescence 
levels in H9c2 cardiomyocytes in cells transfected with siRNA-scrambled and transfected 
with Fxn-siRNA. The histogram shows the quantified red fluorescence from both groups 
of cells. When the anti-frataxin fluorescence level of the control cells was set at 100%, the 
frataxin level of the cells transfected with Fxn-siRNA was 29±5%, a significant decrease 
compared to control cells (n= 3 independent experiments; ***p<0.001; data in 
collaboration with R. Abeti). SEM was used to calculate the error. Scale bar = 20µm. 
 
 
 
4.2.2 Increased ROS in Fxn KD HL-1 and H9c2 
cells 
Increased oxidative stress is a hallmark of frataxin-deficient cells (Abeti et 
al., 2016; Abeti et al., 2015; Navarro et al., 2010; Pastore & Puccio, 2013) 
and any study of Ca2+ signalling in the disease must also include an 
observation of ROS levels. After analyzing transfection and knockdown 
efficiency of Fxn-siRNA, I investigated ROS levels in the two cell models. 
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Dihydroethidium (Het) is a superoxide indicator that displays blue 
fluorescence in the cytosol until oxidized: it then intercalates into the 
nuclear DNA and emits red fluorescence. The rate of fluorescence 
measures superoxide production, which is a function of the rate of cytosolic 
ROS generation. In the example data presented, for HL-1 cells the red 
fluorescence indicates cytosolic ROS levels 1500 seconds following 
incubation in cells transfected with siRNA-scrambled (top left, Fig. 18 A) 
and Fxn-siRNA (bottom left, Fig. 18 A). 10 µM Het was added at the 
beginning of each experiment. The data gathered suggests that superoxide 
production at cell resting condition, and therefore ROS generation in the 
cytosol, is increased in frataxin-deficient cells in both HL-1 (Fig. 18 B & D) 
and H9c2 cells (Fig. 18 C & E).  
 
Oxidative stress was also assessed by measuring mitochondrial ROS 
levels through adding 20 nM of the CM-H2Xros dye to the HL-1 cells, with 
the rate of fluorescence measuring mitochondrial ROS production (Fig. 19 
A). These data also suggest an increase in rate of ROS production in 
frataxin-deficient cells based on the kinetic trace recordings (Fig. 19 B-C). 
The data indicates that an increase in mitochondrial ROS levels may be 
occurring simultaneously with a general increase in cytosolic ROS levels 
in the frataxin-deficient cardiomyocytes. Taken together, this indicates a 
potential pathological increase in ROS levels and thus oxidative stress 
resulting from frataxin deficiency, which may affect Ca2+ signaling and 
homeostasis in the cardiomyocyte model. I therefore moved to 
assessments of Ca2+ homeostasis. 
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Figure 18: Increased rate of generation of cytosolic reactive oxygen species (cROS) 
over time in frataxin-deficient cells from two FRDA cell models. 
A) Ratiometric Het and YFP signal in HL-1 transfected cells. The data shows cells loaded 
with 10 μM Het and excited at 364 (blue signal) and 543 nm (red signal), with the red 
signal indicating oxidation of the Het. YFP fluorescence for the equivalent cells is also 
shown. B) Average kinetic curve showing the average increase in ratiometric Het 
fluorescence (and therefore increase in cytosolic ROS levels) in HL-1 cardiomyocytes 
normalized to 1, with the siRNA-scrambled trace in black and the FXN-siRNA trace in red. 
C) Average kinetic curve showing the average increase in ratiometric Het fluorescence in 
H9c2 cardiomyocytes normalized to 1, with the siRNA-scrambled trace in black and the 
FXN-siRNA trace in red. D) The histogram shows the quantified red fluorescence from 
both groups of cells. The rate of dihydroethidium fluorescence increase in HL-1 cells 
transfected with siRNA-scrambled was normalised to 100%. The data shows a significant 
increase in the fluorescent unit increase per second in FXN-siRNA cells (219±31; n= 3 
independent experiments) compared with siRNA-scrambled cells. The difference is 
statistically significant (***p<0.001). SEM was used to calculate the error.  E) The 
histogram shows the quantified red fluorescence from both groups of cells. The rate of 
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dihydroethidium fluorescence increase in H9c2 cells from 2 coverslips transfected with 
siRNA-scrambled was normalised to 100%. The data shows a significant increase in the 
fluorescent unit increase per second in FXN-siRNA cells (240±54; n= 3 independent 
experiments) compared with siRNA control cells. The difference is statistically significant 
(*p<0.05). SEM was used to calculate the error. Scale bar = 20µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Increased rate of generation of mitochondrial reactive oxygen species 
(mROS) over time in HL-1 cells with lower frataxin levels. 
A) CM-H2Xros and YFP signal in HL-1 cells. Top left: siRNA-scrambled CM-H2Xros 
levels; top right: siRNA-scrambled YFP levels; bottom left: Fxn-siRNA CM-H2Xros levels; 
bottom right: Fxn-siRNA YFP levels. B) Average kinetic curve showing the average 
increase in CM-H2Xros fluorescence (and therefore mitochondrial ROS levels) 
normalised to 1 in HL-1 cardiomyocytes, with the siRNA-scrambled trace in black and the 
FXN-siRNA trace in red. C) The rate of CM-H2Xros fluorescence increase in HL-1 cells 
from 2 coverslips transfected with siRNA-scrambled was normalised to 100%. The HL-1 
cell data shows a significant increase in the normalized fluorescent unit increase per 
second in FXN-siRNA cells (208±16; n= 3 independent experiments) compared with 
siRNA-scrambled cells. The difference is extremely statistically significant (***p<0.001). 
SEM was used to calculate the error. Scale bar = 20µm. 
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4.2.3 Decreased NADH Redox Index in Fxn KD 
HL-1 and H9c2 cells 
During energy production, the function of the mitochondrion is crucial to 
providing ATP via the metabolism of substrates, and this may be affected 
in FRDA (Gonzalez-Cabo et al., 2005; Rotig et al., 1997; Stemmler et al., 
2010). The tricarboxylic acid cycle provides substrates like NADH and 
FADH2, electron carriers that donate electrons to the mitochondrial 
electron transport chain (ETC). The oxidized form of NADH is NAD+. The 
levels of NADH, which donates its electrons to complex I of the ETC, can 
be estimated by NAD(P)H autofluorescence, from which an NADH redox 
index can be obtained that gives an indication of mitochondrial ETC 
activity. This redox index is estimated by observing the difference in the 
fluorescence values between application of FCCP, which drives 
mitochondrial respiration to the maximum and thereby stimulates 
maximum NADH oxidation, and NaCN, which via inhibition of mitochondrial 
respiration stimulates maximum NADH reduction.  
 
The mitochondrial NADH autofluorescence is visualized in Fig. 21 A-B. The 
NADH maximal oxidation is achieved with FCCP (set at 0%) and the 
maximal reduction with NaCN (set at 100%). The redox index is calculated 
based on these parameters by measuring the percentage at baseline prior 
to FCCP addition, and this normalization is done cell by cell. A reduction in 
redox index was found following Fxn knockdown (Fig. 20 A-B). 
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Figure 20: Representative NADH level traces in HL-1 cells following FCCP and 
NaCN addition, showing decreased redox index in Fxn-siRNA cells. 
A) Representative kinetic trace showing average NADH level in HL-1 cells from a siRNA-
scrambled coverslip. The greatest extent of the response to FCCP and NaCN are set as 
‘0’ and ‘1’, the mitochondrial NADH redox index. B) Representative trace showing average 
NADH level in HL-1 cells from a Fxn-siRNA coverslip.  
 
The redox index was statistically confirmed to be significantly decreased in 
HL-1 cells transfected with FXN-siRNA (Fig. 21 C). In H9c2 cells, the redox 
index was also significantly decreased in Fxn-siRNA cardiomyocytes (Fig. 
21 D). These data indicate a changed NAD+/NADH ratio in frataxin-
deficient cells compared to controls, with decreased NAD+ levels. This 
depletion of the NAD+ substrate necessary for NADH production and 
mitochondrial complex I activity is an indication of energy imbalance within 
the cell.  
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Figure 21: NADH Levels: Decrease in cells with lower frataxin levels. 
A) NADH and YFP signal in HL-1 cells. B) NADH and YFP signal in H9c2 cells. C) Average 
redox index in HL-1 cells, showing a redox index of 68±2% in siRNA-scrambled cells and 
of 46±3% in Fxn-siRNA cells (n= 3 independent experiments; ***p<0.001). D) Average 
redox index in siRNA-scrambled and Fxn-siRNA cells among H9c2 cells, showing a value 
of showing a value of 47±3% redox index in siRNA-scrambled cells and a 33±2% redox 
index in Fxn-siRNA cells (n= 3 independent experiments; ***p<0.001). Scale bar = 20µm. 
 
 
 
4.2.4 Mitochondrial Energy Imbalance in FRDA 
Pathophysiology (from Abeti et al., 2018) 
Mitochondria are crucial in regulating Ca2+ homeostasis, as after a 
physiological response they take up Ca2+ to restore cytosolic Ca2+ levels to 
resting conditions. The mitochondrial membrane potential (Δψm) is 
susceptible to changes during this process. This was measured during the 
application of caffeine in order to observe any potential changes in 
mitochondrial function. In both the HL-1 and H9c2 cell lines, a 
depolarisation in Δψm was found corresponding with the caffeine response 
in control cells, as the mitochondria actively uptake Ca2+ to rebalance Ca2+ 
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homeostasis following Ca2+ release into the cytosol. This depolarisation 
was significantly reduced in Fxn-siRNA cells (Fig. 22 A-B).  
 
 
 
Figure 22: Comparison of TMRM levels during caffeine response in HL-1 and H9c2 
cells: abnormal bioenergetics response to caffeine in both cell lines (from Abeti et 
al, 2018). 
A) The average depolarisation was set at 100% for the siRNA-scrambled cells in both cell 
lines. The average equivalent TMRM fluorescence percentage for Fxn-siRNA-transfected 
HL-1 cells was 45±1% (n= 3 independent experiments; ***p<0.001). SEM was used to 
calculate the error. B) The average equivalent TMRM fluorescence percentage for Fxn-
siRNA-transfected H9c2 cells was 44±1% (n= 3 independent experiments; ***p<0.001). 
The depolarisation response in the frataxin-deficient cells of both cell lines is reduced, 
indicating inefficient mitochondrial Ca2+ uptake. SEM was used to calculate the error.  
 
 
 
4.2.6 Caffeine-Induced Ca2+ Response Decrease 
in Fxn KD Cells 
I then indirectly observed SR Ca2+ levels via the response to caffeine 
addition in my cardiomyocyte models. Caffeine is an agonist that is used 
to activate the ryanodine receptor in cardiomyocytes (RYR2), inducing 
Ca2+ release from the SR of the cardiomyocytes. This causes a rise in 
[Ca2+]c, and any variation in the Ca2+ response to caffeine may indicate a 
change in SR Ca2+ content or perhaps a potentiation or inhibition of the 
RYR2 that regulate that content. I loaded the cells with 5 µM Fura-2 and 
recorded the fluorescence each second. Ca2+ was found to be released 
from SR stores consistently in HL-1 cells on application of 10mM caffeine. 
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I compared [Ca2+]c levels between HL-1 cells transfected with Fxn-siRNA 
and those transfected with the siRNA-scrambled control.  
 
In summary, there was a significant decrease in the caffeine-induced Ca2+ 
response in HL-1 and H9c2 cells with Fxn knockdown, as compared to 
those incorporating siRNA-scrambled (Fig. 23 B-E). There was a large 
difference in level of decrease between the HL-1 and H9c2 cells, however, 
which could indicate either an increased potentiation of RYR2 function in 
H9c2 cells leading to a lower SR Ca2+ level due to increased leak, or 
alternatively an inhibition of SERCA pump function in H9c2 cells causing 
less Ca2+ to enter the SR in the first place. The CICR amplitude and 
frequency at first increased in the HL-1 FRDA-model cells, before abruptly 
stabilising above its baseline, indicating a probable energetic collapse of 
the CICR process (Fig. 24 A-B). There was no secondary phase of Ca2+ 
signaling in H9c2 cells due to their adult, non-beating nature. 
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 Figure 23: Caffeine-Induced Ca2+ Transient Amplitude: decrease in cells with 
lower frataxin levels. 
Average amplitude of caffeine-induced [Ca2+]c peak in HL-1 and H9c2 cells. A) Fura-2 and 
YFP fluorescence in HL-1 cells. Top left: siRNA-scrambled Fura-2 levels; top right: siRNA-
scrambled YFP levels; bottom left: Fxn-siRNA Fura-2 levels; bottom right: Fxn-siRNA YFP 
levels. B) Average kinetic curve representing Fura-2 ratio showing the difference between 
the caffeine-induced [Ca2+]c transient in HL-1 cells transfected with siRNA-scrambled and 
FXN-siRNA. The siRNA-scrambled trace is in black and the FXN-siRNA trace is in red. 
The box indicating phase II of the caffeine response is highlighted, and further analysed 
in Figure 22. C) Average kinetic curve representing Fura-2 ratio showing the difference 
between the caffeine-induced [Ca2+]c transient in H9c2 cells transfected with siRNA-
scrambled and FXN-siRNA. The siRNA-scrambled trace is in black and the FXN-siRNA 
trace is in red. Graph from Abeti et al, 2018. D) The corresponding average % caffeine-
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induced [Ca2+]c amplitude of siRNA-transfected HL-1 cells.  The average amplitude of cells 
transfected with siRNA-scrambled was normalized to 100%. The corresponding average 
amplitude from cells transfected with FXN-siRNA was 72±8% (***p<0.001; n= 3 
independent experiments). SEM was used to calculate the error. E) The corresponding 
average % caffeine-induced [Ca2+]c amplitude of siRNA-transfected H9c2 cells.  The 
average amplitude of cells transfected with siRNA-scrambled was normalized to 100%. 
The corresponding average amplitude of cells transfected with FXN-siRNA was 30±3% 
(***p<0.001; n= 3 independent experiments). Graph from Abeti et al, 2018. SEM was 
used to calculate the error. Scale bar = 20µm. 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 24: Phase II of the caffeine-induced Ca2+ signalling response in HL-1 cells 
(from Abeti et al, 2018). 
Phase II response to caffeine. A) The phase II response of the siRNA-scrambled cells is 
displayed above in the black box, and B) the phase II response of the Fxn-siRNA cells is 
displayed below in the red box. Both the amplitude and frequency of response is increased 
in Fxn-siRNA cells, and over 7 minutes of recording following caffeine addition, Fxn-
siRNA-transfected cells end their caffeine response early, most likely due to bioenergetic 
failure of CICR.  
 
 
 
 
4.2.7 Thapsigargin Experiments 
 
Thapsigargin Response Indicates Reduced SR Ca2+ Levels 
in Fxn KD HL-1 and H9c2 cells 
To get further data on SR Ca2+ levels, I carried out experiments on HL-1 
and H9c2 cells using thapsigargin, which works by blocking the SERCA 
pump allowing for measurement of the subsequent Ca2+ leak from the SR. 
Data gathered from thapsigargin experiments on HL-1 cells and H9c2 cells 
showed a significant decrease in the estimation of the SR Ca2+ level in Fxn 
knockdown-transfected cells (Fig 25 C-F). This confirmed the findings from 
the caffeine data, indicating a lower SR Ca2+ content in cells incorporating 
a frataxin mRNA knockdown.  
A B 
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Figure 25: Thapsigargin-Induced Ca2+ Transient Amplitude: decrease in cells with 
lower frataxin levels in both FRDA cell models. 
A) Fura-2 and YFP fluorescence in HL-1 cells. Top left: siRNA-scrambled Fura-2 levels; 
top right: siRNA-scrambled YFP levels; bottom left: Fxn-siRNA Fura-2 levels; bottom right: 
Fxn-siRNA YFP levels. B) Fura-2 and YFP signal in H9c2 cells. Top left: siRNA-scrambled 
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Fura-2 levels; top right: siRNA-scrambled YFP levels; bottom left: Fxn-siRNA Fura-2 
levels; bottom right: Fxn-siRNA YFP levels.  C) Average kinetic curve representing Fura-
2 ratio showing the difference between the thapsigargin-induced [Ca2+]c transient in HL-1 
cells transfected with siRNA-scrambled and FXN-siRNA. The siRNA-scrambled trace is 
in black and the FXN-siRNA trace is in red. D) Average kinetic curve representing Fura-2 
ratio showing the difference between the thapsigargin-induced [Ca2+]c transient in H9c2 
cells transfected with siRNA-scrambled and FXN-siRNA. The siRNA-scrambled trace is 
in black and the FXN-siRNA trace is in red. E) The corresponding average % thapsigargin-
induced [Ca2+]c amplitude of siRNA-transfected HL-1 cells. The average amplitude of cells 
transfected with siRNA-scrambled was normalized to 100%. The corresponding average 
amplitude from cells transfected with FXN-siRNA was 58.9±7.8% (***p<0.001; n= 3 
independent experiments). SEM was used to calculate the error. F) The corresponding 
average % thapsigargin-induced [Ca2+]c amplitude of siRNA-transfected H9c2 cells.  The 
average amplitude of cells transfected with siRNA-scrambled was normalized to 100%. 
while the corresponding average amplitude of cells transfected with FXN-siRNA was 
62.3±5.5% (***p<0.001; n= 3 independent experiments). SEM was used to calculate the 
error. Scale bar = 20µm. 
 
 
 
 
 
 
Dantrolene Increases Amplitude of Thapsigargin-Induced 
Ca2+ Response in both Control and Fxn KD HL-1 and H9c2 
cells  
Dantrolene is an inhibitor of ryanodine receptor function. Its use allowed 
for an understanding of whether the RYR2 were already inhibited or not, 
which could give me more insight into the specific pathological role of the 
RYR2. The cells were preincubated with 20 M dantrolene for two hours, 
and then thapsigargin was added. The data displays an extremely 
significant difference between the cells transfected with scrambled-siRNA 
and Fxn-siRNA in both cells lines, despite the use of dantrolene (Fig. 26 C-
F).  
 
In figure 27 (data produced in collaboration with Dr R. Abeti), Part A 
provides a summary and comparison of the Ca2+ responses to thapsigargin 
and thapsigargin-dantrolene in HL-1 cells described in Figs. 25-26, while 
part B compares the average amplitude of the thapsigargin-induced Ca2+ 
response with and without dantrolene incubation in HL-1 cells. Frataxin-
deficient cells without dantrolene have an average amplitude of 41±14%, 
compared to an average amplitude in frataxin-deficient cells with 
dantrolene of 77±7%, showing a significant increase in average amplitude 
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in dantrolene-treated cells (*p<0.05). Thus, comparison of the data in figs. 
25-26 shows how preincubation with dantrolene increases the amplitude 
of the thapsigargin-induced Ca2+ response in both control and frataxin-
deficient cells (Fig. 27 A-B).  
 
 
 Figure 26: Thapsigargin-Induced Ca2+ Transient Amplitude Following Pre-
Incubation with Dantrolene: decrease in cells with reduced frataxin levels in the HL-
1 FRDA cell model. 
Average amplitude of thapsigargin-induced [Ca2+]c peak in HL-1 cells following 
preincubation with dantrolene. A) Fura-2 and YFP fluorescence in HL-1 cells. Top left: 
siRNA-scrambled Fura-2 levels; top right: siRNA-scrambled YFP levels; bottom left: Fxn-
siRNA Fura-2 levels; bottom right: Fxn-siRNA YFP levels. B) Fura-2 and YFP 
fluorescence in H9c2 cells, following same pattern as A). C) Average kinetic curve 
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representing Fura-2 ratio showing the difference between the thapsigargin-induced [Ca2+]c 
transient in HL-1 cells transfected with siRNA-scrambled and FXN-siRNA. The siRNA-
scrambled trace is in black and the FXN-siRNA trace is in red. D) Average kinetic curve 
representing Fura-2 ratio in H9c2 cells. E) The corresponding average % of thapsigargin-
induced [Ca2+]c amplitude of siRNA-transfected HL-1 cells. The average amplitude of cells 
transfected with siRNA-scrambled was normalized to 100%. The corresponding average 
amplitude of cells transfected with FXN-siRNA was 55±3% (***p<0.001; n= 3 independent 
experiments). SEM was used to calculate the error. F) The corresponding average % of 
thapsigargin-induced [Ca2+]c amplitude of siRNA-transfected HL-1 cells. The average 
amplitude of cells transfected with siRNA-scrambled was normalized to 100%. The 
corresponding average amplitude of cells transfected with FXN-siRNA was 62±6% 
(***p<0.001; n= 3 independent experiments). SEM was used to calculate the error. Scale 
bar = 20µm. 
 
 
 
 
 
Figure 27: Thapsigargin-Induced Ca2+ Transient Amplitude: increase in average 
amplitude in dantrolene-treated frataxin-deficient HL-1 cells. 
A) Average kinetic curve representing Fura-2 ratio summarising the difference between 
the thapsigargin-induced [Ca2+]c transient in HL-1 cells transfected with FXN-siRNA and 
not pre-incubated with dantrolene (Fig. 23), and those undergoing the same treatment 
and also pre-incubated with dantrolene (Fig. 24). Non-dantrolene: the siRNA-scrambled 
trace is in black and the FXN-siRNA trace is in red. Dantrolene: the siRNA-scrambled 
trace is in grey and the FXN-siRNA trace is the dashed line in red. B) A comparison of the 
average amplitude of thapsigargin response in frataxin-deficient cells without dantrolene 
(41±14%), and with dantrolene (77±7%), showing a significant increase in average 
amplitude in dantrolene-treated cells (*p<0.05). SEM was used to calculate the error. Data 
produced in collaboration with Dr R. Abeti. 
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4.2.8 Primary Cell Data 
 
Caffeine-Induced Ca2+ Response Decreased in YG8R 
Mouse Model Cells 
To complement my data from the two heart cell lines, I studied cells from 
the YG8R FRDA mouse (Al-Mahdawi et al., 2006), in order to see firstly if 
we could obtain less heterogeneous results using caffeine to stimulate the 
ryanodine receptors. This was achieved in primary cells from a YG8R 
mouse (n=4) and was compared with control cells from primary cultures 
obtained from wild-type mice of the equivalent breed, C57/BL6. The data 
indicated an extremely significant decrease in SR Ca2+ content due to the 
FXN knockdown, confirming the data from the two FRDA-like 
cardiomyocyte models (Fig. 28 A-B). Data specifically from the Y47R 
control mouse model may be required for a more complete picture. 
Although my primary cell data appears to agree with my hypothesis that 
there will be significantly less Ca2+ in the SR, the smaller amount of data 
currently accumulated from primary cells mean that accumulation of more 
primary cell data and additional experimental techniques such as using 
thapsigargin are a crucial next step. 
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Figure 28: Thapsigargin-Induced Ca2+ Transient Amplitude: decrease in YG8R 
primary cells with lower frataxin levels. 
A) Fura-2 fluorescence in YG8R mouse primary cells. B) The average % caffeine-induced 
[Ca2+]c amplitude of WT/YG8R cells.  The average amplitude of WT cells from the B57/C6 
breed of mice was set at 100%. The corresponding average amplitude from cells from the 
YG8R mouse model was 24±2% (n=3 independent experiments; ***p<0.001), indicating 
a significant decrease in the SR Ca2+ content. 
 
 
 
 
4.2.9 Results Summary 
It is known that changes in iron metabolism, oxidative stress and 
mitochondrial dysfunction result from frataxin deficiency, and that these 
lead to a pathophysiological phenotype in the heart as well as affected 
neural tissue. However, very few FRDA studies have been carried out into 
the potential relevance of Ca2+ homeostasis, which is intimately linked with 
mitochondrial function and ROS levels, and none at all have been 
performed using a FRDA cardiomyocyte model. Therefore, I undertook the 
first study of Ca2+ signalling using two different FRDA heart cell lines, the 
murine adult atrial cell line HL-1 and the rat ventricular neonatal cell line 
H9c2.  
 
I began by characterising my FRDA cell models through testing well-
established physiological effects of FRDA, and then investigated the 
[Ca2+]c levels in two cardiomyocyte cell lines representative of a neonatal 
and an adult phenotype. The increase in ROS levels observed in both 
FRDA cell models (Figs. 18-19) was consistent with that found in previous 
FRDA models (Abeti et al., 2016; Bradley et al., 2004; Emond et al., 2000; 
WT YG8R
0
50
100
150
A
m
p
li
tu
d
e
 o
f 
C
a
ff
e
in
e
 
R
e
s
p
o
n
s
e
, 
%
***
A B
 173 
Lamarche et al., 1980; Puccio et al., 2001). A decreased NADH redox 
index was found in both FRDA cell models, indicating depletion of the NAD+ 
substrate for mitochondrial complex I activity and a general energy 
imbalance due to frataxin depletion (Fig. 20-21). I specifically focused on 
the SR Ca2+ content, and thus RYR2/SERCA activity, in the cardiac FRDA 
model cells to see if these could be affected compared to the control cells.  
 
Reduced Ca2+ levels due to increased leakage from the SR through the 
ryanodine receptors leading to a lower SR Ca2+ content, was established 
using caffeine and thapsigargin, respectively (Figs. 23-25). The findings of 
this study allow for the hypothesis that Ca2+ homeostasis is impaired by 
oxidative stress caused by reduced levels of frataxin in FRDA. More work 
is now necessary to establish a causal link between them.  I also collected 
important preliminary data from FRDA model YG8R mouse primary cells 
on the thapsigargin-induced Ca2+ response that, crucially, supported the 
data from the cell models (Fig. 28). However, additional Ca2+ level 
measurements, ROS activity measurements and NADH level 
measurements will be required to complete the physiological picture in 
primary cells.  
 
In conclusion, the novel finding of a decreased SR Ca2+ content has been 
discovered in FRDA model cardiomyocytes alongside the more 
established increase in ROS levels. This change in Ca2+ homeostasis is 
most likely caused by RYR2 potentiation, causing a leakier SR. These 
data, together with additional data gathered by Dr Abeti that found Δψm 
depolarization (presented in this results section) and [Ca2+]m uptake 
inhibition which was reversed by vitamin E administration in these same 
FRDA model cardiomyocytes (Abeti et al, 2018), are part of the first steps 
indicating how modulation of Ca2+ in cardiomyocytes could be a novel 
therapeutic strategy in FRDA.  
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4.3 Discussion  
Frataxin deficiency is known to cause oxidative stress through the 
generation of iron free radicals and an imbalance in mitochondrial 
bioenergetics (Abeti et al., 2016; Bradley et al., 2004; Puccio et al., 2001; 
Puccio & Koenig, 2000). Hypertrophic cardiomyopathy is a key symptom 
in FRDA, and the function of frataxin in general appears to be more 
relevant in tissues with a higher energy demand such as the heart (Puccio 
et al., 2001).  Ca2+ homeostasis has been assessed in a small amount of 
FRDA cellular models such as neuronal cell lines, some of which have 
established a link between Ca2+ levels and the mitochondrial dysfunction 
and oxidative stress previously established in FRDA pathophysiology 
(Bolinches-Amoros et al., 2014; Mincheva-Tasheva et al., 2014; Molla et 
al., 2017; Ristow et al., 2000; Wong et al., 1999). This link has been 
established in particular in DRG neurons from the YG8R FRDA mouse 
model used in this study (Molla et al., 2017). However, despite the heart 
defects associated with FRDA that can lead to arrhythmia and sudden 
death, Ca2+ homeostasis has never been studied in FRDA model 
cardiomyocytes.  
 
Shifts in Ca2+ homeostasis can lead to changes in heart contraction and 
relaxation, and ultimately to cardiac failure (Limbu et al., 2015). As the 
heart defects in FRDA have strong similarities with other disorders 
involving iron-induced oxidative stress and Ca2+ dysregulation in 
cardiomyocytes (Oudit et al., 2006; Schwartz et al., 2002), a study of Ca2+ 
homeostasis in an FRDA cardiac model could increase the knowledge of 
the pathophysiological mechanisms of FRDA, with a view to potential 
therapies. In order to understand the role of Ca2+ homeostasis in 
cardiomyocytes in FRDA, we used two heart cell models of FRDA, as well 
as primary cardiomyocytes from a mouse model. In particular I aimed to 
study the effect of frataxin deficiency on the SR, as the major regulator of 
intracellular Ca2+ uptake and release in heart cells, as well as to test any 
potential therapeutic measures based on the results obtained.  
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This report showed that frataxin knockdown in cardiomyocytes increases 
both cytosolic and mitochondrial ROS levels (Fig. 18). I then showed that 
my hypothesis that Ca2+ homeostasis is affected in FRDA cardiomyocytes 
was supported. Specifically, a decrease in the SR Ca2+ pool was fully 
established through two experimental procedures using measurement of 
cytosolic Ca2+ levels. Caffeine was added to the cells to elicit the emptying 
of Ca2+ from the SR via RYR2 receptors, and this established a decreased 
release of Ca2+ from the SR in frataxin-deficient cells compared to controls 
(Fig. 23). Thapsigargin, a SERCA pump inhibitor, was used to prohibit the 
SR Ca2+ pool from increasing, and indirectly confirmed a decrease in the 
SR Ca2+ pool by observing reduced Ca2+ leak through the ryanodine 
receptors in FRDA cells (Fig. 25). This decrease in SR Ca2+ leak via 
ryanodine receptors had previously been observed in specific iron-
overload conditions but not FRDA (Cherednichenko et al., 2004; Kawakami 
& Okabe, 1998). Finally, thapsigargin was used following a preincubation 
of the cells with dantrolene, a ryanodine receptor inhibitor, in order to 
assess the role of RYR2 dysfunction in the change in SR Ca2+ content. Use 
of dantrolene maintained the significant difference in Ca2+ response 
between control and FRDA-deficient cells observed using thapsigargin 
without dantrolene, but it significantly increased the amount of Ca2+ in the 
SR store compared to sole use of thapsigargin (Figs. 26-27). These results 
showed that the RYR2 were not pathologically inhibited by dantrolene but 
are perhaps potentiated in FRDA as the SR Ca2+ levels were nearly 
restored by dantrolene.  Thus, the SR Ca2+ pool decrease in FRDA was 
indicated to be at least partially caused by a defect in the RYR2. 
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Figure 29. Summary of Key Findings in FRDA Ca2+ Pathophysiology. 
 
These data were fully established in both the HL-1 and H9c2 cell FRDA 
models, but remain incompletely characterized in the primary cell models, 
although the preliminary data obtained thus far support the findings 
obtained in the cell models (Fig. 28). HL-1 cells, as adult cardiomyocytes, 
are a useful point of comparison with data from the H9c2 cells and the 
neonatal primary cells from the mouse model. That both cell models, and 
the data gathered on primary cells thus far, produce similar results shows 
that the FRDA pathophysiology associated with Ca2+ level dysregulation 
may be present from an early age in patients, despite lack of symptoms 
until adolescence and early adulthood. This is supported by previous 
studies where the early embryonic lethality caused by total frataxin 
knockout in mouse models was not associated with mitochondrial iron 
accumulation (Cossee et al., 2000; Simon et al., 2004), indicating that 
FRDA pathogenesis is primarily determined by a subtle, early increase in 
redox-active mitochondrial iron.  Given the indications from my study of 
Ca2+ signalling in HL-1 and H9c2 cells, further data in primary cells from 
neonatal mice will be of great importance in confirming my original findings, 
as well as for developing potential novel FRDA therapies involving 
pharmacological manipulation of cellular Ca2+ levels. 
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The SR Ca2+ store depletion established in the FRDA-like cells is 
associated with and may be explained by the increase in both cytosolic and 
mitochondrial ROS levels in the two cell models, indicating increased 
oxidative stress (Figs. 18-19). FRDA cells are known to display an 
increased sensitivity to oxidative stress (Babcock et al., 1997; Condo et al., 
2007; Tan et al., 2001; Wong et al., 1999), and in one case this has been 
linked to Ca2+ dysregulation within the cell (Wong et al., 1999).  Depressed 
SERCA2a function, leak through RYR2 on the SR surface and increased 
Na+-Ca2+ Exchanger (NCX) expression have previously been linked with 
SR Ca2+ store depletion, cardiac contractile dysfunction and the resulting 
systolic heart failure and may be responsible for the cardiac symptoms of 
FRDA (Zima & Mazurek, 2016). The NCX may thus be another potential 
avenue of study in FRDA cardiac pathophysiology. 
 
Several studies have detailed the sensitivity to oxidation of certain free 
cysteine (Cys) residues in the active site of both SERCA and RYR2 
proteins, to which hydroxyl radicals can bind (Diaz et al., 2005; Marx et al., 
2000; Xu et al., 1997; Ying et al., 2008; Zima & Mazurek, 2016). In 
cardiomyocytes, RYR2 are particularly important for SR Ca2+ homeostasis, 
and it is known that a reduction in SR Ca2+ content can be exacerbated by 
increased Ca2+ leak through RYR2. RYR2 potentiation is indicated by the 
phase II Ca2+ signalling after caffeine-response in HL-1 cells, indicating a 
probable energetic collapse of the Ca2+-Induced Ca2+-Release (CICR) 
process (Fig. 24). RYR2 potentiation is indicated as reducing SR Ca2+ 
levels in this study. This may primarily be due to hyperphosphorylation of 
the RYR2, which has been associated with oxidative stress and shown to 
increase the probability of RyR opening (Zima & Mazurek, 2016). RYR2 
potentiation may also be associated with increased oxidation, which has 
also been shown to enhance Ca2+ release from cardiomyocytes (Oda et 
al., 2015).  
 
A reduction in the SERCA2a paralog is strongly correlated with heart failure 
(Diaz et al., 2005), and thus may be involved in the intracellular Ca2+ 
dysregulation. The Cys674 residue of the SERCA pump has been 
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observed to be a particularly crucial residue for oxidative regulation (Adachi 
et al., 2004; Sharov et al., 2006). Decreased SERCA function may be 
indicated by a compensatory increase in SERCA protein levels in HL-1 and 
H9c2 frataxin-deficient cells, although preliminary attempts to study this via 
Western blot experiments are not presented in this study due to unclear 
data. A further comparative measurement of the specific levels of the 
crucial Cys674 residue between control and frataxin-deficient cells would 
also be of great use in physiologically defining the precise role of the 
SERCA2a protein in the Ca2+ dysregulation in FRDA. It will be important to 
establish whether the SR Ca2+ content is primarily reduced by excessive 
Ca2+ efflux through RYR2, or if both the RYR2 and SERCA pump have a 
pathological role in FRDA (Fig. 29). Given the nature of the direct link 
between decreased frataxin and increased sensitivity to oxidative stress, 
the data gathered thus far indicate that the iron-induced ROS pathway may 
play the dominant role in FRDA pathophysiology.   
 
The results in this study can be corroborated with those of my colleague 
Dr Rosella Abeti, who discovered a partial inhibition of [Ca2+]m, as had been 
previously seen in other FRDA models (Bolinches-Amoros et al., 2014; 
Abeti et al, 2018). As thapsigargin had been shown to cause a gradual, 
detectable Ca2+ leak from the SERCA into the cytosol, we wanted to see if 
mitochondrial Ca2+ uptake was affected due to the SR-mitochondria 
microdomains (Csordas et al., 2006; Garcia-Perez et al., 2008). Together 
with the mitochondrial ROS data and TMRM data showing increased 
oxidative stress and increased mitochondrial depolarization in frataxin-
deficient cells respectively (Fig. 19 & Fig. 22), this finding indicates that 
there may be an element of the cellular Ca2+ dysregulation that will need 
to be explained at the mitochondrial level.  
 
As cellular Ca2+ homeostasis is intimately linked to mitochondrial function, 
bioenergetics impairment has also been claimed as the primary cause of 
FRDA cardiomyopathy (Perdomini et al., 2014; Puccio et al., 2001). 
However, this impairment may be fully mechanistically linked to the iron-
induced ROS increase in FRDA. ROS levels were also shown to be 
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increased in the mitochondria in our study, which may also affect the 
mitochondrial Ca2+ uniporter 1 (MCU), crucial for [Ca2+]m uptake and known 
to be affected by high levels of oxidative stress (Dong et al., 2017). The 
RYR2 on the SR form microdomains with mitochondria in cardiomyocytes, 
which interact with and control local interorganellar Ca2+ signalling in the 
cell (Csordas et al., 2006; Garcia-Perez et al., 2008). Thus, both the 
change in the SR Ca2+ pool and the increase in oxidative stress discovered 
in this report is likely to affect mitochondrial function, including its role as 
the secondary cellular Ca2+ buffer after the SR. It is also known that RYR2-
mediated Ca2+ fluxes control mitochondrial Ca2+ and ATP levels in the cell 
(Bround et al., 2013), which may account for the changes in [Ca2+]m 
observed.  
 
Further studies on the effect of RYR2 alteration on mitochondrial Ca2+ 
levels may be necessary to fully characterize the role of the RYR2 in the 
FRDA pathophysiological mechanism. Mitochondrial dysfunction is likely 
to both be at least partially responsible for and affected by the increased 
ROS levels observed in frataxin-deficient cardiomyocytes. The decreased 
mitochondrial ISC synthesis resulting from frataxin deficiency (Rotig et al., 
1997) is expected to lead to reduced or faulty respiratory chain function 
and consequent ROS production due to the key role of the clusters in the 
structure and function of respiratory complexes I, II and III, and the protein 
aconitase. Decreased ISC synthesis has been directly associated with 
increased mitochondrial iron levels (Chen et al., 2004; Radisky et al., 
1999), which itself can lead to increased free radical generation (Babcock 
et al., 1997; Cavadini et al., 2002) and create a vicious cycle alongside 
decreased respiratory chain function, leading to decreased ATP synthesis 
and cell death. Progressive cardiomyopathy in FRDA has also been 
proposed to result from iron-catalysed mitochondrial dysfunction (Michael 
et al., 2006).   
 
Ca2+ itself is known to stimulate three proteins of the tricarboxylic acid 
cycle, and thereby the electron transport chain, driving ATP synthesis. 
Thus, a Ca2+ signaling defect in the cell could in theory be the cause, as 
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well as the consequence of mitochondrial dysfunction and an increase in 
ROS levels. A recent study by the Palau group indicated that Ca2+ 
overload, in conjunction with oxidative stress and mitochondrial defects, 
may be directly responsible for neurological symptoms in FRDA (Molla et 
al., 2017). Mitochondrial ROS and a cellular dysregulation of Ca2+ 
homeostasis via the SR may work in tandem to produce the FRDA cardiac 
phenotype. The Ca2+- and ROS-based findings in this study are 
corroborated with the finding of a decreased NADH redox index in both 
FRDA cell models, indicating an NAD+ depletion. The potential decrease 
in mitochondrial complex I activity could indicate a lower mitochondrial ETC 
activity, although more direct experiments on the production and activity of 
the mitochondrial complexes are needed in this FRDA model (Fig. 20-21). 
The NADH data should also be further corroborated with data on FADH2 
levels to obtain a more complete picture of the extent of mitochondrial ETC 
activity in FRDA cells. This finding allows the Ca2+ levels to be considered 
alongside both the established FRDA physiological marker of 
mitochondrial dysfunction as well as that of oxidative stress, although more 
work is necessary to establish a causal link between them. Thus, the 
mechanics of the bioenergetics pathway must be further explored 
alongside the iron overload pathway in elucidating the precise role of Ca2+ 
homeostasis in FRDA pathophysiology.  
 
The iron-induced oxidative stress could lead to reduced peak systolic Ca2+ 
levels, slowed rates of Ca2+ relaxation, and elevated diastolic Ca2+ levels, 
as observed in studies of other heart conditions associated with iron 
overload (Oudit et al., 2006; Schwartz et al., 2002). Although no conclusive 
findings were obtained regarding these symptoms in this study, increased 
spontaneous heart activity levels in HL-1 cells with the frataxin knockdown 
incorporated was observed via repeating Ca2+ spikes. This has been 
shown to underlie arrhythmias and sudden death often in combination with 
a slowed Ca2+ re-uptake in the sarcoplasmic reticulum (Payne et al., 2011). 
Unfortunately, a full comparative study of this effect necessitated a beating 
monolayer of cardiomyocytes in every cell type. This was only possible in 
an inconsistent manner in the early passages of HL-1 cell culture, and not 
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possible at all in the neonatal H9c2 cells and the neonatal primary cell 
cultures, which did not form beating monolayers. No difference was evident 
in basal Ca2+ levels following Fxn knockdown either. Thus, further studies 
of potential pathological differences in Ca2+ spike frequency as well as 
shifts in the pattern of Ca2+ signaling during systole and diastole may 
require electrophysiological experiments and in vivo tests on primary cells 
or other cell models. 
 
One potential further avenue for the study of Ca2+ homeostasis imbalance 
in FRDA cardiomyocytes, in addition to study of the SR or RYR2, is looking 
at Ca2+ flux in L-type Ca2+ channels on the plasma membrane. In iron-
overload conditions, free non-transferrin-bound iron has been shown to 
permeate through L-type Ca2+ channels. The permeation of 0.5mM Fe2+ 
(reactive ferrous iron) through the cardiac L-type Ca2+ channels has been 
shown to cause a slowing of the Ca2+ current inactivation, resulting in a 
50% increase in net Ca2+ influx and in the time integral of the Ca2+ current 
in iron overload studies using cardiomyocytes (Lacampagne et al., 1995; 
Oudit et al., 2003; Shirotani et al., 2001). This may be a factor in the 
impaired diastolic function that occurs in early-stage iron overload. Higher 
concentrations of ferrous iron (2-4mM) elicit instead a reduction in the Ca2+ 
current due to increased competition with the Fe2+, leading to the systolic 
dysfunction seen in late-stage iron cardiomyopathy (Lacampagne et al., 
1995). These findings may be of great relevance to the mechanism of 
cardiomyopathy in FRDA. 
 
In addition, there is new potential for FRDA therapies that perform a 
pharmacological manipulation of cellular Ca2+ levels. One potential therapy 
involves the lipid-soluble antioxidant vitamin E, that in conjunction with 
coenzyme Q10 (CoQ10) has shown a beneficial effect on mitochondrial 
bioenergetics in cardiomyocytes and muscle cells (Hart et al., 2005; Lodi, 
Rajagopalan, et al., 2001). Further experiments by Dr Rosella Abeti 
showed that the inhibition of [Ca2+]m was rescued by application of the 
antioxidant vitamin E post-thapsigargin response in HL-1 frataxin-deficient 
cells (Abeti et al, 2018). Although these experiments are not presented in 
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this thesis, they greatly emphasise how oxidative stress and Ca2+ 
deregulation are related in the FRDA model. A series of TUNEL 
experiments also indicated increased apoptosis following hypoxia-
reoxygenation injury in frataxin-deficient cells compared to controls, and 
also showed prevention of apoptosis in these cells following vitamin E 
administration (Abeti et al, 2018). These results indicate a greater 
propensity for FRDA-like cells to suffer from hypoxia-reoxygenation injury, 
as occurs in FRDA (Payne et al., 2011), as well as a possible therapeutic 
role of vitamin E in treating the cardiac aspects of the disease. 
 
Although vitamin E has been proposed as a therapy for the symptoms of 
FRDA cardiomyopathy, it was not previously considered due to a lack of 
natural history studies specifically on the cardiac symptoms of FRDA 
(Cooper & Schapira, 2007). A common current treatment for FRDA 
patients presenting with cardiac abnormalities is bisoprolol, which blocks 
beta-adrenergic receptors that are activated by the sympathetic nervous 
system. The sympathetic nervous system is activated during heart 
dysfunction in order to increase ionotropic support (including Ca2+), which 
also increases oxidative stress leading to the potentiation of ryanodine 
receptor function (Rehsia & Dhalla, 2010). This mechanism is entirely 
consistent with the data from this study, and consequently a key 
therapeutic concern is to protect the heart muscle from oxidative stress and 
RYR2 potentiation via use of an antioxidant. These results support the 
hypothesis that defects in RYR2 function are the major contributor to the 
Ca2+ dysregulation observed in the FRDA cardiomyocyte model used 
(Bolinches-Amoros et al., 2014; Mincheva-Tasheva et al., 2014; Zima & 
Mazurek, 2016), and adds weight to the proposal for vitamin E as a 
therapeutic factor in FRDA cardiomyopathy. 
 
There is some indication in FRDA model DRG neurons that a cellular or 
mitochondrial Ca2+ overload is specifically occurring, and therapies 
involving Ca2+ chelators have been proposed in this model to prevent the 
dying-back neurodegeneration that occurs in FRDA DRG cells (Molla et 
al., 2017). However, the subtle, dynamic nature of Ca2+ homeostasis in 
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heart cells, due to its crucial function in excitation-contraction coupling, 
makes a basic modulation of cellular Ca2+ levels highly unlikely to be of use 
in restoring normal Ca2+ homeostasis. Furthermore, Ca2+ levels appear to 
be reduced in the cytosol and mitochondria in FRDA-like heart cells, not 
overloaded. Future potential therapies may need to be directed towards 
subcellular targets, such as modulating the function of Ca2+ buffer 
organelles such as the SR and the mitochondria. The tight interconnection 
of the SR-mitochondrial network and its importance in heart function makes 
it likely that a successful therapy will be directed at this level. Therapy may 
become possible if specific residues or active sites of the SR or RYR2 are 
discovered that are affected by high ROS levels in FRDA model 
cardiomyocytes, which can then be specifically targeted to restore function 
alongside use of antioxidants such as idebenone or vitamin E to combat 
the symptoms of FRDA (Payne et al., 2011). Alternatively, due to the 
interconnection of dysregulated Ca2+ levels with ROS levels and 
mitochondrial dysfunction, modulation of Ca2+ levels may not be the only 
or necessary therapeutic target in resolving the cardiac phenotype in 
FRDA. 
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Chapter 5 : Final Discussion 
Over the around 150 years since the disease was first characterised as a 
unique disorder, the description of its genetic aetiology, pathophysiology 
and phenotype has developed. However, it was only in the 1970s that the 
understanding of the FRDA phenotype became detailed enough for a 
specific set of reliable diagnostic criteria to be drawn up (Geoffroy et al., 
1976; Harding, 1981). It is only since the discovery of the genetic basis of 
the disease (Campuzano et al., 1996) that we have been able to perform 
genotype-phenotype correlations for FRDA patients, which revealed that 
the phenotype spectrum previously proposed for FRDA left out up to a 
quarter of FRDA cases due to their atypical symptoms. These symptoms 
included very early or very late disease onset, retained reflexes, spasticity 
and limited disease progression (Durr et al., 1996; Filla et al., 1997; 
McCabe et al., 2000; Schols et al., 1997). These genetic advancements 
also led to a more accurate genotype-phenotype characterisation, 
improving diagnostic accuracy and genetic counselling at a clinical level. 
 
In the genetics study, out of a total of 2000 DNA samples from genetically 
undiagnosed ataxia patients not referred by their clinicians for an FRDA 
test (the largest study of its kind ever performed), only three were identified 
as having two pathological GAA expansions, and thus as positive for FRDA 
(0.15% of the cohort). This indicates that the risk that an ataxic patient, with 
symptoms atypical for FRDA, in fact has the FRDA genotype is extremely 
low, confirming my hypothesis made in Chapter 1. These data strengthen 
the current diagnostic model where the FRDA test is only carried out upon 
consultant referral. No point mutations and no exonic deletions were 
discovered among the 12 individuals with only one pathological GAA 
expansion, which was consistent with previous data. Thus, these 12 were 
confirmed as FRDA gene carriers, all of which were symptomatic for 
separate ataxic disorders. This gives a carrier rate of 0.6%, or 1/167. A 
large variation has previously been seen in carrier frequency, with which 
the carrier frequency of this study is broadly compatible.  
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The three FRDA-positive patients display atypical symptoms for classical 
FRDA, and their late age at onset also suggests that disease progression 
is slower in these patients. This is all consistent with a diagnosis of LOFA 
(in one patient, who had an age of onset of around 25) and VLOFA (in the 
other two patients, who both had ages of onset of over 50). This FRDA 
variant is phenotypically distinct from classical FRDA, and is characterised 
by a milder phenotype, slower disease progression and a more variable 
set of symptoms, all of which are the case in the three FRDA-positive 
patients. In one case, the ataxia was attributed to excessive alcoholism, 
and in the other two it is possible unusual symptoms such as blackouts 
may have confused the clinicians. Nevertheless, it could be argued that 
these patients should have been referred for an FRDA test in any case, 
especially when environmental factors may obscure the role of any genetic 
factor, as with the patient suffering from alcoholism. The well-being of the 
patient, as well as any potential therapeutic benefit in future, rests upon a 
correct diagnosis.  
 
There is an extremely small chance that FRDA patients with exonic 
deletions may not have been detected, and alternative testing may need to 
be carried out in future to rule out this possibility with certainty. The 
extremely small expansion size in five of the six alleles from my three 
FRDA-positive patients is a confirmation of the strong correlation between 
expansion size and disease severity (including incidence of 
cardiomyopathy), and its inverse correlation with age at onset (Durr et al., 
1996; Filla et al., 1997; Montermini et al., 1997; Rajagopalan et al., 2010). 
This is broadly compatible with the knowledge that 50% of variability in age 
at onset has been shown to be caused by expansion size (Filla et al., 
1997). The great variety in the age at onset between one of the FRDA 
patients in my study and their sibling indicated that further study of 
intrafamilial cases may shed light on the clinical heterogeneity of FRDA 
and the importance of other factors in determining the severity. However, 
the sibling was originally diagnosed with multiple sclerosis, and although 
an actual FRDA diagnosis is extremely likely retrospectively (see Chapter 
3, Discussion), it is not yet confirmed by the data. Intrafamilial variety in 
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GAA expansion size may be explained by somatic mosaicism and 
interruptions in the expansion as well as other reasons (Pandolfo, 1999), 
all of which warrant further study in FRDA genetic research. Ultimately 
however, the clinical symptoms presented in my genetic screening, in 
addition to the study performed on the other cohort of patients who were 
originally referred for FRDA by Dr M. H. Parkinson, bear out the theory that 
the FRDA patient phenotype is almost fully accounted for by the current 
genotype-phenotype characterisation of FRDA, including crucially its 
variant LOFA/VLOFA form. Despite the clinical heterogeneity of FRDA, it 
is consistent and diagnosable enough to make the risk of misdiagnosing 
atypical FRDA patients very low indeed. The data also strengthens the 
already well-established point that atypical cases of FRDA are almost 
always caused by extremely small or large GAA expansion sizes 
(Parkinson et al., 2013). 
 
This thesis also describes an expansion and clarification of the current 
knowledge of the pathways involved in FRDA pathophysiology. Although 
frataxin is a multifunctional protein, it was known that the major functional 
role of frataxin is in ISC biogenesis (Puccio et al., 2001; Rotig et al., 1997). 
ISC deficiency is linked to an increasing amount of diseases as it can lead 
to multiple, aggregating cellular dysfunctions (Lill, 2009). Mitochondrial iron 
accumulation is linked with ISC deficiency in yeast studies (Chen et al., 
2004; Radisky et al., 1999), although it is detected after the original ISC 
defects (Puccio et al., 2001). This mitochondrial iron accumulation has 
been more established in FRDA cardiac pathology studies than in ones 
focusing on the neurology. It is in turn linked with increased oxidative stress 
(Abeti et al., 2016; Bradley et al., 2004; Emond et al., 2000; Schulz et al., 
2000), the potential major causal factor in the cell degeneration and death 
that presents in FRDA (Chen et al., 2004; Schulz & Pandolfo, 2013). 
Oxidative stress has more recently been associated with abnormal Ca2+ 
homeostasis in FRDA (Gonzalez-Cabo & Palau, 2013).  
 
This has been explored for the first time in cardiomyocytes in this thesis, 
which has established a key role for cellular Ca2+ dysregulation in FRDA 
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cell degeneration and death (confirming my original hypothesis in Chapter 
1), that is partially rescued with the administration of vitamin E. All 
experiments were carried out and compared in two separate FRDA rodent 
cellular model populations, one neonatal (H9c2) and one adult (HL-1). 
They modelled FRDA via knockdown of the frataxin gene using siRNA. A 
lower Ca2+ leak from the sarcoplasmic reticulum through the ryanodine 
receptors and a lower sarcoplasmic reticulum Ca2+ content was 
established using caffeine and thapsigargin respectively. These data can 
be inserted into the current framework of FRDA research, given my other 
findings of an increase in ROS levels in both models indicating that the 
Ca2+ deregulation may be due to the effect of pathological levels of 
oxidative stress previously observed in the disease. These findings are 
among the first that have found a change in Ca2+ levels alongside the 
established oxidative stress data in FRDA. More work is now necessary to 
establish a causal link between them. I also collected important data from 
FRDA model YG8R mouse primary cells on the thapsigargin-induced Ca2+ 
response: however, ROS activity and NADH level measurements will be 
required to complete the physiological picture in those cells. Given the 
indications from my study of Ca2+ signalling in FRDA-like cell lines, these 
further data in FRDA model primary cells from neonatal mice will be of 
great importance in verifying my original findings. 
 
The finding of a decreased SR Ca2+ content in FRDA-like cardiomyocytes 
corresponded with previous findings in heart cells following oxidative 
damage, including an increased SR Ca2+ leak through RYR2 in SR vesicles 
isolated from canine cardiac muscle (Kawakami & Okabe, 1998) as well as 
from rat ventricular cardiomyocytes (Cherednichenko et al., 2004). An 
imbalance in [Ca2+]m and a decreased depolarisation in Δψm was also 
discovered by my colleague Dr Abeti in frataxin-deficient cells, which could 
be rescued by preincubating the cells with vitamin E (Abeti et al, 2018). A 
link between Ca2+, mitochondrial dysfunction and oxidative stress has 
already been detected in studies on FRDA model DRG neurons (Molla et 
al., 2017), indicating a possible future research avenue in FRDA 
cardiomyopathy studies. However, as it is also known the heart defects 
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present in FRDA are associated with iron-induced oxidative stress and 
Ca2+ dysregulation in other disorders relevant to my study (Oudit et al., 
2006; Schwartz et al., 2002), it will be important to understand the precise 
pathophysiological mechanism of Ca2+ dysregulation in the disease. It is 
still unclear whether the primary pathological result of frataxin deficiency is 
directly oxidative stress and increased ROS hypersensitivity leading to ISC 
loss, iron overload, and cell death, or whether oxidative stress is only an 
indirect result of iron overload or indeed ISC loss itself (Figure 4, Chapter 
1). A role for the directly increased ROS sensitivity of frataxin-deficient cells 
is implied but not confirmed by my results concerning RYR2 function in the 
heart, which indicate that specific residues of the protein may be 
particularly sensitive to severe oxidation. It is already known that frataxin 
has a specific role in protection against iron-induced oxidative damage 
(Gakh et al., 2006; O’Neill et al., 2005).  
 
Future studies should focus more specifically on the cysteine residues of 
the SERCA (such as Cys674) and RYR2 which are directly affected by 
oxidative stress, in order to confirm the crucial pathophysiological role of 
ROS hypersensitivity in FRDA, understand which residues are most crucial 
to the FRDA pathology, and clarify what role the SERCA pump has in 
FRDA in addition to the role of the RYR2. The potential discovery of a role 
in FRDA for specific residues in the RYR2 and SERCA also has clear 
therapeutic benefits. Given the close relationship between the SR and the 
mitochondria in heart muscle cells, further studies linking the effect of 
RYR2 potentiation with mitochondrial Ca2+ levels may be highly useful in 
more fully characterising the role of the RYR2 in the FRDA 
pathophysiological mechanism. The decrease in the SR Ca2+ pool is likely 
to affect the role of the mitochondria as the secondary cellular Ca2+ buffer 
after the SR, as also indicated by the increased mitochondrial ROS levels. 
The potentially pathological difference in the phase II response of Ca2+ 
spike frequency following caffeine application indicates a potential 
difference in electrical spark activity in the heart that may be further 
understood through future electrophysiological studies and in vivo tests, 
which may be able to explain specific shifts in the pattern of Ca2+ signalling 
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during heart systole and diastole better than physiological experiments. 
Hypoxia-reoxygenation injury was accentuated in frataxin-deficient cells, 
and experiments by my colleague Dr Abeti showed that this could be 
partially rescued by vitamin E administration (Abeti et al, 2018). Thus, 
vitamin E, for which former proposals as a therapeutic route for FRDA 
cardiomyopathy had lacked robustness due to a lack of natural history 
studies on that aspect of the condition, emerged more strongly as a 
potential FRDA therapy (Cooper & Schapira, 2007). This study supports 
the hypothesis that Ca2+ homeostasis is affected in FRDA and forms a 
gateway to further work alongside the recent Mollá paper (Molla et al., 
2017). 
 
 
The data showing a decrease in intracellular Ca2+ levels corresponds with 
previous studies carried out in FRDA-like DRG neurons (Mincheva-
Tasheva et al., 2013; Molla et al., 2017). The data showing a decreased 
[Ca2+]m with lower frataxin levels in heart cells corresponds with previous 
data in 3T3-L1 adipocytes, which showed a direct correlation between 
frataxin levels and mitochondrial Ca2+ buffer capacity (Bolinches-Amoros 
et al., 2014). Although this is a notable step forward, there are various 
directions future FRDA research could take to build upon our current 
knowledge. Oxidative stress has been shown to incur SERCA pump 
inhibition in SR vesicles isolated from rabbit cardiac and skeletal muscle 
(Xu et al., 1997) as well as guinea pig ventricular cardiomyocytes 
(Goldhaber & Qayyum, 2000). Further experiments on SERCA pump 
function could prove useful for understanding the relative responsibility for 
the RYR2 defect in FRDA pathophysiology. Oxidative stress has also 
elicited a reduced L-type Ca2+ current in guinea pig ventricular 
cardiomyocytes (Lacampagne et al., 1995). As Ca2+ influx occurs mostly 
through L-type Ca2+ channels in cardiomyocytes, it will be important to 
study whether the Ca2+ influx rate or perhaps L-type channel function itself 
is affected in FRDA. Also, a previous study showed that mitochondrial ROS 
levels can function as a bidirectional regulator of Ca2+ sparks in both a 
dose- and time-dependent manner (Yan et al., 2008). As mitochondrial 
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ROS levels appear to increase in FRDA-like cardiomyocytes, it would be 
interesting to more closely study the relationship between ROS levels and 
Ca2+ spark frequency and observe if mitochondrial ROS levels are 
particularly related to the Ca2+ dysregulation observed. The ROS 
generation and associated Ca2+ dysregulation may also itself cause iron 
accumulation, meaning a study of iron levels in FRDA-like cardiomyocytes 
could provide more detail concerning the precise pathophysiology of the 
disease in heart cells.  
 
Ultimately, studies previously carried out by the Giunti group (Abeti et al., 
2016; Abeti et al., 2015) had already shown that a potential FRDA therapy 
need not address the ISC deficit directly, as FRDA model mouse cerebellar 
granular neurons were rescued from their toxic ROS-based 
pathophysiology by blocking lipid peroxidation and activation of 
mitochondrial antioxidant pathways. A further publication by myself and my 
colleagues in the Giunti group may be added to this thesis as the initation 
of the study of Ca2+ signaling in FRDA-model heart cells (Abeti et al, 2018). 
In neurons as in heart cells, it may be that the most clinically relevant of 
the multiple physiological pathways in FRDA is that driven by increased 
oxidative stress. In the heart, this pathway is intimately connected with Ca2+ 
dysregulation at the level of the SR-mitochondria microdomain, and now 
more work is needed to understand its precise pathophysiology. 
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